

chain nodes :  
 7 8 9 10 13 15  
 ring nodes :  
 1 2 3 4 5 6  
 chain bonds :  
 4-7 7-8 8-9 9-10 13-15  
 ring bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6  
 exact/norm bonds :  
 4-7 7-8 9-10 13-15  
 exact bonds :  
 8-9  
 normalized bonds :  
 1-2 1-6 2-3 3-4 4-5 5-6  
 isolated ring systems :  
 containing 1 :

Match level :  
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom 13:CLASS  
 14:Atom 15:Atom

Generic attributes :  
 15:  
 Saturation : Unsaturated  
 Number of Carbon Atoms : less than 7  
 Number of Hetero Atoms : 2 or more  
 Type of Ring System : Monocyclic

Element Count :  
 Node 15: Limited  
 C,C3  
 N,N2  
 O,O0  
 S,S0

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 1840



L1 SCREEN CREATED

=> screen 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L2 SCREEN CREATED

=>

Uploading C:\Program Files\Stnexp\Queries\10595807.str



```
chain nodes :
7 8 9 10 13 15
ring nodes :
1 2 3 4 5 6
chain bonds :
4-7 7-8 8-9 9-10 13-15
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
4-7 7-8 9-10 13-15
exact bonds :
8-9
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6
isolated ring systems :
containing 1 :
```

Match level :

10/595,807

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:Atom  
13:CLASS 14:Atom 15:Atom

Generic attributes :

15:

Saturation : Unsaturated

Number of Carbon Atoms : less than 7

Number of Hetero Atoms : 2 or more

Type of Ring System : Monocyclic

Element Count :

Node 15: Limited

C,C3

N,N2

O,O0

S,S0

L3 STRUCTURE UPLOADED

=> que L3 AND L1 NOT L2

L4 QUE L3 AND L1 NOT L2


=> d 14

L4 HAS NO ANSWERS

L1 SCR 1840

L2 SCR 2016 OR 2026 OR 2039 OR 2040 OR 2045 OR 2047

L3 STR



Structure attributes must be viewed using STN Express query preparation.  
 L4 QUE L3 AND L1 NOT L2

=> s l4 sss sam  
 SAMPLE SEARCH INITIATED 16:37:52 FILE 'REGISTRY'  
 SAMPLE SCREEN SEARCH COMPLETED - 29601 TO ITERATE

6.8% PROCESSED 2000 ITERATIONS 3 ANSWERS  
 INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
 SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
 BATCH \*\*COMPLETE\*\*  
 PROJECTED ITERATIONS: 581725 TO 602315  
 PROJECTED ANSWERS: 489 TO 1287

L5 3 SEA SSS SAM L3 AND L1 NOT L2

=> => s l4 sss ful  
 FULL SEARCH INITIATED 16:38:37 FILE 'REGISTRY'  
 FULL SCREEN SEARCH COMPLETED - 596139 TO ITERATE

85.9% PROCESSED 511997 ITERATIONS 857 ANSWERS  
 93.6% PROCESSED 557729 ITERATIONS 857 ANSWERS  
 100.0% PROCESSED 596139 ITERATIONS 857 ANSWERS



10/595,807

SEARCH TIME: 00.00.38

L6                857 SEA SSS FUL L3 AND L1 NOT L2

=> => s 16

L7                26 L6

=> d 17 1-26 bib,ab,hitstr

L7 ANSWER 1 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2009:948768 CAPLUS  
 TI Preparation of compounds with Janus-associated kinase inhibitory  
 activities for treatment of myeloproliferative disorders and cancer  
 IN Almeida, Lynsie; Ioannidis, Stephanos; Johannes, Jeffrey; Lamb, Michelle;  
 Su, Mei; Yang, Bin  
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SO PCT Int. Appl., 78pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009095712	A2	20090806	WO 2009-GB50074	20090126
W: AE, AG, AL, AM, AO, <u>AT</u> , AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2008-24482P P 20080129

AB The invention relates to compds. of Formula I [A = pyridinyl, pyrimidinyl;  
 R1, R3 = halogen; R2 = C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl,  
 (hetero)cyclyl, alkoxy, mercapto, amino group, formyl, etc.], and to their  
 salts, their preparation, pharmaceutical compns., and their use as  
 janus-associated kinase inhibitors for treatment of myeloproliferative  
 disorders and cancer. Thus 5-chloro-N2-[(1S)-1-(5-fluoropyridin-2-  
 yl)propyl]-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine was prepared  
 by the reaction of [(1S)-1-(5-fluoropyridin-2-yl)propyl]amine  
 hydrochloride and 2,5-dichloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-  
 amine.

IT 1174754-99-4P	1174755-01-1P	1174755-03-3P
1174755-05-5P	1174755-07-7P	1174755-08-8P
1174755-11-3P	1174755-13-5P	1174755-15-7P
1174755-17-9P	1174755-40-8P	1174755-42-0P
1174755-44-2P	1174755-46-4P	1174755-49-7P
1174755-51-1P	1174755-53-3P	1174755-55-5P
1174755-58-8P	1174755-59-9P	1174755-60-2P
1174755-61-3P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)


(preparation of compds. with janus-associated kinase inhibitory activities  
 for treatment of myeloproliferative disorders and cancer)

RN 1174754-99-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)propyl]-  
 N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.


10/595,807



RN 1174755-01-1 CAPLUS

CN 2-Pyridinepropanamide,  $\beta$ -[[5-chloro-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-5-fluoro-N-methyl-, ( $\beta$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1174755-03-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1R)-1-(5-fluoro-2-pyridinyl)-2-methoxyethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1174755-05-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N2-[(1R)-1-(5-fluoro-2-pyridinyl)-2-methoxyethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1174755-07-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-fluoro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)propyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1174755-08-8 CAPLUS  
 CN 2-Pyridinepropanol,  $\gamma$ -[[5-chloro-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-5-fluoro-, ( $\gamma$ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1174755-11-3 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(S)-cyclopropyl(5-fluoro-2-pyridinyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1174755-13-5 CAPLUS  
 CN 2-Pyridineethanol,  $\beta$ -[[5-chloro-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-5-fluoro-, ( $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.


10/595,807



RN 1174755-15-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1R)-1-(3,5-difluoro-2-pyridinyl)-2-methoxyethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.




RN 1174755-17-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1R)-1-(5-fluoro-2-pyrimidinyl)-2-methoxyethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1174755-40-8 CAPLUS  
 CN 2-Pyridinepropanamide,  $\beta$ -[[5-chloro-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-5-fluoro-N-methyl- (CA INDEX NAME)




RN 1174755-42-0 CAPLUS  
 CN 2-Pyridinepropanamide,  $\beta$ -[[5-chloro-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-5-fluoro-N-methyl-, ( $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1174755-44-2 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-chloro-N2-[1-(5-fluoro-2-pyridinyl)-2-methoxyethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 1174755-46-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)-2-methoxyethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1174755-49-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-fluoro-N2-[1-(5-fluoro-2-pyridinyl)-2-methoxyethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 1174755-51-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)-2-methoxyethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1174755-53-3 CAPLUS

CN 2-Pyridinepropanol, γ-[[5-chloro-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-5-fluoro- (CA INDEX NAME)






RN 1174755-55-5 CAPLUS


CN 2-Pyridinepropanol,  $\gamma$ -[[5-chloro-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-5-fluoro-, ( $\gamma$ R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1174755-58-8 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[1-(3,5-difluoro-2-pyridinyl)-2-methoxyethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 1174755-59-9 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(3,5-difluoro-2-pyridinyl)-2-methoxyethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1174755-60-2 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[1-(5-fluoro-2-pyrimidinyl)-2-methoxyethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 1174755-61-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)-2-methoxyethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 2 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2009:553014 CAPLUS  
 DN 150:515192

TI Pyrimidine derivatives as FGFR modulators and their preparation,  
 pharmaceutical compositions and use in the treatment of cancer

IN Foote, Kevin Michael; Theoclitou, Maria-Elena

PA Astrazeneca AB, Swed.; Astrazeneca UK Limited

SO PCT Int. Appl., 79pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009056886	A1	20090507	WO 2008-GB51018	20081030
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2007-984418P P 20071101

OS MARPAT 150:515192

AB There is provided pyrimidine compds. of formula I and their pharmaceutical salts thereof. There is also provided processes for their preparation, pharmaceutical compns. containing them, a process for preparing the pharmaceutical compns., and their use in therapy, for example in the treatment of proliferative disease such as cancer and particular ly in disease mediated by a FGFR inhibitory effect. Compds. of formula I wherein E is CH<sub>2</sub> and O; R is H and (un)substituted C1-3 alkyl; R1 is F, OH, CN, (un)substituted C1-3 alkoxy and CONH<sub>2</sub> and derivs.; R2 is H and (un)substituted C1-3 alkyl; R3 is H, F and CONH<sub>2</sub> and derivs.; R4 is H, (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted C2-6 alkynyl, (un)substituted C3-5 cycloalkyl, (un)substituted C1-6 alkoxy, CONH<sub>2</sub> and derivs., NH<sub>2</sub> and derivs. and SOO-2R13; R13 is C1-6 alkyl and C3-6 cycloalkyl; when Q is (un)substituted CH, then Q1 is N and CH; when Q is N, then Q1 is CH; and their pharmaceutical salts thereof, are claimed. Example compound II was prepared by N-arylation of 5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-amine with 4-chloro-N-(pyridin-2-ylmethyl)pyrimidin-2-amine. All the invention compds. were evaluated for their FGFR modulating activity. From the assay, it was determined that II and other tested compds. exhibited the normalized inhibition of 50% against FGFR1.

IT 1150262-68-2P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(drug candidate and intermediate; preparation of pyrimidine derivs. as FGFR modulators useful in the treatment of cancer)

RN 1150262-68-2 CAPLUS

CN 2-Pyridinecarboxamide, 6-[[[4-[[5-[2-(3-methoxyphenyl)ethyl]-1H-pyrazol-3-

yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




IT 1150262-52-4P 1150262-55-7P 1150262-58-0P  
 1150262-61-5P 1150262-64-8P 1150262-66-0P  
 1150262-71-7P 1150262-75-1P 1150262-78-4P  
 1150262-80-8P 1150262-84-2P 1150262-88-6P  
 1150262-90-0P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine derivs. as FGFR modulators useful in the treatment of cancer)


RN 1150262-52-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-N2-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 1150262-55-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-[2-(3-methoxyphenyl)ethyl]-1H-pyrazol-3-yl]-N2-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 1150262-58-0 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-[2-(3-methoxyphenyl)ethyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1150262-61-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-[(3-fluorophenyl)methoxy]-1H-pyrazol-3-yl]-N2-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 1150262-64-8 CAPLUS

CN Phenol, 3-[2-[5-[[2-[(2-pyridinylmethyl)amino]-4-pyrimidinyl]amino]-1H-pyrazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1150262-66-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-[(3,5-dimethoxyphenyl)methoxy]-1H-pyrazol-3-yl]-N2-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 1150262-71-7 CAPLUS


CN 2-Pyridinecarboxamide, 6-[[[4-[[5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1150262-75-1 CAPLUS

CN 2-Pyridinecarboxamide, 6-[[[4-[[5-[2-(4-methoxy-2-pyridinyl)ethyl]-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)

10/595,807




RN 1150262-78-4 CAPLUS  
 CN 2-Pyridinecarboxamide, 6-[[[4-[[5-[2-[3-[(methylamino)carbonyl]phenyl]ethyl]-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)



RN 1150262-80-8 CAPLUS  
 CN 2-Pyridinecarboxamide, 6-[[[4-[[5-[2-(3-hydroxyphenyl)ethyl]-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




10/595,807



RN 1150262-84-2 CAPLUS

CN Benzonitrile, 3-[2-[5-[[2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]amino]-4-pyrimidinyl]amino]-1H-pyrazol-3-yl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1150262-88-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-[2-(3-pyridinyl)ethyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1150262-90-0 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-[2-(3-pyridinyl)ethyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)

methoxyphenyl)ethyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 1150263-07-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of pyrimidine derivs. as FGFR modulators useful in the treatment of cancer)

RN 1150263-07-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-[2-(3-methoxyphenyl)ethyl]-1H-pyrazol-3-yl]-N2-(2-pyridinylmethyl)-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

IT 1150263-61-8P


RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prophetic intermediate; preparation of pyrimidine derivs. as FGFR modulators useful in the treatment of cancer)

RN 1150263-61-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-[2-(3-methoxyphenyl)ethyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2009:258696 CAPLUS  
 DN 150:283074  
 TI Preparation of N-(pyrazol-3-yl)-N'-(1-pyridin-2-ylethyl)pyrimidine-2,4-diamine derivatives as JAK inhibitors for the treatment of cancer  
 IN Ioannidis, Stephanos; Lamb, Michelle  
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SO PCT Int. Appl., 73pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009027736	A2	20090305	WO 2008-GB50739	20080827
	WO 2009027736	A3	20090423		
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRAI US 2007-968282P P 20070827

OS MARPAT 150:283074

AB Title compds. I [ring A = (un)substituted aromatic carbocyclyl or aromatic heterocyclyl; R1 = H, halo, CN, alkyl, alkenyl, alkynyl, etc.; R3 and R4 independently = CN, alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, etc.; n = 1-4], and their pharmaceutically acceptable salts, are prepared Thus, e.g., II was prepared by catalytic coupling reaction of (pyridin-4-yl)boronic acid with 6-chloro-N-[(1S)-1-(5-fluoropyridin-2-yl)ethyl]-N'-(5-methoxy-1H-pyrazol-3-yl)pyrimidine-2,4-diamine (preparation given). II showed JAK inhibitory activity in in vitro assay with IC50 value of < 0.003  $\mu$ M. I provide a treatment for myeloproliferative disorders and cancer.

IT 1124383-74-9P 1124383-75-0P,  
 N-[(1S)-1-(5-Fluoropyridin-2-yl)ethyl]-6-(3-methoxyphenyl)-N'-(5-methoxy-1H-pyrazol-3-yl)pyrimidine-2,4-diamine 1124383-76-1P,  
 N-[(1S)-1-(5-Fluoropyridin-2-yl)ethyl]-6-(4-methoxyphenyl)-N'-(5-methoxy-1H-pyrazol-3-yl)pyrimidine-2,4-diamine 1124383-77-2P,  
 N-[(1S)-1-(5-Fluoropyridin-2-yl)ethyl]-N'-(5-methoxy-1H-pyrazol-3-yl)-6-(pyridin-3-yl)pyrimidine-2,4-diamine 1124383-78-3P,  
 6-(3-Fluorophenyl)-N-[(S)-1-(5-fluoropyridin-2-yl)ethyl]-N'-(5-methoxy-1H-pyrazol-3-yl)pyrimidine-2,4-diamine 1124383-79-4P,  
 6-(4-Fluorophenyl)-N-[(1S)-1-(5-fluoropyridin-2-yl)ethyl]-N'-(5-methoxy-1H-pyrazol-3-yl)pyrimidine-2,4-diamine 1124383-80-7P,  
 N-[(1S)-1-(5-Fluoropyridin-2-yl)ethyl]-N'-(5-methoxy-1H-pyrazol-3-yl)-6-(1H-pyrazol-4-yl)pyrimidine-2,4-diamine 1124383-81-8P,  
 N-[(1S)-1-(5-Fluoropyridin-2-yl)ethyl]-6-(1H-indol-5-yl)-N'-(5-methoxy-1H-pyrazol-3-yl)pyrimidine-2,4-diamine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)

(preparation pyrimidinediamine derivs. as JAK inhibitors for the treatment of cancer)

RN 1124383-74-9 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-(5-methoxy-1H-pyrazol-3-yl)-6-(4-pyridinyl)-, 2,2,2-trifluoroacetate (1:?) (CA INDEX NAME)

CM 1

CRN 1124383-73-8

CMF C20 H19 F N8 O


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 1124383-75-0 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-6-(3-methoxyphenyl)-N4-(5-methoxy-1H-pyrazol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1124383-76-1 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-6-(4-methoxyphenyl)-N4-(5-methoxy-1H-pyrazol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1124383-77-2 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-(5-methoxy-1H-pyrazol-3-yl)-6-(3-pyridinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1124383-78-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(3-fluorophenyl)-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-(5-methoxy-1H-pyrazol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1124383-79-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(4-fluorophenyl)-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-(5-methoxy-1H-pyrazol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1124383-80-7 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-(5-methoxy-1H-pyrazol-3-yl)-6-(1H-pyrazol-4-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1124383-81-8 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-6-(1H-indol-5-yl)-N4-(5-methoxy-1H-pyrazol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.





IT 1124383-72-7P, 6-Chloro-N-[(1S)-1-(5-fluoropyridin-2-yl)ethyl]-  
 N'-(5-methoxy-1H-pyrazol-3-yl)pyrimidine-2,4-diamine  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (preparation pyrimidinediamine derivs. as JAK inhibitors for the treatment  
 of cancer)  
 RN 1124383-72-7 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-chloro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-  
 (5-methoxy-1H-pyrazol-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 4 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2009:179700 CAPLUS  
 DN 150:214415  
 TI Preparation of pyrimidine compounds as FGFR inhibitors  
 IN Foote, Kevin Michael; Theoclitou, Maria-Elena  
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SO PCT Int. Appl., 66pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009019518	A1	20090212	WO 2008-GB50673	20080807
	W:				
	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2007-954846P P 20070809

OS MARPAT 150:214415

AB Title compds. I [R1 = (un)substituted alkyl, cycloalkyl, alkenyl, 4- to 6-membered heterocyclyl, alkoxy, etc.; R2 = H or (un)substituted alkyl; R3 = (un)substituted alkyl, cycloalkyl, 3- to 5-membered saturated heterocyclyl, 5- or 6-membered aromatic ring, alkylaminocarbonyl, etc.; R4 = H, OH, NH2, alkylamino, dialkylamino, etc.], and their pharmaceutically acceptable salts, are prepared as FGFR inhibitor. Thus, e.g., II was prepared by condensation reaction of (5-methyl-1,2-oxazol-3-yl)methanamine with 2-chloro-N-[5-[(propan-2-yl)oxy]-1H-pyrazol-3-yl]pyrimidin-4-amine which was prepared from 2,4-dichloropyrimidine with 5-[(propan-2-yl)oxy]-1H-pyrazol-3-amine. I were evaluated for their inhibition of FGFR activity in kinase assays using Caliper technol., e.g., II exhibited IC50 value of 0.16  $\mu$ M. There is also provided processes of I for their preparation, pharmaceutical compns. containing them, a process

for

preparing the pharmaceutical compns., and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in disease mediated by a FGFR inhibitory effect.

IT 1111802-38-0P, N'-[5-[2-(3-Methoxyphenyl)ethyl]-1H-pyrazol-3-yl]-


N-[(5-methyl-1,2-oxazol-3-yl)methyl]pyrimidine-2,4-diamine

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of pyrimidine compds. as FGFR inhibitors)

RN 1111802-38-0 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-[2-(3-methoxyphenyl)ethyl]-1H-pyrazol-3-yl]-N2-[(5-methyl-3-isoxazolyl)methyl]- (CA INDEX NAME)



IT 1111802-37-9P, N-[(5-Methyl-1,2-oxazol-3-yl)methyl]-N'-[5-  
 [(propan-2-yl)oxy]-1H-pyrazol-3-yl]pyrimidine-2,4-diamine  
 1111802-41-5P, N'-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-  
 yl]-N-[(5-methyl-1,2-oxazol-3-yl)methyl]pyrimidine-2,4-diamine  
 1111802-42-6P, N'-[5-[2-(3,5-Dimethoxyphenyl)methoxy]-1H-pyrazol-3-  
 yl]-N-[(5-methyl-1,2-oxazol-3-yl)methyl]pyrimidine-2,4-diamine  
 1111802-43-7P, 3-[2-[3-[[2-[[5-Methyl-1,2-oxazol-3-  
 yl)methyl]amino]pyrimidin-4-yl]amino]-1H-pyrazol-5-yl]ethyl]phenol  
 1111802-44-8P, N'-[5-[2-(3-Fluorophenyl)methoxy]-1H-pyrazol-3-yl]-N-  
 [(5-methyl-1,2-oxazol-3-yl)methyl]pyrimidine-2,4-diamine  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of pyrimidine compds. as FGFR inhibitors)  
 RN 1111802-37-9 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-N2-[(5-  
 methyl-3-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1111802-41-5 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-  
 yl]-N2-[(5-methyl-3-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1111802-42-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-[(3,5-dimethoxyphenyl)methoxy]-1H-pyrazol-3-yl]-N2-[(5-methyl-3-isoxazolyl)methyl]- (CA INDEX NAME)



RN 1111802-43-7 CAPLUS


CN Phenol, 3-[2-[3-[[2-[(5-methyl-3-isoxazolyl)methyl]amino]-4-pyrimidinyl]amino]-1H-pyrazol-5-yl]ethyl]- (CA INDEX NAME)



RN 1111802-44-8 CAPLUS

10/595,807

CN 2,4-Pyrimidinediamine, N4-[5-[(3-fluorophenyl)methoxy]-1H-pyrazol-3-yl]-N2-  
[(5-methyl-3-isoxazolyl)methyl]- (CA INDEX NAME)



RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2009:140345 CAPLUS  
 DN 150:214411  
 TI Pyrimidine derivatives as JAK-2 inhibitors in combination with other  
 agents and their preparation and use in the treatment of diseases  
 IN Lamb, Peter  
 PA Exelixis, Inc., USA  
 SO PCT Int. Appl., 854pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009017838	A2	20090205	WO 2008-US9360	20080731
	WO 2009017838	A3	20090702		
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRAI US 2007-962776P P 20070801

OS MARPAT 150:214411

AB A method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a JAK-2 compound of formula I, or a pharmaceutical composition comprising a therapeutically effective amount

of the JAK-2 compound of formula I and a pharmaceutically acceptable carrier, in combination with an active agent selected from of a Raf inhibitor, an EGFR inhibitor, a VEGFR inhibitor, a ErbB2 inhibitor, a BCR-Abl, inhibitor, a Flt3 inhibitor, a Src inhibitor, a c Kit inhibitor, an Akt inhibitor, a Ret inhibitor, an IFG1R inhibitor, an m-Tor inhibitor, a PI3K inhibitor, a PI3Kalpha inhibitor, wherein the mammal is in need of the treatment. Compds. of formula I wherein D and E are independently H, halo, CF3, heterocycloalkyl and alkyl; D and E taken together to form a 5- to 7-membered heteroaryl, and 5- to 7-membered heterocycloalkyl; L is a bond, O and NH; Z is alkoxy, cycloalkyl, and (un)substitued heteroaryl; Z and R25 taken together for form a 5- to 6-membered heterocycloalkyl, 5- to 6-membered heteroaryl, 5- to 6-membered cycloalkyl, etc.; each R25 is independently alkyl, alkenyl, lower alkyl, halo, haloalkyl, haloalkoxy, amino, etc.; R1 is H; R2 is (un)substituted aryl, (un)substituted heteroaryl, alkyl, etc.; n is 0 - 4; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by acylation of 2-(4-aminophenylamino)-5-(4-acetylaminophenyl)pyrimidine with 2,6-dichlorobenzoyl chloride. All the invention compds. were evaluated for their JAK-2 inhibitory activity (some data given).

IT	543711-08-6P	543712-32-9P	852441-70-4P
	852441-73-7P	852441-78-2P	898276-24-9P
	898276-26-1P	898276-29-4P	898276-30-7P
	898276-32-9P	898276-34-1P	898276-37-4P


898276-38-5P	898276-41-0P	898276-45-4P
898276-61-4P	898276-71-6P	898276-72-7P
898276-73-8P	898276-82-9P	898276-93-2P
898277-00-4P	898277-06-0P	898277-12-8P
898277-37-7P	898277-62-8P	898277-65-1P
898277-68-4P	898277-74-2P	898277-76-4P
898277-78-6P	898277-92-4P	898278-04-1P
898278-12-1P	898278-13-2P	898278-14-3P
898278-15-4P	898278-16-5P	898278-24-5P
898278-25-6P	898278-31-4P	898278-32-5P
898278-43-8P	898278-66-5P	898279-81-7P
898279-82-8P	898279-83-9P	898279-87-3P
898279-88-4P	898279-89-5P	898279-90-8P
898279-91-9P	898279-92-0P	898279-93-1P
898279-96-4P	898279-97-5P	898279-98-6P
898279-99-7P	898280-03-0P	898280-05-2P
898280-06-3P	898280-07-4P	898280-08-5P
898280-09-6P	898280-11-0P	898280-14-3P
898280-31-4P	898280-44-9P	898280-45-0P
898280-46-1P	898280-58-5P	898280-59-6P
898280-60-9P	898280-61-0P	898280-62-1P
898280-63-2P	898280-64-3P	898280-65-4P
898280-66-5P	898280-67-6P	898280-68-7P
898280-69-8P	898280-70-1P	898280-71-2P
898280-72-3P	898280-73-4P	898280-75-6P
898280-76-7P	898280-77-8P	898280-78-9P
898280-79-0P	898280-80-3P	898280-81-4P
898280-82-5P	898280-83-6P	898280-84-7P
898280-85-8P	898280-86-9P	898280-87-0P
898280-88-1P	898280-89-2P	898280-90-5P
898280-91-6P	898280-92-7P	898280-93-8P
898280-94-9P	898280-95-0P	898280-96-1P
898280-97-2P	898280-98-3P	898280-99-4P
898281-00-0P	898281-01-1P	898281-02-2P
898281-03-3P	898281-04-4P	898281-05-5P
898281-06-6P	898281-07-7P	898281-08-8P
898281-09-9P	898281-10-2P	898281-11-3P
898281-12-4P	898281-13-5P	898281-14-6P
898281-15-7P	898281-16-8P	898281-17-9P
898281-18-0P	898281-19-1P	898281-20-4P
898281-21-5P	898281-22-6P	898281-23-7P
898281-24-8P	898281-25-9P	898281-26-0P
898281-27-1P	898281-28-2P	898281-29-3P
898281-30-6P	898281-31-7P	898281-32-8P
898281-33-9P	898281-34-0P	898281-35-1P
898281-36-2P	898281-37-3P	898281-38-4P
898281-39-5P	898281-40-8P	898281-41-9P
898281-42-0P	898281-43-1P	898281-44-2P
898281-47-5P	898281-50-0P	1001060-95-2P
1001060-99-6P	1001061-02-4P	1001061-03-5P
1001061-04-6P	1001061-05-7P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine derivs. as JAK-2 inhibitors in combination with other agents useful in treatment of diseases)


RN 543711-08-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 543712-32-9 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 852441-70-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 852441-73-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(1-phenylethyl)- (CA INDEX NAME)




10/595,807



RN 852441-78-2 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 898276-24-9 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-methyl-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-26-1 CAPLUS

CN 2,4-Pyrimidinediamine, 6-methyl-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-29-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methoxy-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-30-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-32-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-5-methyl-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-34-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-phenyl-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-37-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-38-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]-6-propoxy- (CA INDEX NAME)




RN 898276-41-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-45-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopentyl-1H-pyrazol-3-yl)-6-methyl-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-61-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(2-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 898276-71-6 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[3-(diethylamino)propyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-72-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-73-8 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[2-(diethylamino)ethyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-82-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(dimethylamino)ethoxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-93-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898277-00-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(3-bromo-5-isoxazolyl)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898277-06-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898277-12-8 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-cyclohexyl-5-isoxazolyl)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl- (CA INDEX NAME)




RN 898277-37-7 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N6-(5-cyclopropyl-1H-pyrazol-3-yl)-N4,N4-dimethyl-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898277-62-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(2-methyl-5-thiazolyl)methyl]- (CA INDEX NAME)




RN 898277-65-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-furanylmethyl)- (CA INDEX NAME)




RN 898277-68-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(5-methyl-2-furanyl)methyl]- (CA INDEX NAME)




RN 898277-74-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 898277-76-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-phenylethyl)- (CA INDEX NAME)




RN 898277-78-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(4-chlorophenyl)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 898277-92-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[2-(2-thienyl)ethyl]- (CA INDEX NAME)






RN 898278-04-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 898278-12-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(2-chlorophenyl)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898278-13-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[4-(4-methyl-1-piperazinyl)phenyl]methyl]- (CA INDEX NAME)




RN 898278-14-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3,5-dimethoxyphenyl)methyl]- (CA INDEX NAME)




RN 898278-15-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(phenylmethyl)- (CA INDEX NAME)




RN 898278-16-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-phenylpropyl)- (CA INDEX NAME)



RN 898278-24-5 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(4-piperidinylmethyl)- (CA INDEX NAME)



RN 898278-25-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 898278-31-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(2,5-dimethoxyphenyl)methyl]- (CA INDEX NAME)




RN 898278-32-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(2-methoxyphenyl)methyl]-6-methyl- (CA INDEX NAME)




RN 898278-43-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[2-(2-thienyl)-4-thiazolyl]methyl]- (CA INDEX NAME)




RN 898278-66-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(4-methoxyphenyl)-5-isoxazolyl]methyl]-6-methyl- (CA INDEX NAME)




RN 898279-81-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-morpholinyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898279-82-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-methyl-1-piperazinyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898279-83-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898279-87-3 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(4-morpholinyl)ethoxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898279-88-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[[ (2S)-1-methyl-2-pyrrolidinyl]methoxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 898279-89-5 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(3S)-3-methyl-1-piperazinyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 898279-90-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(1-methyl-4-piperidinyl)oxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898279-91-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-morpholinyl)- (CA INDEX NAME)



RN 898279-92-0 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]-6-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 898279-93-1 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)






RN 898279-96-4 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[2-(4-methyl-1-piperazinyl)ethyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898279-97-5 CAPLUS


CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]-N6-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 898279-98-6 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(3R)-3-methyl-1-piperazinyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 898279-99-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-03-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(1-methyl-3-pyrrolidinyl)oxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-05-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(1-methyl-3-piperidinyl)oxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-06-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[2-(dimethylamino)ethoxy]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-07-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl)methyl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898280-08-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-(4-morpholinyl)- (CA INDEX NAME)




RN 898280-09-6 CAPLUS

CN 4-Pyrimidinecarboxamide, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[3-(1-phenyl-5-isoxazolyl)methyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 898280-11-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[(5-phenyl-3-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-14-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-methyl-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 898280-31-4 CAPLUS


CN 2,4-Pyrimidinediamine, 6-chloro-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 898280-44-9 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-[(3R)-3-methyl-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 898280-45-0 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N6-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)



RN 898280-46-1 CAPLUS


CN 2,4,6-Pyrimidinetriamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N6-[2-(4-methyl-1-piperazinyl)ethyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898280-58-5 CAPLUS


CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[3-(diethylamino)propyl]-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)





RN 898280-59-6 CAPLUS


CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[2-(diethylamino)ethyl]-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 898280-60-9 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(3S)-3-methyl-1-piperaziny]- (CA INDEX NAME)


Absolute stereochemistry.



RN 898280-61-0 CAPLUS


CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[2-(dimethylamino)ethyl]-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)

10/595,807




RN 898280-62-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methyl-3-pyrrolidinyl)oxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-63-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-[(1-methyl-3-pyrrolidinyl)oxy]- (CA INDEX NAME)




RN 898280-64-3 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methyl-3-pyrrolidinyl)oxy]- (CA INDEX NAME)




RN 898280-65-4 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-[2-(diethylamino)ethyl]-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N6-[5-(1-methylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 898280-66-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 898280-67-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methyl-3-piperidinyloxy)]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-68-7 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methyl-3-piperidinyloxy)]- (CA INDEX NAME)




RN 898280-69-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898280-70-1 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[(5-phenyl-1H-imidazol-2-yl)methyl]- (CA INDEX NAME)



RN 898280-71-2 CAPLUS


CN 2,4-Pyrimidinediamine, 6-[2-(dimethylamino)ethoxy]-N2-[[3-(1-methylethyl)-5-isoxazolyl)methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)

10/595,807




RN 898280-72-3 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 898280-73-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[2-(4-morpholinyl)ethoxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-75-6 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-[3-(diethylamino)propyl]-N2-[[3-(1-methylethyl)-5-isoxazolyl)methyl]-N6-[5-(1-methylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 898280-76-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methyl-4-piperidinyloxy)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-77-8 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 898280-78-9 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)






RN 898280-79-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[3-(diethylamino)propyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-80-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl)methyl]-6-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 898280-81-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-[(1-methyl-3-piperidinyl)oxy]- (CA INDEX NAME)




RN 898280-82-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methyl-4-piperidinyl)oxy]- (CA INDEX NAME)




RN 898280-83-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]-6-(4-morpholinyl)- (CA INDEX NAME)




RN 898280-84-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898280-85-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-[(1-methyl-4-piperidinyl)oxy]- (CA INDEX NAME)




RN 898280-86-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(4-fluorophenyl)-5-isoxazolyl]methyl]-6-(4-morpholinyl)- (CA INDEX NAME)



RN 898280-87-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(4-fluorophenyl)-5-isoxazolyl]methyl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898280-88-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(4-


10/595,807

fluorophenyl)-5-isoxazolyl]methyl]-6-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 898280-89-2 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(4-fluorophenyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-morpholinyl)- (CA INDEX NAME)




RN 898280-90-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(4-fluorophenyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898280-91-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(4-fluorophenyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 898280-92-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898280-93-8 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898280-94-9 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-(1-piperazinyl)- (CA INDEX NAME)






RN 898280-95-0 CAPLUS

CN Ethanone, 1-[4-[6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[3-(1-methylethyl)-5-isoxazolyl]methyl]amino]-4-pyrimidinyl]-1-piperazinyl]-  
(CA INDEX NAME)




RN 898280-96-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-[4-(methanesulfonyl)-1-piperazinyl]-  
(CA INDEX NAME)




RN 898280-97-2 CAPLUS

CN 1-Piperazinecarboxaldehyde, 4-[6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[3-(1-methylethyl)-5-isoxazolyl]methyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 898280-98-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-N2-[[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898280-99-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(4-methyl-1-piperazinyl)-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-00-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-6-[2-(4-morpholinyl)ethoxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-01-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[[3-(4-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-02-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(3,4-difluorophenyl)-5-isoxazolyl]methyl]-6-methyl- (CA INDEX NAME)




RN 898281-03-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(2,4-difluorophenyl)-5-isoxazolyl]methyl]-6-methyl- (CA INDEX NAME)




RN 898281-04-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[[3-(2-pyrazinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-05-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-06-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-07-7 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-6-(4-methyl-1-piperazinyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898281-08-8 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)- (CA INDEX NAME)




RN 898281-09-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-N2-[[3-(4-pyrimidinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 898281-10-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(3-furanyl)-5-isoxazolyl]methyl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898281-11-3 CAPLUS


CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 898281-12-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-13-5 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-14-6 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-bicyclo[2.2.1]hept-2-yl-N6-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 898281-15-7 CAPLUS


CN 2,4,6-Pyrimidinetriamine, N4-bicyclo[2.2.1]hept-2-yl-N6-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898281-16-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]-6-[(1R,4R)-5-(phenylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 898281-17-9 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl)methyl]-6-[(1R,4R)-5-(phenylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 898281-18-0 CAPLUS


CN	2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-N2-[[3-(4-pyrimidinyl)-5-isoxazolyl]methyl]-	(CA INDEX NAME)
----	--	-----------------



RN 898281-19-1 CAPLUS


CN	2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(dimethylamino)ethoxy]-N2-[3-(4-pyrimidinyl)-5-isoxazolyl]methyl)-	(CA
	INDEX NAME)	

10/595,807




RN 898281-20-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(5-fluoro-2-pyridinyl)-5-isoxazolyl]methyl]-6-methyl- (CA INDEX NAME)



RN 898281-21-5 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-N2-[[3-(2-thienyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 898281-22-6 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-

(dimethylamino)ethoxy]-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-23-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-N2-[[3-(5-pyrimidinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-24-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-N2-[[3-(5-pyrimidinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-25-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(diethylamino)ethoxy]-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-26-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)



RN 898281-27-1 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(diethylamino)ethoxy]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898281-28-2 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]-6-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)






RN 898281-29-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-N2-[[3-(2-thiazolyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-30-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(dimethylamino)ethoxy]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-31-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[2-(dimethylamino)ethoxy]-N2-[(3-methyl-5-isoxazolyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898281-32-8 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[2-(diethylamino)ethoxy]-N2-[(3-methyl-5-isoxazolyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898281-33-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)-6-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 898281-34-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[2-(3-phenyl-5-isoxazolyl)ethyl]- (CA INDEX NAME)




RN 898281-35-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[1-(3-phenyl-5-isoxazolyl)ethyl]- (CA INDEX NAME)




RN 898281-36-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[1-(3-ethyl-5-isoxazolyl)methyl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898281-37-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[1-(3-ethyl-5-isoxazolyl)methyl]-6-(4-morpholinyl)- (CA INDEX NAME)




RN 898281-38-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(dimethylamino)ethoxy]-N2-[(3-ethyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-39-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(diethylamino)ethoxy]-N2-[(3-ethyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-40-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-ethyl-5-isoxazolyl)methyl]-6-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 898281-41-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(2-amino-4-pyrimidinyl)-5-isoxazolyl]methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898281-42-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-ethyl-1-piperazinyl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-43-1 CAPLUS

CN 4-Piperidineethanol, 1-[6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[3-(1-methylethyl)-5-isoxazolyl]methyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 898281-44-2 CAPLUS

CN 1-Piperazineethanol, 4-[6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[3-(1-methylethyl)-5-isoxazolyl]methyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 898281-47-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[4-(dimethylamino)phenyl]methyl]- (CA INDEX NAME)




RN 898281-50-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1001060-95-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]-6-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)



RN 1001060-99-6 CAPLUS


CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N6-[2-(4-methyl-1-piperazinyl)ethyl]-  
(CA INDEX NAME)



RN 1001061-02-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[[3-phenyl-5-isoxazolyl]methyl]-6-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)






RN 1001061-03-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(3S)-3-methyl-1-piperazinyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 1001061-04-6 CAPLUS


CN 2,4,6-Pyrimidinetriamine, N4-[2-(diethylamino)ethyl]-N6-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)

10/595,807



RN 1001061-05-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[[3-(3-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



L7 ANSWER 6 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2009:116288 CAPLUS  
 DN 150:191535  
 TI N-Pyrazolyl fused pyrimidinamine derivatives as JAK inhibitors and their preparation, pharmaceutical compositions and use in the treatment of myeloproliferative disorders and cancer  
 IN Ioannidis, Stephanos; Lamb, Michelle; Su, Mei  
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SO PCT Int. Appl., 92pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2009013545	A2	20090129	WO 2008-GB50617	20080723
	WO 2009013545	A3	20090702		
	W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRAI	US 2007-952222P	P	20070726		

OS MARPAT 150:191535

AB The invention relates to compds. of formula I and to their salts, pharmaceutical compns., methods of use, and methods for their preparation. These compds. provide a treatment for myeloproliferative disorders and cancer. Compds. of formula I wherein ring A is (un)substituted 5-membered aromatic heterocyclic ring; X is O, NH and S; D is CH and N; R1 and each R4 are independently halo, CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, carbocyclyl, heterocyclyl, etc.; R3 is H, halo, CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, etc.; n is 0, 1, 2, 3 and 4; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by amination of 5-chloro-2-methyl-N-(5-methyl-1H-pyrazol-3-yl)[1,3]thiazolo[5,4-d]pyrimidin-7-amine with (1S)-1-(5-fluoropyrimidin-2-yl)ethanamine hydrochloride to give compound II•HCl, which was hydrolyzed to give compound II. All the invention compds. were evaluated for their JAK inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value of 0.003  $\mu$ M.


IT 935666-95-8P, 6-Chloro-2-[[[(S)-1-(5-fluoropyrimidin-2-yl)ethyl]amino]-4-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidine  
 1107653-72-4P, 6-Chloro-2-[[[(S)-1-(5-fluoropyridin-2-yl)ethyl]amino]-4-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidine  
 1107653-73-5P, 4-[(1,3-Dioxolan-2-ylmethyl)amino]-2-[[[(S)-1-(5-fluoropyridin-2-yl)ethyl]amino]-6-[(3-methyl-1H-pyrazol-5-yl)amino]pyrimidine 1107653-74-6P,  
 (S)-4-[(2,2-Dimethoxyethyl)amino]-2-[[1-(5-fluoropyrimidin-2-yl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]pyrimidine  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of N-pyrazolyl fused pyrimidinamine derivs. as JAK inhibitors useful in treatment of myeloproliferative disorders and cancers)

RN 935666-95-8 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1107653-72-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 1107653-73-5 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(1,3-dioxolan-2-ylmethyl)-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N6-(3-methyl-1H-pyrazol-5-yl)- (CA INDEX NAME)

Absolute stereochemistry.


10/595,807



RN 1107653-74-6 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(2,2-dimethoxyethyl)-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N6-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.



L7 ANSWER 7 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:1359514 CAPLUS  
 DN 149:556354  
 TI Synthesis of 9-(pyrazol-3-yl)-9H-purine-2-amine and  
 3-(pyrazol-3-yl)-3H-imidazo[4,5-b]pyridin-5-amine derivatives for treating  
 cancer  
 IN Davies, Audrey; Ioannidis, Stephanos; Lamb, Michelle; Su, Mei; Wang, Tao;  
 Zhang, Hai-Jun  
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SO PCT Int. Appl., 102pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008135785	A1	20081113	WO 2008-GB50321	20080502
W: AE, AG, AL, AM, AO, <del>AT</del> , AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRAI US 2007-916270P P 20070504

OS MARPAT 149:556354

AB The present invention relates to the synthesis of the title compds. I [D =  
 N, CH; Q = N, CR3, R3 = H, halo, cyano, C1-C6-alkyl, etc.; R1 = H, cyano,  
 C2-C6-alkynyl, 3-5-membered carbocyclyl, etc.; R2 = H, halo, cyano,  
 heterocyclyl, etc.; R4 = H, cyano, carbocyclyl, heterocyclyl, etc.; R5 =  
 halo, cyano, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, etc.]. These  
 compds. provide a treatment for myeloproliferative disorders and cancer.

IT 935667-07-5P 1079275-37-8P 1079275-49-2P  
 1079275-50-5P 1079275-70-9P 1079275-72-1P  
 1079275-73-2P 1079275-74-3P 1079275-77-6P  
 1079275-81-2P 1079275-86-7P 1079275-88-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)

(synthesis of pyrazolylpurinamines and pyrazolylimidazopyridinamines  
 and tyrosine kinase activity geared toward treating cancer)

RN 935667-07-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(5-  
 fluoro-2-pyrimidinyl)ethyl]-5-nitro- (CA INDEX NAME)


Absolute stereochemistry.



RN 1079275-37-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-5-nitro- (CA INDEX NAME)


Absolute stereochemistry.



RN 1079275-49-2 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-5-nitro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1079275-50-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-[5-(1-

methylethoxy)-1H-pyrazol-3-yl]-5-nitro- (CA INDEX NAME)


Absolute stereochemistry.



RN 1079275-70-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)-5-nitro- (CA INDEX NAME)

Absolute stereochemistry.




RN 1079275-72-1 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[[[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-5-nitro-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.






RN 1079275-73-2 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[[[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-5-nitro- (CA INDEX NAME)


Absolute stereochemistry.



RN 1079275-74-3 CAPLUS

CN Methanone, [2-[[[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-5-nitro-4-pyrimidinyl]-4-morpholinyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 1079275-77-6 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)-5-nitro-N6-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1079275-81-2 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-6-methoxy-N4-(5-methyl-1H-pyrazol-3-yl)-5-nitro- (CA INDEX NAME)


Absolute stereochemistry.



RN 1079275-86-7 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-5-nitro- (CA INDEX NAME)


Absolute stereochemistry.



RN 1079275-88-9 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 2-[[[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-5-nitro-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

10/595,807

RE.CNT 1      THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L7 ANSWER 8 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:881095 CAPLUS  
 DN 149:224215  
 TI Identification of 4-Aminopyrazolylpyrimidines as Potent Inhibitors of Trk Kinases  
 AU Wang, Tao; Lamb, Michelle L.; Scott, David A.; Wang, Haixia; Block, Michael H.; Lyne, Paul D.; Lee, John W.; Davies, Audrey M.; Zhang, Hai-Jun; Zhu, Yanyi; Gu, Fei; Han, Yongxin; Wang, Bin; Mohr, Peter J.; Kaus, Robert J.; Josey, John A.; Hoffmann, Ethan; Thress, Ken; MacIntyre, Terry; Wang, Haiyun; Omer, Charles A.; Yu, Dingwei  
 CS Departments of Cancer Chemistry, Cancer Bioscience, Drug Metabolism and Pharmacokinetics, AstraZeneca R and D Boston, Waltham, MA, 02451, USA  
 SO Journal of Medicinal Chemistry (2008), 51(15), 4672-4684  
 CODEN: JMCMAR; ISSN: 0022-2625  
 PB American Chemical Society  
 DT Journal  
 LA English  
 OS CASREACT 149:224215  
 AB The design, synthesis and biol. evaluation of a series of 4-(pyrazolylamino)pyrimidines I (R1 = H, Me, SMe, cyclopropyl, Me2CHO, n-PrO, Me3C; R2 = H, Br, Cl, F, Me; R3 = H, HOCH2CH2NH, (S)-HOCH2CH(OH)CH2NH, etc.; R4 = Me, CH2OH, CH2CONMe2, CH2CONHMe; R5 = Ph, 2-ClC6H4, 4-FC6H4, 5-fluoro-2-pyridyl, 5-fluoro-2-pyrimidyl) as potent Trk kinase inhibitors is reported. High-throughput screening identified a promising hit in the 4-(pyrazolylamino)pyrimidine chemotype. Initial optimization of the series led to more potent Trk inhibitors. Further optimization using two strategies resulted in significant improvement of phys. properties and led to the discovery of I (R1 = Me2CHO; R2 = Cl; R3 = H; R4 = (S)-Me; R5 = 5-fluoro-2-pyridyl) (AZ-23), a potent, orally bioavailable Trk A/B inhibitor. The compound offers the potential to test the hypothesis that modulation of Trk activity will be of benefit in the treatment of cancer and other indications in vivo.  
 IT 852441-69-1P  
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (docking studies; synthesis and biol. evaluation of 2-( $\alpha$ -arylalkylamino)-4-(pyrazolylamino)pyrimidines as potent inhibitors of Trk kinases)  
 RN 852441-69-1 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 852441-88-4P 915720-17-1P 915720-21-7P  
 915720-28-4P  
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (synthesis and biol. evaluation of  
 2-( $\alpha$ -arylalkylamino)-4-(pyrazolylamino)pyrimidines as potent  
 inhibitors of Trk kinases)  
 RN 852441-88-4 CAPLUS  
 CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 915720-17-1 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-21-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-28-4 CAPLUS

CN 1,3-Propanediol, 2-[[[5-chloro-2-[[[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]amino]-6-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-4-pyrimidinyl]oxy]-

Absolute stereochemistry.



IT	852441-78-2P	852441-85-1P	852442-04-7P
	852442-05-8P	852442-82-1P	852443-15-3P
	852443-29-9P	852443-47-1P	898276-61-4P
	898277-74-2P	898277-78-6P	898278-12-1P
	898278-25-6P	915720-18-2P	915720-25-1P
	935666-85-6P	1043435-32-0P	1043435-43-3P
	1043435-52-4P	1043435-60-4P	1043435-62-6P
	1043435-66-0P	1043435-68-2P	1043435-70-6P
	1043435-72-8P	1043435-74-0P	1043435-76-2P
	1043435-82-0P	1043435-87-5P	1043435-90-0P
	1043435-93-3P		


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis and biol. evaluation of  
2-( $\alpha$ -arylalkylamino)-4-(pyrazolylamino)pyrimidines as potent  
inhibitors of Trk kinases)

RN 852441-78-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 852441-85-1 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-, ( $\beta$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-04-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]-5-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-05-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-5-fluoro-N2-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-82-1 CAPLUS

CN Benzenepropanamide,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro-N,N-dimethyl-, ( $\beta$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-15-3 CAPLUS

CN 1,2-Propanediol, 3-[[2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-4-pyrimidinyl]amino]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-29-9 CAPLUS

CN 1,2-Propanediol, 3-[[5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino]-4-pyrimidinyl]amino]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-47-1 CAPLUS


CN 1,3-Propanediol, 2-[[5-chloro-2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino]-6-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 898276-61-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(2-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 898277-74-2 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 898277-78-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(4-chlorophenyl)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)

10/595,807



RN 898278-12-1 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(2-chlorophenyl)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 898278-25-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 915720-18-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-5-fluoro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.


10/595,807



RN 915720-25-1 CAPLUS

CN 1,2-Propanediol, 3-[[5-chloro-2-[[[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]amino]-6-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-4-pyrimidinyl]amino]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 935666-85-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[[[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 1043435-32-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(phenylmethyl)-, 2,2,2-trifluoroacetate (20:27) (CA INDEX NAME)

CM 1

CRN 898278-15-4


CMF C17 H17 Br N6



CM 2


CRN 76-05-1

CMF C2 H F3 O2



RN 1043435-43-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(4-fluorophenyl)methyl]- (CA INDEX NAME)



RN 1043435-52-4 CAPLUS

CN Benzeneethanol, β-[[[5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-, (βR)-, 2,2,2-trifluoroacetate (5:8) (CA INDEX NAME)


10/595,807

CM 1

CRN 852441-72-6

CMF C18 H19 Br N6 O


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 1043435-60-4 CAPLUS

CN Benzenepropanamide,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro-N-methyl-, ( $\beta$ S)-, 2,2,2-trifluoroacetate (2:3) (CA INDEX NAME)

CM 1


CRN 852442-83-2

CMF C20 H21 Cl F N7 O

Absolute stereochemistry.




10/595,807



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 1043435-62-6 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]-, 2,2,2-trifluoroacetate (2:3) (CA INDEX NAME)

CM 1

CRN 852442-06-9

CMF C18 H19 F N6


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 1043435-66-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(4-fluorophenyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 1043435-68-2 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[[5-(methylthio)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)-, 2,2,2-trifluoroacetate (20:23) (CA INDEX NAME)


CM 1

CRN 852442-48-9

CMF C16 H16 Cl F N6 O S


Absolute stereochemistry.

10/595,807



CM 2

CRN 76-05-1  
CMF C2 H F3 O2




RN 1043435-70-6 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(4-fluorophenyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)-, 2,2,2-trifluoroacetate (5:4) (CA INDEX NAME)

CM 1

CRN 852441-95-3  
CMF C16 H16 Cl F N6


Absolute stereochemistry.



CM 2

10/595,807

CRN 76-05-1  
CMF C2 H F3 O2




RN 1043435-72-8 CAPLUS  
CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[(5-propoxy-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)-, 2,2,2-trifluoroacetate (4:5)  
(CA INDEX NAME)

CM 1


CRN 852442-78-5  
CMF C18 H20 Cl F N6 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1  
CMF C2 H F3 O2



RN 1043435-74-0 CAPLUS  
CN Benzeneethanol,  $\beta$ -[[5-chloro-4-(1H-pyrazol-3-ylamino)-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)-, 2,2,2-trifluoroacetate (4:5)  
(CA INDEX NAME)


10/595,807

CM 1

CRN 852442-50-3

CMF C15 H14 Cl F N6 O


Absolute stereochemistry.



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 1043435-76-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[(1S)-1-(4-fluorophenyl)ethyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)


CM 1

CRN 852441-79-3

CMF C19 H22 Cl F N6

Absolute stereochemistry.


10/595,807



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 1043435-82-0 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-[[2-(4-morpholinyl)ethyl]amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)


CM 1

CRN 852443-08-4

CMF C24 H30 Cl F N8 O2

Absolute stereochemistry.


10/595,807



CM 2

CRN 76-05-1

CMF C2 H F3 O2



RN 1043435-87-5 CAPLUS

CN Ethanol, 2-[[5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[1-(4-fluorophenyl)ethyl]amino]-4-pyrimidinyl]amino]-, 2,2,2-trifluoroacetate (20:27) (CA INDEX NAME)


CM 1

CRN 852443-23-3

CMF C20 H23 Cl F N7 O

Absolute stereochemistry.


10/595,807



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 1043435-90-0 CAPLUS

CN 1,3-Propanediol, 2-[[[5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino]-4-pyrimidinyl]amino]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

RN 1043435-93-3 CAPLUS




CN 1,2-Propanediol, 3-[[6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[ (1S)-1-(4-fluorophenyl)ethyl]amino]-4-pyrimidinyl]amino]-, (2R)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 852443-14-2

CMF C21 H26 F N7 O2


Absolute stereochemistry.



CM 2


CRN 76-05-1

CMF C2 H F3 O2



IT 852442-02-5P 852442-03-6P 852442-49-0P  
 852443-57-3P 852443-59-5P 915720-45-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (synthesis and biol. evaluation of  
 2-( $\alpha$ -arylalkylamino)-4-(pyrazolylamino)pyrimidines as potent  
 inhibitors of Trk kinases)  
 RN 852442-02-5 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-  
 [(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-03-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5,6-dichloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-49-0 CAPLUS

CN Benzeneethanol,  $\beta$ -[[4,5-dichloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 852443-57-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N2-[(1S)-1-(4-fluorophenyl)ethyl]-N4-(5-

methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-59-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5,6-dichloro-N2-[(1S)-1-(4-fluorophenyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-45-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5,6-dichloro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



10/595,807

OSC.G	2	THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
RE.CNT	36	THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 9 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:556901 CAPLUS  
 DN 148:509958  
 TI Pyrazolyl derivatives with analgesic activity and therefore useful in the treatment or prophylaxis of pain.  
 IN Claesson, Alf  
 PA Astrazeneca AB, Swed.  
 SO PCT Int. Appl., 24 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2008054291	A1	20080508	WO 2007-SE966	20071031
W:				
AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW:				
AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2007314657	A1	20080508	AU 2007-314657	20071031
CA 2668321	A1	20080508	CA 2007-2668321	20071031
US 20080108633	A1	20080508	US 2007-931554	20071031
KR 2009077063	A	20090714	KR 2009-709099	20071031
PRAI US 2006-863839P	P	20061101		
WO 2007-SE966	W	20071031		

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB This invention relates to new use of pyrazolyl derivs. and pharmaceutically acceptable salts thereof, which have been found to possess analgesic activity and are accordingly useful in the treatment or prophylaxis of pain conditions in the human or animal body, for example in the manufacture of medicaments for the treatment or prevention of pain in a warm blooded animal such as man. Example compound I was effective on the inflammatory pain induced by intra-articular ankle injection of carrageenan in rats. The pyrazolyl derivs. act as potent analgesics by acting as inhibitors of TrkA and TrkB.

IT 915720-16-0, (S)-5-Bromo-N'-(5-cyclopropyl-1H-pyrazol-3-yl)-N-[1-(5-fluoropyridin-2-yl)ethyl]pyrimidine-2,4-diamine 915720-17-1, (S)-5-Chloro-N'-(5-cyclopropyl-1H-pyrazol-3-yl)-N-[1-(5-fluoropyridin-2-yl)ethyl]pyrimidine-2,4-diamine 915720-21-7, 5-Chloro-N-[(1S)-1-(5-fluoropyridin-2-yl)ethyl]-N'-(5-isopropoxy-1H-pyrazol-3-yl)pyrimidine-2,4-diamine 915720-22-8, 5-Fluoro-N-[(1S)-1-(5-fluoropyridin-2-yl)ethyl]-N'-(5-isopropoxy-1H-pyrazol-3-yl)pyrimidine-2,4-diamine 915720-23-9, (S)-5-Bromo-N-[1-(5-fluoropyridin-2-yl)ethyl]-N'-(5-isopropoxy-1H-pyrazol-3-yl)pyrimidine-2,4-diamine 915720-32-0, (S)-5-Chloro-N'-(5-cyclopropyl-1H-pyrazol-3-yl)-N-[1-(3,5-difluoropyridin-2-yl)ethyl]pyrimidine-2,4-diamine 915720-33-1, (S)-5-Chloro-N-[1-(3,5-difluoropyridin-2-yl)ethyl]-N'-(5-isopropoxy-1H-pyrazol-3-yl)pyrimidine-2,4-diamine 915720-34-2,

(S)-5-Bromo-N-[1-(3,5-difluoropyridin-2-yl)ethyl]-N'-(5-isopropoxy-1H-pyrazol-3-yl)pyrimidine-2,4-diamine 915720-35-3,  
 (S)-N-[1-(3,5-Difluoropyridin-2-yl)ethyl]-5-fluoro-N'-(5-isopropoxy-1H-pyrazol-3-yl)pyrimidine-2,4-diamine 915720-50-2,  
 5-Chloro-N-[(1S)-1-(5-fluoropyridin-2-yl)ethyl]-N'-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine 915720-53-5 1022086-14-1  
 1022086-15-2 1022086-16-3 1022086-17-4  
 1022086-18-5 1022086-19-6 1022086-20-9  
 1022086-21-0 1022086-22-1 1022086-23-2  
 1022086-24-3 1022086-25-4 1022086-27-6  
 1022086-30-1 1022086-32-3 1022086-33-4  
 1022086-34-5 1022086-35-6 1022086-36-7


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(pyrazolyl derivs. with analgesic activity that act via inhibition of Trk kinase)

RN 915720-16-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-17-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-21-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-22-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-23-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-32-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(3,5-difluoro-2-pyridinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-33-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(3,5-difluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 915720-34-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(1S)-1-(3,5-difluoro-2-pyridinyl)ethyl]-



N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-35-3 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(3,5-difluoro-2-pyridinyl)ethyl]-5-fluoro-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-50-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 915720-53-5 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 915720-21-7  
 CMF C17 H19 Cl F N7 O


Absolute stereochemistry.



CM 2

CRN 110-16-7  
 CMF C4 H4 O4

Double bond geometry as shown.




RN 1022086-14-1 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-, sulfate (1:?) (CA INDEX NAME)

CM 1

CRN 915720-23-9  
 CMF C17 H19 Br F N7 O

Absolute stereochemistry.


10/595,807



CM 2

CRN 7664-93-9

CMF H2 O4 S



RN 1022086-15-2 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-, sulfate (1:?) (CA INDEX NAME)

CM 1

CRN 915720-21-7

CMF C17 H19 Cl F N7 O


Absolute stereochemistry.



CM 2

10/595,807

CRN 7664-93-9  
CMF H2 O4 S




RN 1022086-16-3 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(1S)-1-(3,5-difluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-, sulfate (1:?) (CA INDEX NAME)

CM 1


CRN 915720-34-2  
CMF C17 H18 Br F2 N7 O

Absolute stereochemistry.



CM 2

CRN 7664-93-9  
CMF H2 O4 S




RN 1022086-17-4 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(3,5-difluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-, sulfate (1:?) (CA INDEX NAME)

CM 1

10/595,807


CRN 915720-33-1  
CMF C17 H18 Cl F2 N7 O

Absolute stereochemistry.



CM 2

CRN 7664-93-9  
CMF H2 O4 S




RN 1022086-18-5 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-fluoro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-, sulfate (1:?) (CA INDEX NAME)

CM 1

CRN 915720-22-8  
CMF C17 H19 F2 N7 O


Absolute stereochemistry.



CM 2

CRN 7664-93-9

CMF H2 O4 S



RN 1022086-19-6 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(3,5-difluoro-2-pyridinyl)ethyl]-5-fluoro-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-, sulfate (1:?) (CA INDEX NAME)

CM 1

CRN 915720-35-3

CMF C17 H18 F3 N7 O


Absolute stereochemistry.



CM 2

CRN 7664-93-9

CMF H2 O4 S



RN 1022086-20-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-

10/595,807


1-(5-fluoro-2-pyridinyl)ethyl]-, sulfate (1:?) (CA INDEX NAME)

CM 1

CRN 915720-16-0

CMF C17 H17 Br F N7


Absolute stereochemistry.



CM 2

CRN 7664-93-9

CMF H2 O4 S



RN 1022086-21-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-, sulfate (1:?) (CA INDEX NAME)


CM 1

CRN 915720-17-1

CMF C17 H17 Cl F N7

Absolute stereochemistry.


10/595,807



CM 2

CRN 7664-93-9

CMF H2 O4 S



RN 1022086-22-1 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-  
[(1S)-1-(3,5-difluoro-2-pyridinyl)ethyl]-, sulfate (1:?) (CA INDEX NAME)

CM 1

CRN 915720-32-0

CMF C17 H16 Cl F2 N7

Absolute stereochemistry.




CM 2



10/595,807

CRN 7664-93-9  
CMF H2 O4 S




RN 1022086-23-2 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)-, sulfate (1:?) (CA INDEX NAME)

CM 1


CRN 915720-50-2  
CMF C15 H15 Cl F N7

Absolute stereochemistry.



CM 2

CRN 7664-93-9  
CMF H2 O4 S




RN 1022086-24-3 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-, (2Z)-2-butenedioate (1:?) (CA INDEX NAME)

CM 1

10/595,807

CRN 915720-23-9  
CMF C17 H19 Br F N7 O


Absolute stereochemistry.



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.




RN 1022086-25-4 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(1S)-1-(3,5-difluoro-2-pyridinyl)ethyl]-  
N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-, (2Z)-2-butenedioate (1:?) (CA  
INDEX NAME)

CM 1

CRN 915720-34-2  
CMF C17 H18 Br F2 N7 O

Absolute stereochemistry.

10/595,807




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 1022086-27-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(3,5-difluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-, (2Z)-2-butenedioate (1:?) (CA INDEX NAME)

CM 1

CRN 915720-33-1

CMF C17 H18 Cl F2 N7 O


Absolute stereochemistry.



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.




RN 1022086-30-1 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-fluoro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-, (2Z)-2-butenedioate (1:?) (CA INDEX NAME)

CM 1

CRN 915720-22-8  
CMF C17 H19 F2 N7 O


Absolute stereochemistry.



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.



RN 1022086-32-3 CAPLUS  
CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(3,5-difluoro-2-pyridinyl)ethyl]-5-fluoro-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-, (2Z)-2-butenedioate (1:?) (CA INDEX NAME)


10/595,807

CM 1

CRN 915720-35-3

CMF C17 H18 F3 N7 O

Absolute stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 1022086-33-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-, (2Z)-2-butenedioate (1:?) (CA INDEX NAME)


CM 1

CRN 915720-16-0

CMF C17 H17 Br F N7

Absolute stereochemistry.

10/595,807




CM 2

CRN 110-16-7

CMF C4 H4 O4

Double bond geometry as shown.



RN 1022086-34-5 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-  
[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-, (2Z)-2-butenedioate (1:?) (CA  
INDEX NAME)

CM 1

CRN 915720-17-1

CMF C17 H17 Cl F N7


Absolute stereochemistry.



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.




RN 1022086-35-6 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(3,5-difluoro-2-pyridinyl)ethyl]-, (2Z)-2-butenedioate (1:?) (CA INDEX NAME)

CM 1

CRN 915720-32-0  
CMF C17 H16 Cl F2 N7


Absolute stereochemistry.



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.




RN 1022086-36-7 CAPLUS  
CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)-, (2Z)-2-butenedioate (1:?) (CA INDEX NAME)

CM 1

10/595,807

CRN 915720-50-2  
CMF C15 H15 Cl F N7


Absolute stereochemistry.



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT



L7 ANSWER 10 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:43949 CAPLUS  
 DN 148:135983  
 TI Methods of using IGF1R and abl kinase modulators for the treatment of  
 cancer, and use with other therapies  
 IN Zhang, Wentao  
 PA Exelixis, Inc., USA  
 SO PCT Int. Appl., 187pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008005538	A2	20080110	WO 2007-US15585	20070703
	WO 2008005538	A3	20080724		
	W:		AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW		
	RW:		AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA		
	AU 2007269540	A1	20080110	AU 2007-269540	20070703
	CA 2656290	A1	20080110	CA 2007-2656290	20070703
	EP 2043651	A2	20090408	EP 2007-796723	20070703
	R:		AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS		
PRAI	US 2006-818568P	P	20060705		
	WO 2007-US15585	W	20070703		

OS CASREACT 148:135983; MARPAT 148:135983

AB The invention provides methods for treating cancer with a compound which inhibits kinases, more specifically IGF1R and Abl, in combination with treatments(s) selected from surgery, radiation, monoclonal antibody, bone marrow or peripheral blood stem cell transplantation, and one or more chemotherapeutic agent(s).


IT 898281-48-6P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(IGF1R and abl kinase modulators for treatment of cancer, and use with other therapies)

RN 898281-48-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



IT 898279-99-7P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (IGF1R and abl kinase modulators for treatment of cancer, and use with other therapies)  
 RN 898279-99-7 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



IT	543711-08-6	543711-24-6	543712-32-9
	852441-70-4	852441-73-7	852441-77-1
	852441-78-2	898276-24-9	898276-26-1
	898276-28-3	898276-29-4	898276-30-7
	898276-32-9	898276-34-1	898276-37-4
	898276-38-5	898276-39-6	898276-41-0
	898276-43-2	898276-45-4	898276-61-4
	898276-71-6	898276-72-7	898276-73-8
	898276-78-3	898276-82-9	898276-83-0
	898276-93-2	898277-00-4	898277-06-0
	898277-12-8	898277-37-7	898277-56-0
	898277-62-8	898277-64-0	898277-65-1
	898277-68-4	898277-74-2	898277-76-4
	898277-78-6	898277-92-4	898277-93-5
	898278-04-1	898278-05-2	898278-06-3
	898278-10-9	898278-12-1	898278-13-2
	898278-14-3	898278-15-4	898278-16-5

898278-20-1	898278-24-5	898278-25-6
898278-27-8	898278-29-0	898278-31-4
898278-32-5	898278-33-6	898278-43-8
898278-50-7	898278-54-1	898278-59-6
898278-63-2	898278-66-5	898278-68-7
898278-69-8	898278-71-2	898278-74-5
898278-75-6	898278-81-4	898278-86-9
898278-87-0	898278-89-2	898278-90-5
898278-95-0	898278-96-1	898278-99-4
898279-01-1	898279-30-6	898279-39-5
898279-42-0	898279-46-4	898279-47-5
898279-52-2	898279-53-3	898279-58-8
898279-80-6	898279-81-7	898279-82-8
898279-83-9	898279-84-0	898279-86-2
898279-87-3	898279-88-4	898279-89-5
898279-90-8	898279-91-9	898279-92-0
898279-93-1	898279-95-3	898279-96-4
898279-97-5	898279-98-6	898280-00-7
898280-03-0	898280-04-1	898280-05-2
898280-06-3	898280-07-4	898280-08-5
898280-09-6	898280-10-9	898280-11-0
898280-13-2	898280-14-3	898280-15-4
898280-16-5	898280-17-6	898280-18-7
898280-20-1	898280-22-3	898280-25-6
898280-26-7	898280-29-0	898280-31-4
898280-42-7	898280-44-9	898280-45-0
898280-46-1	898280-47-2	898280-48-3
898280-49-4	898280-50-7	898280-55-2
898280-56-3	898280-57-4	898280-58-5
898280-59-6	898280-60-9	898280-62-1
898280-63-2	898280-64-3	898280-65-4
898280-66-5	898280-67-6	898280-68-7
898280-69-8	898280-70-1	898280-71-2
898280-72-3	898280-73-4	898280-75-6
898280-76-7	898280-77-8	898280-78-9
898280-79-0	898280-80-3	898280-81-4
898280-82-5	898280-83-6	898280-84-7
898280-85-8	898280-86-9	898280-87-0
898280-88-1	898280-89-2	898280-90-5
898280-91-6	898280-92-7	898280-93-8
898280-94-9	898280-95-0	898280-96-1
898280-97-2	898280-98-3	898280-99-4
898281-00-0	898281-01-1	898281-02-2
898281-03-3	898281-04-4	898281-05-5
898281-06-6	898281-07-7	898281-08-8
898281-09-9	898281-10-2	898281-11-3
898281-12-4	898281-13-5	898281-14-6
898281-15-7	898281-16-8	898281-17-9
898281-18-0	898281-19-1	898281-20-4
898281-21-5	898281-22-6	898281-23-7
898281-24-8	898281-25-9	898281-26-0
898281-27-1	898281-28-2	898281-29-3
898281-30-6	898281-31-7	898281-32-8
898281-33-9	898281-34-0	898281-35-1
898281-36-2	898281-37-3	898281-38-4
898281-39-5	898281-40-8	898281-41-9
898281-42-0	898281-43-1	898281-44-2


898281-47-5      1001060-90-7      1001060-91-8  
 1001060-92-9      1001060-93-0      1001060-94-1  
 1001060-95-2      1001060-96-3      1001060-97-4  
 1001060-98-5      1001060-99-6      1001061-01-3  
 1001061-02-4      1001061-03-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)

(IGF1R and abl kinase modulators for treatment of cancer, and use with  
 other therapies)


RN 543711-08-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-  
 pyridinylmethyl)- (CA INDEX NAME)




RN 543711-24-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-  
 pyridinylmethyl)- (CA INDEX NAME)



RN 543712-32-9 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-  
 5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 852441-70-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-  
 1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 852441-73-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(1-phenylethyl)- (CA INDEX NAME)




RN 852441-77-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(1-phenylpropyl)- (CA INDEX NAME)




RN 852441-78-2 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.




RN 898276-24-9 CAPLUS  
 CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-methyl-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898276-26-1 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-methyl-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-28-3 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-29-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methoxy-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-30-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-32-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-5-methyl-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-34-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-phenyl-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-37-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898276-38-5 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]-6-propoxy- (CA INDEX NAME)



RN 898276-39-6 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]-6-(1-pyrrolidinyl)- (CA INDEX NAME)






RN 898276-41-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-43-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-45-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopentyl-1H-pyrazol-3-yl)-6-methyl-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-61-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(2-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 898276-71-6 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[3-(diethylamino)propyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-72-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-73-8 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[2-(diethylamino)ethyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-78-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898276-82-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(dimethylamino)ethoxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-83-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[3-phenyl-5-isoxazolyl)methyl]amino]-, methyl ester (CA INDEX NAME)




RN 898276-93-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898277-00-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[3-bromo-5-isoxazolyl)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898277-06-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898277-12-8 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-cyclohexyl-5-isoxazolyloxy)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl- (CA INDEX NAME)




RN 898277-37-7 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N6-(5-cyclopropyl-1H-pyrazol-3-yl)-N4,N4-dimethyl-N2-[(3-phenyl-5-isoxazolyloxy)methyl]- (CA INDEX NAME)




RN 898277-56-0 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-cyclohexyl-5-isoxazolyloxy)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898277-62-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(2-methyl-5-thiazolyl)methyl]- (CA INDEX NAME)




RN 898277-64-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopentyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898277-65-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-furanylmethyl)- (CA INDEX NAME)




RN 898277-68-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(5-methyl-2-furanyl)methyl]- (CA INDEX NAME)




RN 898277-74-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 898277-76-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-phenylethyl)- (CA INDEX NAME)




RN 898277-78-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(4-chlorophenyl)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898277-92-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[2-(2-thienyl)ethyl]- (CA INDEX NAME)




RN 898277-93-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclohexyl-1H-pyrazol-3-yl)-6-methyl-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898278-04-1 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 898278-05-2 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl- (CA INDEX NAME)






RN 898278-06-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-thiazolylmethyl)- (CA INDEX NAME)




RN 898278-10-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[4-(dimethylamino)phenyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898278-12-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(2-chlorophenyl)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898278-13-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[4-(4-methyl-1-piperazinyl)phenyl]methyl]- (CA INDEX NAME)




RN 898278-14-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3,5-dimethoxyphenyl)methyl]- (CA INDEX NAME)




RN 898278-15-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(phenylmethyl)- (CA INDEX NAME)




RN 898278-16-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-phenylpropyl)- (CA INDEX NAME)




RN 898278-20-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(3-cyclohexyl-5-isoxazolyl)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 898278-24-5 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(4-piperidinylmethyl)- (CA INDEX NAME)



RN 898278-25-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 898278-27-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 898278-29-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(2-chlorophenyl)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-methyl- (CA INDEX NAME)




RN 898278-31-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(2,5-dimethoxyphenyl)methyl]- (CA INDEX NAME)




RN 898278-32-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(2-methoxyphenyl)methyl]-6-methyl- (CA INDEX NAME)




RN 898278-33-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 898278-43-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[2-(2-thienyl)-4-thiazolyl]methyl]- (CA INDEX NAME)




RN 898278-50-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[2-(3-chlorophenyl)ethyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898278-54-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[2-(4-chlorophenyl)ethyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898278-59-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898278-63-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[2-(2,4-dichlorophenyl)ethyl]- (CA INDEX NAME)




RN 898278-66-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(4-methoxyphenyl)-5-isoxazolyl]methyl]-6-methyl- (CA INDEX NAME)




RN 898278-68-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[2-(3,4-dimethoxyphenyl)ethyl]- (CA INDEX NAME)




RN 898278-69-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]-6-(phenylmethoxy)- (CA INDEX NAME)




RN 898278-71-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898278-74-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(2-furanyl)-1H-pyrazol-3-yl]-N2-(4-pyridinylmethyl)- (CA INDEX NAME)






RN 898278-75-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(2-furanyl)-1H-pyrazol-3-yl]-N2-[(1R)-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 898278-81-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[2-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)




RN 898278-86-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclohexyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898278-87-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 898278-89-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(4-methoxyphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898278-90-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(2-phenyl-2H-1,2,3-triazol-4-yl)methyl]- (CA INDEX NAME)




RN 898278-95-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(4-phenyl-2-thienyl)methyl]- (CA INDEX NAME)




RN 898278-96-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[2-(2-chlorophenyl)ethyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898278-99-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898279-01-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(4-methoxyphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898279-30-6 CAPLUS

CN 1H-Pyrazole-4-carbonitrile, 3-[[6-methyl-2-[[3-phenyl-5-isoxazolyl]methyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 898279-39-5 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-[[[5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 898279-42-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(diphenylmethyl)- (CA INDEX NAME)




RN 898279-46-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(3-phenyl-5-isoxazolyl)methyl]-N4-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898279-47-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[5-(4-chlorophenyl)-2-thienyl]methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898279-52-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3,3-diphenylpropyl)- (CA INDEX NAME)




RN 898279-53-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2,2-diphenylethyl)- (CA INDEX NAME)




RN 898279-58-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(1,2-diphenylethyl)- (CA INDEX NAME)




RN 898279-80-6 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-[3-(diethylamino)propyl]-N6-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898279-81-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-morpholinyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898279-82-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-methyl-1-piperazinyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898279-83-9 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 898279-84-0 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]-6-(1-piperazinyl)- (CA INDEX NAME)






RN 898279-86-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(4-fluorophenyl)-5-isoxazolyl]methyl]-6-methyl- (CA INDEX NAME)



RN 898279-87-3 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(4-morpholinyl)ethoxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898279-88-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[[ (2S)-1-methyl-2-pyrrolidinyl]methoxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 898279-89-5 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(3S)-3-methyl-1-piperazinyl]methoxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 898279-90-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(1-methyl-4-piperidinyl)oxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898279-91-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-morpholinyl)- (CA INDEX NAME)




RN 898279-92-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]-6-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 898279-93-1 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898279-95-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]-6-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)




RN 898279-96-4 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[2-(4-methyl-1-piperazinyl)ethyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898279-97-5 CAPLUS


CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]-N6-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)



RN 898279-98-6 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(3R)-3-methyl-1-piperazinyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 898280-00-7 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[2-(4-morpholinyl)ethyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-03-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(1-methyl-3-pyrrolidinyl)oxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898280-04-1 CAPLUS


CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]-N6-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 898280-05-2 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(1-methyl-3-piperidinyl)oxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)






RN 898280-06-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[2-(dimethylamino)ethoxy]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-07-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl)methyl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898280-08-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-(4-morpholinyl)- (CA INDEX NAME)




RN 898280-09-6 CAPLUS

CN 4-Pyrimidinecarboxamide, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[3-(3-phenyl-5-isoxazolyl)methyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 898280-10-9 CAPLUS

CN Methanone, [6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[ (3-phenyl-5-isoxazolyl)methyl]amino]-4-pyrimidinyl] (1-methyl-4-piperidinyl)- (CA INDEX NAME)




RN 898280-11-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[(5-phenyl-3-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-13-2 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(2-bromophenyl)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl- (CA INDEX NAME)




RN 898280-14-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-methyl-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 898280-15-4 CAPLUS


CN 4-Pyrimidinecarboxamide, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-N-[2-(4-methyl-1-piperazinyl)ethyl]-2-[[3-(phenyl-5-isoxazolyl)methyl]amino]- (CA INDEX NAME)



RN 898280-16-5 CAPLUS


CN 4-Pyrimidinecarboxamide, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-N-[3-

(diethylamino)propyl]-2-[[ (3-phenyl-5-isoxazolyl)methyl]amino]- (CA INDEX NAME)




RN 898280-17-6 CAPLUS

CN 4-Pyrimidinecarboxamide, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-N-[2-(diethylamino)ethyl]-2-[[ (3-phenyl-5-isoxazolyl)methyl]amino]- (CA INDEX NAME)



RN 898280-18-7 CAPLUS


CN 4-Pyrimidinecarboxamide, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[ (3-phenyl-5-isoxazolyl)methyl]amino]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)



RN 898280-20-1 CAPLUS


CN 4-Pyrimidinecarboxamide, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-N-[2-(4-morpholinyl)ethyl]-2-[[ (3-phenyl-5-isoxazolyl)methyl]amino]- (CA INDEX NAME)

NAME)




RN 898280-22-3 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(3-chlorophenyl)-5-isoxazolyl]methyl]-6-methyl-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 898280-25-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(3-chlorophenyl)-5-isoxazolyl]methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl- (CA INDEX NAME)




RN 898280-26-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(1H-imidazol-2-ylmethyl)-6-methyl- (CA INDEX NAME)




RN 898280-29-0 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[[3-(3-bromophenyl)-5-isoxazolyl]methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl- (CA INDEX NAME)



RN 898280-31-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-chloro-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 898280-42-7 CAPLUS  
 CN Methanone, [5-[[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-methyl-2-pyrimidinyl]amino]methyl]-3-isoxazolyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 898280-44-9 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-[(3R)-3-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.






RN 898280-45-0 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N6-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)




RN 898280-46-1 CAPLUS


CN 2,4,6-Pyrimidinetriamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N6-[2-(4-methyl-1-piperazinyl)ethyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898280-47-2 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinylmethyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-48-3 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[[4-(4-chlorophenyl)-2-thienyl]methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl- (CA INDEX NAME)




RN 898280-49-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-furanylmethyl)-6-methyl- (CA INDEX NAME)




RN 898280-50-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[(5-methyl-3-phenyl-4-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-55-2 CAPLUS

CN 4-Thiazolecarboxamide, N-[2-(3-chlorophenyl)ethyl]-2-[[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-methyl-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 898280-56-3 CAPLUS

CN 4-Thiazolecarboxamide, 2-[[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-methyl-2-pyrimidinyl]amino]methyl]-N-[2-(2-fluorophenyl)ethyl]- (CA INDEX NAME)




RN 898280-57-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[phenyl(4-phenyl-2-oxazolyl)methyl]- (CA INDEX NAME)




RN 898280-58-5 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[3-(diethylamino)propyl]-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898280-59-6 CAPLUS  
 CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[2-(diethylamino)ethyl]-N2-[3-(1-methylethyl)-5-isoxazolylmethyl]- (CA INDEX NAME)




RN 898280-60-9 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[3-(1-methylethyl)-5-isoxazolylmethyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(3S)-3-methyl-1-piperaziny]- (CA INDEX NAME)


Absolute stereochemistry.




RN 898280-62-1 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methyl-3-pyrrolidinyloxy)]-N2-[3-(phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898280-63-2 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-[(1-methyl-3-pyrrolidinyl)oxy]- (CA INDEX NAME)




RN 898280-64-3 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methyl-3-pyrrolidinyl)oxy]- (CA INDEX NAME)




RN 898280-65-4 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-[2-(diethylamino)ethyl]-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N6-[5-(1-methylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 898280-66-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 898280-67-6 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methyl-3-piperidinyl)oxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898280-68-7 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methyl-3-piperidinyl)oxy]- (CA INDEX NAME)




RN 898280-69-8 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)






RN 898280-70-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[(5-phenyl-1H-imidazol-2-yl)methyl]- (CA INDEX NAME)




RN 898280-71-2 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[2-(dimethylamino)ethoxy]-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 898280-72-3 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 898280-73-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[2-(4-morpholinyl)ethoxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-75-6 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-[3-(diethylamino)propyl]-N2-[[3-(1-methylethyl)-5-isoxazolyl)methyl]-N6-[5-(1-methylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 898280-76-7 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methyl-4-piperidinyl)oxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898280-77-8 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 898280-78-9 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 898280-79-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[3-(diethylamino)propyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-80-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl)methyl]-6-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 898280-81-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-[(1-methyl-3-piperidinyl)oxy]- (CA INDEX NAME)




RN 898280-82-5 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methyl-4-piperidinyl)oxy]- (CA INDEX NAME)



RN 898280-83-6 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]-6-(4-morpholinyl)- (CA INDEX NAME)




RN 898280-84-7 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898280-85-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-[(1-methyl-4-piperidinyl)oxy]- (CA INDEX NAME)




RN 898280-86-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(4-fluorophenyl)-5-isoxazolyl]methyl]-6-(4-morpholinyl)- (CA INDEX NAME)



RN 898280-87-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(4-fluorophenyl)-5-isoxazolyl]methyl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898280-88-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(4-




10/595,807

fluorophenyl)-5-isoxazolyl]methyl]-6-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 898280-89-2 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(4-fluorophenyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-morpholinyl)- (CA INDEX NAME)




RN 898280-90-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(4-fluorophenyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898280-91-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(4-fluorophenyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 898280-92-7 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 898280-93-8 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898280-94-9 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-(1-piperazinyl)- (CA INDEX NAME)




RN 898280-95-0 CAPLUS

CN Ethanone, 1-[4-[6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[3-(1-methylethyl)-5-isoxazolyl]methyl]amino]-4-pyrimidinyl]-1-piperazinyl]-  
(CA INDEX NAME)




RN 898280-96-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-[4-(methanesulfonyl)-1-piperazinyl]-  
(CA INDEX NAME)




RN 898280-97-2 CAPLUS

CN 1-Piperazinecarboxaldehyde, 4-[6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[3-(1-methylethyl)-5-isoxazolyl]methyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 898280-98-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-99-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(4-methyl-1-piperazinyl)-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-00-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-6-[2-(4-morpholinyl)ethoxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-01-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[[3-(4-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-02-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(3,4-difluorophenyl)-5-isoxazolyl]methyl]-6-methyl- (CA INDEX NAME)




RN 898281-03-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(2,4-difluorophenyl)-5-isoxazolyl]methyl]-6-methyl- (CA INDEX NAME)



RN 898281-04-4 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[[3-(2-pyrazinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 898281-05-5 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)






RN 898281-06-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-07-7 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-6-(4-methyl-1-piperazinyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898281-08-8 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)- (CA INDEX NAME)




RN 898281-09-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-N2-[[3-(4-pyrimidinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 898281-10-2 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(3-furanyl)-5-isoxazolyl]methyl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 898281-11-3 CAPLUS


CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 898281-12-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-13-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-14-6 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-bicyclo[2.2.1]hept-2-yl-N6-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 898281-15-7 CAPLUS


CN 2,4,6-Pyrimidinetriamine, N4-bicyclo[2.2.1]hept-2-yl-N6-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898281-16-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]-6-[(1R,4R)-5-(phenylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 898281-17-9 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl)methyl]-6-[(1R,4R)-5-(phenylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 898281-18-0 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-N2-[[3-(4-pyrimidinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 898281-19-1 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(dimethylamino)ethoxy]-N2-[[3-(4-pyrimidinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)

10/595,807




RN 898281-20-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(5-fluoro-2-pyridinyl)-5-isoxazolyl]methyl]-6-methyl- (CA INDEX NAME)



RN 898281-21-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(2-thienyl)-5-isoxazolyl]methyl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898281-22-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(2-thienyl)-5-isoxazolyl]methyl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




10/595,807

(dimethylamino)ethoxy]-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-23-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-N2-[[3-(5-pyrimidinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-24-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-N2-[[3-(5-pyrimidinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-25-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(diethylamino)ethoxy]-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-26-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 898281-27-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(diethylamino)ethoxy]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-28-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]-6-[2-(1-pyrrolidinyloxy)ethyl]- (CA INDEX NAME)




RN 898281-29-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-N2-[[3-(2-thiazolyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-30-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(dimethylamino)ethoxy]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-31-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[2-(dimethylamino)ethoxy]-N2-[(3-methyl-5-isoxazolyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898281-32-8 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[2-(diethylamino)ethoxy]-N2-[(3-methyl-5-isoxazolyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898281-33-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)-6-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 898281-34-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[2-(3-phenyl-5-isoxazolyl)ethyl]- (CA INDEX NAME)




RN 898281-35-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[1-(3-phenyl-5-isoxazolyl)ethyl]- (CA INDEX NAME)




RN 898281-36-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[1-(3-ethyl-5-isoxazolyl)methyl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898281-37-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[1-(3-ethyl-5-isoxazolyl)methyl]-6-(4-morpholinyl)- (CA INDEX NAME)




RN 898281-38-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(dimethylamino)ethoxy]-N2-[(3-ethyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-39-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(diethylamino)ethoxy]-N2-[(3-ethyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-40-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-ethyl-5-isoxazolyl)methyl]-6-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)



RN 898281-41-9 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[[3-(2-amino-4-pyrimidinyl)-5-isoxazolyl]methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 898281-42-0 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-ethyl-1-piperazinyl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)






RN 898281-43-1 CAPLUS

CN 4-Piperidineethanol, 1-[6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[3-(1-methylethyl)-5-isoxazolyl]methyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 898281-44-2 CAPLUS

CN 1-Piperazineethanol, 4-[6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[3-(1-methylethyl)-5-isoxazolyl]methyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 898281-47-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[4-(dimethylamino)phenyl]methyl]- (CA INDEX NAME)




RN 1001060-90-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3,4-dimethoxyphenyl)methyl]- (CA INDEX NAME)




RN 1001060-91-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[(4-phenyl-2-thiazolyl)methyl]- (CA INDEX NAME)




RN 1001060-92-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]- (CA INDEX NAME)




RN 1001060-93-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[2-(4-chlorophenyl)-5-thiazolyl]methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 1001060-94-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[2-(3-chlorophenyl)-5-thiazolyl]methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 1001060-95-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]-6-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 1001060-96-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-methyl-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1001060-97-4 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[3-phenyl-5-isoxazolyl)methyl]amino]-, butyl ester (CA INDEX NAME)




RN 1001060-98-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(1H-imidazol-5-ylmethyl)-6-methyl- (CA INDEX NAME)




RN 1001060-99-6 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N6-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)




RN 1001061-01-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(dimethylamino)ethoxy]-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 1001061-02-4 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[(3-phenyl-5-isoxazolyl)methyl]-6-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 1001061-03-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(3S)-3-methyl-1-piperazinyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 1001061-04-6 1001061-05-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(IGF1R and abl kinase modulators for treatment of cancer, and use with other therapies)


RN 1001061-04-6 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-[2-(diethylamino)ethyl]-N6-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 1001061-05-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[[3-(3-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




IT 898281-46-4P 898281-49-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(IGF1R and abl kinase modulators for treatment of cancer, and use with other therapies)


RN 898281-46-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[[3-(3-phenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 898281-49-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



10/595,807



L7 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2008:10164 CAPLUS  
 DN 148:121723  
 TI Pyrimidine derivatives useful in the treatment of cancer and their  
 preparation  
 IN Buttar, David; Foote, Kevin Michael; Nowak, Thorsten; Rudge, David Alan;  
 Theoclitou, Maria-Elena; Thomas, Andrew Peter  
 PA AstraZeneca AB, Swed.; AstraZeneca UK Limited  
 SO PCT Int. Appl., 385 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2008001070	A1	20080103	WO 2007-GB2381	20070627
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2007263655	A1	20080103	AU 2007-263655	20070627
	CA 2654852	A1	20080103	CA 2007-2654852	20070627
	US 20080004302	A1	20080103	US 2007-769417	20070627
	EP 2044063	A1	20090408	EP 2007-733374	20070627
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
	NO 2008005217	A	20090112	NO 2008-5217	20081215
	MX 2008016523	A	20090119	MX 2008-16523	20081219
	IN 2008MN02748	A	20090320	IN 2008-MN2748	20081224
	KR 2009024270	A	20090306	KR 2009-701201	20090120
	CN 101501030	A	20090805	CN 2007-80029896	20090211
PRAI	US 2006-818259P	P	20060630		
	US 2007-908428P	P	20070328		
	WO 2007-GB2381	W	20070627		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 148:121723

AB There is provided a compound of formula I: processes for the manufacture thereof,

pharmaceutical compns. thereof and uses in therapy. Compds. of formula I wherein R1 is (un)substituted C1-6 alkyl, (un)substituted C2-6 alkenyl, (un)substituted 4- to 6-membered heterocyclyl, etc.; R2 is H, and (un)substituted C1-3 alkyl; R3 is (un)substituted C1-5 alkyl, (un)substituted C3-5 cycloalkyl, CO<sub>2</sub>H, CN, etc.; R4 is H (un)substituted C1-6 alkyl, (un)substituted C1-6 alkenyl, (un)substituted C1-6 alkynyl, etc.; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by amidation of 2-chloro-N-(5-methyl-1H-pyrazol-3-yl)pyrimidin-4-amine with (3-methoxyisoxazol-5-yl)methanamine. All the invention compds. were

1000894-54-1P

(drug candidate and intermediate; preparation of pyrimidine derivs. useful in the treatment of cancer)

1000894-54-1 CAPLUS

Benzoic acid, 3-[[[5-[[2-[[3-methyl-5-isoxazolyl)methyl]amino]-4-pyrimidinyl]amino]-1H-pyrazol-3-yl]oxy)methyl]-, methyl ester, hydrochloride (1:1) (CA INDEX NAME)

Cc1ccc(COc2cc[nH]2)cc1CNCCc3cc4c(c[nH]3)C=C(C)O4
$$\text{MeO}-\text{C} \begin{array}{l} \diagup \\ \parallel \\ \text{O} \end{array}$$

● HCl

IT	1000892-87-4P	1000892-89-6P	1000892-91-0P
	1000892-92-1P	1000892-94-3P	1000892-96-5P
	1000892-98-7P	1000893-00-4P	1000893-02-6P


1000893-04-8P	1000893-06-0P	1000893-08-2P
1000893-10-6P	1000893-12-8P	1000893-14-0P
1000893-16-2P	1000893-18-4P	1000893-20-8P
1000893-22-0P	1000893-24-2P	1000893-26-4P
1000893-28-6P	1000893-30-0P	1000893-32-2P
1000893-34-4P	1000893-36-6P	1000893-42-4P
1000893-43-5P	1000893-45-7P	1000893-47-9P
1000893-49-1P	1000893-50-4P	1000893-52-6P
1000893-54-8P	1000893-56-0P	1000893-58-2P
1000893-60-6P	1000893-62-8P	1000893-64-0P
1000893-67-3P	1000893-68-4P	1000893-69-5P
1000893-70-8P	1000893-71-9P	1000893-73-1P
1000893-75-3P	1000893-77-5P	1000893-78-6P
1000893-79-7P	1000893-81-1P	1000893-83-3P
1000893-84-4P	1000893-85-5P	1000893-86-6P
1000893-88-8P	1000893-90-2P	1000893-94-6P
1000893-95-7P	1000893-98-0P	1000893-99-1P
1000894-01-8P	1000894-02-9P	1000894-03-0P
1000894-04-1P	1000894-05-2P	1000894-07-4P
1000894-09-6P	1000894-10-9P	1000894-12-1P
1000894-14-3P	1000894-16-5P	1000894-17-6P
1000894-19-8P	1000894-21-2P	1000894-23-4P
1000894-25-6P	1000894-27-8P	1000894-28-9P
1000894-30-3P	1000894-32-5P	1000894-34-7P
1000894-36-9P	1000894-38-1P	1000894-40-5P
1000894-42-7P	1000894-44-9P	1000894-46-1P
1000894-48-3P	1000894-50-7P	1000894-52-9P
1000894-57-4P	1000894-59-6P	1000894-61-0P
1000894-63-2P	1000894-65-4P	1000894-66-5P
1000894-68-7P	1000894-70-1P	1000894-72-3P
1000894-74-5P	1000894-76-7P	1000894-77-8P
1000894-78-9P	1000894-80-3P	1000894-82-5P
1000894-84-7P	1000894-86-9P	1000894-88-1P
1000894-90-5P	1000894-91-6P	1000894-92-7P
1000894-94-9P	1000894-95-0P	1000894-96-1P
1000894-97-2P	1000894-98-3P	1000894-99-4P
1000895-00-0P	1000895-02-2P	1000895-03-3P
1000895-04-4P	1000895-05-5P	1000895-07-7P
1000895-09-9P	1000895-10-2P	1000895-11-3P
1000895-12-4P	1000895-13-5P	1000895-14-6P
1000895-15-7P	1000895-16-8P	1000895-17-9P
1000895-18-0P	1000895-19-1P	1000895-20-4P
1000895-21-5P	1000895-22-6P	1000895-23-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrimidine derivs. useful in the treatment of cancer)


RN 1000892-87-4 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 1000892-89-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-methyl-N2-[(3-methyl-5-isoxazolyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 1000892-91-0 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-cyclopropyl-5-isoxazolyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 1000892-92-1 CAPLUS

CN 3-Isioxazolecarboxamide, 5-[[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1000892-94-3 CAPLUS

CN 1H-Pyrazole-3-methanol, 5-[[2-[[[(3-methyl-5-isoxazolyl)methyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 1000892-96-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-(5-propyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 1000892-98-7 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-cyclopropyl-5-isoxazolyl)methyl]-N4-(5-propyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 1000893-00-4 CAPLUS

CN 3-Isioxazolecarboxamide, 5-[[[4-[(5-propyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1000893-02-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000893-04-8 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-cyclopropyl-5-isoxazolyl)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 1000893-06-0 CAPLUS

CN 3-Isioxazolecarboxamide, 5-[[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1000893-08-2 CAPLUS

CN 3-Isioxazolecarboxamide, 5-[[[4-[[5-(hydroxymethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1000893-10-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopentyl-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000893-12-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopentyl-1H-pyrazol-3-yl)-N2-[(3-cyclopropyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000893-14-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopentyl-1H-pyrazol-3-yl)-N2-[[3-(tetrahydro-2-furanyl)-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000893-16-2 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-cyclopropyl-5-isoxazolyl)methyl]-N4-[5-(2-methylpropyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1000893-18-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000893-20-8 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-cyclopropyl-5-isoxazolyl)methyl]-N4-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1000893-22-0 CAPLUS

CN 3-Isoxazolecarboxamide, 5-[[[4-[[5-(3-methoxypropyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)



RN 1000893-24-2 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(3-ethoxypropyl)-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 1000893-26-4 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[(3-cyclopropyl-5-isoxazolyl)methyl]-N4-[5-(3-ethoxypropyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)






RN 1000893-28-6 CAPLUS

CN 3-Isoxazolecarboxamide, 5-[[[4-[[5-(3-ethoxypropyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)



RN 1000893-30-0 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[(3-cyclobutyl-5-isoxazolyl)methyl]-N4-[5-(3-methoxypropyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1000893-32-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-[2-(4-methoxyphenyl)ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1000893-34-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[(3-cyclopropyl-5-isoxazolyl)methyl]-N4-[5-[2-(4-methoxyphenyl)ethyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)


10/595,807




RN 1000893-36-6 CAPLUS

CN 3-Isoxazolecarboxamide, 5-[[[4-[[5-[2-(4-methoxyphenyl)ethyl]-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1000893-42-4 CAPLUS  
 CN 3-Isoxazolecarboxamide, 5-[[[4-[[5-[2-(3-methoxyphenyl)ethyl]-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1000893-43-5 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-[5-(2-phenylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)


10/595,807




RN 1000893-45-7 CAPLUS  
CN 2,4-Pyrimidinediamine, N4-[5-[2-(2-methoxyphenyl)ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)




RN 1000893-47-9 CAPLUS  
CN 2,4-Pyrimidinediamine, N4-[5-[2-(4-methoxyphenyl)ethyl]-1H-pyrazol-3-yl]-N2-[[3-(2-pyrimidinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 1000893-49-1 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[5-[2-(3-methoxyphenyl)ethyl]-1H-pyrazol-3-yl]-N2-[[3-(2-pyrimidinyl)-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 1000893-50-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-[5-(phenoxyethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1000893-52-6 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[(3-cyclopropyl-5-isoxazolyl)methyl]-N4-[5-(phenoxyethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 1000893-54-8 CAPLUS


CN 3-Isioxazolecarboxamide, 5-[[[4-[[5-(phoxymethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1000893-56-0 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-[5-[2-[4-(phenylmethoxy)phenyl]ethyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)

PAGE 1-A






RN 1000893-58-2 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-[5-[2-[3-(phenylmethoxy)phenyl]ethyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1000893-60-6 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-[5-[2-[2-(phenylmethoxy)phenyl]ethyl]-1H-pyrazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)





RN 1000893-62-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-[2-[3-(2-methoxyethoxy)phenyl]ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000893-64-0 CAPLUS

CN Phenol, 3-[2-[5-[[2-[(3-methyl-5-isoxazolyl)methyl]amino]-4-


10/595,807

pyrimidinyl]amino]-1H-pyrazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1000893-67-3 CAPLUS

CN 1,3-Benzenediol, 5-[2-[5-[[2-[(3-methyl-5-isoxazolyl)methyl]amino]-4-pyrimidinyl]amino]-1H-pyrazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1000893-68-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-[(3,5-dimethoxyphenoxy)methyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 1000893-69-5 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-[2-(2,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




10/595,807

RN 1000893-70-8 CAPLUS  
CN 2,4-Pyrimidinediamine, N4-[5-[2-(3,4-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● HCl

RN 1000893-71-9 CAPLUS  
CN 2,4-Pyrimidinediamine, N4-[5-[2-(4-methoxy-2-methylphenyl)ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1000893-73-1 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[5-[2-[3-fluoro-5-(trifluoromethyl)phenyl]ethyl]-  
 1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000893-75-3 CAPLUS

CN 3-Isoxazolecarboxamide, 5-[[[4-[[5-(2-phenylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1000893-77-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-[5-[2-[3-(trifluoromethoxy)phenyl]ethyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1000893-78-6 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-[5-[2-(3-methylphenyl)ethyl]-1H-pyrazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 1000893-79-7 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[5-[2-(3-bromophenyl)ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)




RN 1000893-81-1 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[5-[2-(1,3-benzodioxol-5-yl)ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000893-83-3 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-[5-[2-[3-(4-morpholinyl)phenyl]ethyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)






RN 1000893-84-4 CAPLUS

CN Phenol, 3-[2-[5-[[2-[(3-cyclopropyl-5-isoxazolyl)methyl]amino]-4-pyrimidinyl]amino]-1H-pyrazol-3-yl]ethyl]- (CA INDEX NAME)



RN 1000893-85-5 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-[2-(3-chloro-5-fluorophenyl)ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000893-86-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-[2-[3-(aminomethyl)phenyl]ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1000893-88-8 CAPLUS  
 CN Benzamide, N,N-dimethyl-3-[2-[5-[[2-[[ (3-methyl-5-isoxazolyl)methyl]amino]-4-pyrimidinyl]amino]-1H-pyrazol-3-yl]ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1000893-90-2 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[5-[2-(2,4-dimethoxy-5-pyrimidinyl)ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1000893-94-6 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[5-[2-(5-fluoro-2-methoxy-4-pyridinyl)ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]-, hydrochloride (1:1)  
 (CA INDEX NAME)



RN 1000893-95-7 CAPLUS

CN Phenol, 3-[2-[5-[[2-[[[3-[(dimethylamino)methyl]-5-isoxazolyl]methyl]amino]-4-pyrimidinyl]amino]-1H-pyrazol-3-yl]ethyl]- (CA INDEX NAME)




RN 1000893-98-0 CAPLUS


CN 3-Isioxazolecarboxamide, 5-[[[4-[[5-[2-(3-hydroxyphenyl)ethyl]-1H-pyrazol-3-

yl]amino]-2-pyrimidinyl]amino]methyl]-N-methyl- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 1000893-99-1 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000894-01-8 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[(3-cyclopropyl-5-isoxazolyl)methyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1000894-02-9 CAPLUS

CN 2,4-Pyrimidinediamine, 6-methyl-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000894-03-0 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-cyclopropyl-5-isoxazolyl)methyl]-6-methyl-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1000894-04-1 CAPLUS

CN 2,4-Pyrimidinediamine, 6-methoxy-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000894-05-2 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-cyclopropyl-5-isoxazolyl)methyl]-6-methoxy-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1000894-07-4 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-[5-(phenylmethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 1000894-09-6 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-[(3,5-dimethoxyphenyl)methoxy]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 1000894-10-9 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-[(3-ethylphenyl)methoxy]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)






RN 1000894-12-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(2-methoxy-1-methylethoxy)-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000894-14-3 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-cyclopropyl-5-isoxazolyl)methyl]-N4-[5-(2-methoxy-1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1000894-16-5 CAPLUS

CN 3-Isoxazolecarboxylic acid, 5-[[[4-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]-, ethyl ester (CA INDEX NAME)




RN 1000894-17-6 CAPLUS

CN 3-Isoxazolecarboxamide, 5-[[[4-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1000894-19-8 CAPLUS

CN 3-Isoxazolecarboxamide, N-methyl-5-[[[4-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1000894-21-2 CAPLUS

CN 3-Isoxazolecarboxamide, N,N-dimethyl-5-[[[4-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1000894-23-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-N2-[[3-(5-pyrimidinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 1000894-25-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-N2-[[3-(2-pyrimidinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 1000894-27-8 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-N2-[[3-(tetrahydro-3-furanyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 1000894-28-9 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-N2-[[3-

(tetrahydro-2-furanyl)-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000894-30-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-N2-[[3-(tetrahydro-2H-pyran-4-yl)-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 1000894-32-5 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-ethoxy-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 1000894-34-7 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-[5-[[3-(4-morpholinyl)phenyl]methoxy]-1H-pyrazol-3-yl]- (CA INDEX NAME)

10/595,807




RN 1000894-36-9 CAPLUS  
 CN Phenol, 3-[[[3-[[2-[[[(3-methyl-5-isoxazolyl)methyl]amino]-4-pyrimidinyl]amino]-1H-pyrazol-5-yl]oxy]methyl]-, 1-methanesulfonate (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1000894-38-1 CAPLUS  
 CN Carbamic acid, N-[3-[[[5-[[2-[[[(3-methyl-5-isoxazolyl)methyl]amino]-4-pyrimidinyl]amino]-1H-pyrazol-3-yl]oxy]methyl]phenyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1000894-40-5 CAPLUS  
 CN Methanone, [3-[[[5-[[2-[[[(3-methyl-5-isoxazolyl)methyl]amino]-4-pyrimidinyl]amino]-1H-pyrazol-3-yl]oxy]methyl]phenyl]-4-morpholinyl- (CA INDEX NAME)

10/595,807




RN 1000894-42-7 CAPLUS  
 CN Benzamide, N-methyl-3-[[[5-[[2-[[[(3-methyl-5-isoxazolyl)methyl]amino]-4-pyrimidinyl]amino]-1H-pyrazol-3-yl]oxy]methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1000894-44-9 CAPLUS


CN Benzonitrile, 3-[[[5-[[2-[[[(3-methyl-5-isoxazolyl)methyl]amino]-4-pyrimidinyl]amino]-1H-pyrazol-3-yl]oxy]methyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 1000894-46-1 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-[(3-chlorophenyl)methoxy]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)





RN 1000894-48-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-[(3-fluorophenyl)methoxy]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)




RN 1000894-50-7 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[3-methyl-5-isoxazolyl)methyl]-N4-[5-[[3-


10/595,807

(trifluoromethyl)phenyl]methoxy]-1H-pyrazol-3-yl]-, hydrochloride (1:1)  
(CA INDEX NAME)




RN 1000894-52-9 CAPLUS  
CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-[5-[[4-(trifluoromethyl)phenyl]methoxy]-1H-pyrazol-3-yl]-, hydrochloride (1:1)  
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● HCl

RN 1000894-57-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[5-[(4-ethoxy-3-methoxyphenyl)methoxy]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1000894-59-6 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[5-[(4-fluoro-3-methoxyphenyl)methoxy]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]-, hydrochloride (1:1)  
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● HCl

RN 1000894-61-0 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-[5-(2-phenoxyethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1000894-63-2 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[(3-cyclobutyl-5-isoxazolyl)methyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1000894-65-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[(3-cyclopropyl-5-isoxazolyl)methyl]-N4-[5-(phenylmethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 1000894-66-5 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-[5-(2-thienyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1000894-68-7 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[5-(2-furanyl)-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000894-70-1 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-[5-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)ethyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1000894-72-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-[2-(2-furanyl)ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000894-74-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(3-furanylmethoxy)-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000894-76-7 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-[5-[2-(tetrahydro-3-furanyl)ethyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1000894-77-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-[2-(3-furanyl)ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 1000894-78-9 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[(3-cyclopropyl-5-isoxazolyl)methyl]-N4-[5-[2-(2-furanyl)ethyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 1000894-80-3 CAPLUS




CN 3-Isoxazolecarboxamide, 5-[[[4-[[5-[2-(2-furanyl)ethyl]-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)



RN 1000894-82-5 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-[2-(2-furanyl)ethyl]-1H-pyrazol-3-yl]-N2-[[3-(2-pyrimidinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 1000894-84-7 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-[5-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)

10/595,807




RN 1000894-86-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-[5-[2-(3-pyridinyl)ethyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1000894-88-1 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-[5-[2-(4-pyridinyl)ethyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1000894-90-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-[5-[2-(4-methyl-3-thienyl)ethyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1000894-91-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-[2-(1,3-dimethyl-1H-pyrazol-5-yl)ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000894-92-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-[2-(1-methyl-1H-imidazol-2-yl)ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 1000894-94-9 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[(3-cyclopropyl-5-isoxazolyl)methyl]-N4-[5-(2-furanyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1000894-95-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-[2-[5-[(dimethylamino)methyl]-2-furanyl]ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)

10/595,807




RN 1000894-96-1 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[5-[2-[3-(1-methylethoxy)phenyl]ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000894-97-2 CAPLUS  
 CN 3-Isoxazolecarboxamide, 5-[[[4-[[5-[2-[3-(cyclopropylmethoxy)phenyl]ethyl]-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1000894-98-3 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[5-[2-(2,6-dimethoxy-4-pyridinyl)ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000894-99-4 CAPLUS

2,4-Pyrimidinediamine, N4-[5-[2-(3-aminophenyl)ethyl]-1H-pyrazol-3-yl]-N2-  
[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000895-00-0 CAPLUS

CN 3-Isoxazolecarboxamide, 5-[[[4-[[5-[2-(3-chloro-5-methoxyphenyl)ethyl]-1H-

NC(=O)c1cc(CNCC2=CN=CN=C2)nc1


RN	1000895-02-2	CAPLUS
CN	2,4-Pyrimidinediamine, N2-[[3-[(dimethylamino)methyl]-5-isoxazolyl]methyl]-N4-[5-[2-(5-methoxy-3-pyridinyl)ethyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)	





RN 1000895-03-3 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-[2-(5-methoxy-2-thienyl)ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 1000895-04-4 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-[2-(2-methoxy-5-thiazolyl)ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)

10/595,807



RN 1000895-05-5 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-[(3-methoxy-5-methylphenyl)methoxy]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000895-07-7 CAPLUS

CN Benzamide, 3-methoxy-N-methyl-5-[2-[5-[[2-[(3-methyl-5-isoxazolyl)methyl]amino]-4-pyrimidinyl]amino]-1H-pyrazol-3-yl]ethyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1000895-09-9 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-[5-[2-[3-(2-pyrimidinyl)oxy]phenyl]ethyl]-1H-pyrazol-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 1000895-10-2 CAPLUS


CN 2-(1H)-Pyridinone, 6-[2-[5-[[2-[(3-methyl-5-isoxazolyl)methyl]amino]-4-pyrimidinyl]amino]-1H-pyrazol-3-yl]ethyl]-, hydrochloride (1:2) (CA INDEX NAME)



RN 1000895-11-3 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-[(5-fluoro-2-methoxy-4-pyridinyl)methoxy]-1H-

pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000895-12-4 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[[3-[(dimethylamino)methyl]-5-isoxazolyl]methyl]-N4-[5-[2-(5-fluoro-2-methoxy-4-pyridinyl)ethyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1000895-13-5 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[5-[(4-methoxy-2-pyridinyl)methoxy]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 1000895-14-6 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[5-[2-(5-methoxy-3-pyridinyl)ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000895-15-7 CAPLUS  
 CN Acetamide, N-[3-methoxy-5-[2-[5-[[2-[[3-methyl-5-isoxazolyl)methyl]amino]-4-pyrimidinyl]amino]-1H-pyrazol-3-yl]ethyl]phenyl]- (CA INDEX NAME)




RN 1000895-16-8 CAPLUS  
 CN 3-Isoxazolecarboxamide, 5-[[[4-[[5-[2-[3-(1-methylethoxy)phenyl]ethyl]-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1000895-17-9 CAPLUS  
 CN Benzamide, N-methyl-3-[2-[5-[[2-[[3-methyl-5-isoxazolyl)methyl]amino]-4-pyrimidinyl]amino]-1H-pyrazol-3-yl]ethyl]- (CA INDEX NAME)



PAGE 1-A




PAGE 2-A




RN 1000895-18-0 CAPLUS  
 CN Benzamide, N,3-dimethyl-5-[2-[5-[[2-[[3-methyl-5-isoxazolyl)methyl]amino]-4-pyrimidinyl]amino]-1H-pyrazol-3-yl]ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1000895-19-1 CAPLUS  
 CN 2-Pyridinecarboxamide, 4-methoxy-N-methyl-6-[2-[5-[[2-[[ (3-methyl-5-isoxazolyl)methyl]amino]-4-pyrimidinyl]amino]-1H-pyrazol-3-yl]ethyl]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 1000895-20-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 1000895-21-5 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-N2-[[3-(3-methyl-3-oxetanyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 1000895-22-6 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylcyclopropyl)-5-isoxazolyl]methyl]-  
 N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 1000895-23-7 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-methoxy-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




IT 1000893-38-8P 1000893-40-2P 1000893-66-2P  
 1000893-72-0P 1000893-92-4P 1000893-96-8P  
 1000894-55-2P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (intermediate and drug candidate; preparation of pyrimidine derivs. useful in the treatment of cancer)  
 RN 1000893-38-8 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-[5-[2-(3-methoxyphenyl)ethyl]-1H-pyrazol-3-yl]-  
 N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000893-40-2 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-cyclopropyl-5-isoxazolyl)methyl]-N4-[5-[2-(3-methoxyphenyl)ethyl]-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 1000893-66-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000893-72-0 CAPLUS

CN Benzonitrile, 3-[2-[5-[[2-[(3-methyl-5-isoxazolyl)methyl]amino]-4-pyrimidinyl]amino]-1H-pyrazol-3-yl]ethyl]- (CA INDEX NAME)



RN 1000893-92-4 CAPLUS


CN 3-Isioxazolemethanol, 5-[[[4-[[5-[2-(3-methoxyphenyl)ethyl]-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 1000893-96-8 CAPLUS


CN 3-Isioxazolecarboxamide, 5-[[[4-[[5-[2-(3-methoxyphenyl)ethyl]-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]-N-methyl- (CA INDEX NAME)

PAGE 1-A






RN 1000894-55-2 CAPLUS  
 CN Benzoic acid, 3-[[[5-[[2-[[[(3-methyl-5-isoxazolyl)methyl]amino]-4-pyrimidinyl]amino]-1H-pyrazol-3-yl]oxy]methyl]- (CA INDEX NAME)



IT 1000895-81-7P 1000896-12-7P 1000896-32-1P  
 1000896-36-5P 1000896-38-7P 1000896-47-8P  
 1000896-96-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (intermediate; preparation of pyrimidine derivs. useful in the treatment of  
 cancer)


RN 1000895-81-7 CAPLUS  
 CN 3-Isioxazolemethanol, 5-[[[4-[[3-[2-(3-hydroxyphenyl)ethyl]-1H-pyrazol-5-yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)





RN 1000896-12-7 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-[2-(6-methoxy-2-pyridinyl)ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



RN 1000896-32-1 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-N2-[2-(6-methoxy-2-pyridinyl)ethyl]-, hydrochloride (1:1) (CA INDEX NAME)

[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000896-36-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 1000896-38-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N2-[(3-cyclopropyl-5-isoxazolyl)methyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 1000896-47-8 CAPLUS


CN 3-Isioxazolecarboxamide, 5-[[[5-bromo-4-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)



RN 1000896-96-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(3-cyclopropyl-5-isoxazolyl)methyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)

10/595,807




IT 1000896-94-5P

RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prophetic intermediate; preparation of pyrimidine derivs. useful in the treatment of cancer)

RN 1000896-94-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-[2-(1,3-benzodioxol-5-yl)ethyl]-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2007:483093 CAPLUS  
 DN 146:482083  
 TI 4-(Pyrazol-3-ylamino)pyrimidine derivatives as tyrosine kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer  
 IN Feng, Xiaomei; Guan, Huiping; Kan, Ying; Ioannidis, Stephanos; Peng, Bo; Su, Meic; Wang, Bin; Wang, Tao; Zhang, Hai-Jun  
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SO PCT Int. Appl., 92pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

common inventors

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007049041	A1	20070503	WO 2006-GB3978	20061026
W: AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006307657	A1	20070503	AU 2006-307657	20061026
CA 2626375	A1	20070503	CA 2006-2626375	20061026
EP 1945631	A1	20080723	EP 2006-794902	20061026
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
JP 2009513615	T	20090402	JP 2008-537190	20061026
NO 2008001893	A	20080520	NO 2008-1893	20080422
US 20080287475	A1	20081120	US 2008-91382	20080424
MX 2008005398	A	20080924	MX 2008-5398	20080425
IN 2008DN03467	A	20090320	IN 2008-DN3467	20080426
KR 2008063846	A	20080707	KR 2008-711816	20080516
CN 101346371	A	20090114	CN 2006-80048845	20080623
PRAI US 2005-731299P	P	20051028		
US 2006-803061P	P	20060524		
WO 2006-GB3978	W	20061026		

## ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OS MARPAT 146:482083

AB This invention relates to compds. having the formula I and to their pharmaceutical compns. and to their methods of use. These compds. provide a treatment for cancer. Compds. of formula I wherein R1 is H, OH, amino, mercapto, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, etc.; R2 and R3 are independently H, halo, NO2, CN, OH, amino, carboxy, carbamoyl, mercapto, sulfamoyl, C1-6 alkyl, etc.; R4 is CN, carboxy, carbamoyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkanoyl, etc.; R5 is halo, NO2, CN< OH, amino, carboxyl, carbamoyl, mercapto, sulfamoyl, C1-6 alkyl, etc.; n is 0, 1, 2, and 3; and their pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by substitution of

2,5-dichloro-N-(5-isopropoxy-1H-pyrazol-3-yl)pyrimidin-4-amine with 1-(5-fluoropyrimidin-2-yl)amine; the resulting racemic II underwent HPLC resolution to give the (R)- and (S)-II. All the invention compds. were evaluated for their tyrosine kinase inhibitory activity. From the assay, it was determined that the rac-II exhibited an IC<sub>50</sub> value of 0.033  $\mu$ M against Trk.


IT 935666-95-8P 935667-11-1P 935667-13-3P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate and intermediate; preparation of (pyrazolylamino)pyrimidine derivs. as tyrosine kinase inhibitors useful in the treatment of cancers)  
 RN 935666-95-8 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-chloro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 935667-11-1 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-chloro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methoxy-1H-pyrazol-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 935667-13-3 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5,6-dichloro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methoxy-1H-pyrazol-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.




IT 935666-84-5P

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)  
(drug candidate; preparation of (pyrazolylamino)pyrimidine derivs. as tyrosine kinase inhibitors useful in the treatment of cancers)

RN 935666-84-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)



IT 935666-85-6P 935666-86-7P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of (pyrazolylamino)pyrimidine derivs. as tyrosine kinase inhibitors useful in the treatment of cancers)

RN 935666-85-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 935666-86-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1R)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT	935666-87-8P	935666-88-9P	935666-89-0P
	935666-90-3P	935666-91-4P	935666-92-5P
	935666-93-6P	935666-94-7P	935666-96-9P
	935666-97-0P	935666-98-1P	935666-99-2P
	935667-00-8P	935667-01-9P	935667-02-0P
	935667-03-1P	935667-04-2P	935667-05-3P
	935667-06-4P	935667-07-5P	935667-08-6P
	935667-09-7P	935667-10-0P	935667-12-2P
	935667-14-4P	935667-15-5P	935667-16-6P
	935667-17-7P	935667-18-8P	935667-19-9P
	935667-20-2P		


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of (pyrazolylamino)pyrimidine derivs. as tyrosine kinase inhibitors useful in the treatment of cancers)

RN 935666-87-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 935666-88-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 935666-89-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 935666-90-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methoxy-1H-pyrazol-3-yl)- (CA INDEX NAME)




Absolute stereochemistry.



RN 935666-91-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 935666-92-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-5-fluoro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 935666-93-6 CAPLUS

CN Methanesulfonamide, N-[5-chloro-2-[[ (1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]amino]-6-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-4-pyrimidinyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 935666-94-7 CAPLUS

CN Methanesulfonamide, N-[5-fluoro-2-[[ (1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]amino]-6-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-4-pyrimidinyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 935666-96-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 935666-97-0 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-5-methyl-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 935666-98-1 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)-5-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 935666-99-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1R)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 935667-00-8 CAPLUS

CN Sulfamide, N-[5-chloro-2-[[ (1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-4-pyrimidinyl]-N,N',N'-trimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 935667-01-9 CAPLUS

CN Sulfamide, N-[5-chloro-2-[[ (1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]amino]-6-[(5-methoxy-1H-pyrazol-3-yl)amino]-4-pyrimidinyl]-N,N',N'-trimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 935667-02-0 CAPLUS

CN Methanesulfonamide, N-[5-chloro-2-[[1-(5-fluoro-2-pyrimidinyl)ethyl]amino]-6-[(5-methoxy-1H-pyrazol-3-yl)amino]-4-pyrimidinyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 935667-03-1 CAPLUS

CN Sulfamide, N-[2-[[1-(5-fluoro-2-pyrimidinyl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-4-pyrimidinyl]-N,N',N'-trimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 935667-04-2 CAPLUS

CN Methanesulfonamide, N-[5-fluoro-2-[[ (1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-4-pyrimidinyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 935667-05-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(dimethylamino)-1H-pyrazol-3-yl]-5-fluoro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 935667-06-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(dimethylamino)-1H-pyrazol-3-yl]-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 935667-07-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-5-nitro- (CA INDEX NAME)

Absolute stereochemistry.




RN 935667-08-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-

N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 935667-09-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methoxy-1H-pyrazol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 935667-10-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-[5-(2,2,2-trifluoroethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 935667-12-2 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methoxy-1H-pyrazol-3-yl)-6-(4-morpholinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 935667-14-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methoxy-1H-pyrazol-3-yl)-6-(4-morpholinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 935667-15-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 935667-16-6 CAPLUS

CN 4-Pyrimidinecarbonitrile, 5-chloro-2-[[ (1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]amino]-6-[(5-methoxy-1H-pyrazol-3-yl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 935667-17-7 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methoxy-1H-pyrazol-3-yl)-6-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 935667-18-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N2-[(1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]-N4-(5-methoxy-1H-pyrazol-3-yl)-6-(4-morpholinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 935667-19-9 CAPLUS

CN Methanesulfonamide, N-[5-chloro-2-[[ (1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-4-pyrimidinyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 935667-20-2 CAPLUS

CN Sulfamide, N-[5-chloro-2-[[ (1S)-1-(5-fluoro-2-pyrimidinyl)ethyl]amino]-6-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-4-pyrimidinyl]-N,N',N'-trimethyl- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G	2	THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
RE.CNT	1	THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L7 ANSWER 13 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2006:1226353 CAPLUS  
 DN 146:7977  
 TI 3-(Pyrazol-3-ylamino)pyrimidines as Trk A kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of

Cancers  
 IN Wang, Bin; Wang, Tao  
 PA AstraZeneca AB, Swed.; AstraZeneca Uk Limited  
 SO PCT Int. Appl., 78pp.  
 CODEN: PIXXD2

DT Patent

LA English

common inventors

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006123113	A2	20061123	WO 2006-GB1760	20060512
	WO 2006123113	A3	20070104		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	AU 2006248780	A1	20061123	AU 2006-248780	20060512
	CA 2608009	A1	20061123	CA 2006-2608009	20060512
	EP 1899323	A2	20080319	EP 2006-727105	20060512
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR			
	JP 2008540622	T	20081120	JP 2008-511776	20060512
	NO 2007005647	A	20071213	NO 2007-5647	20071106
	IN 2007DN08679	A	20071214	IN 2007-DN8679	20071112
	ZA 2007009732	A	20081126	ZA 2007-9732	20071112
	MX 2007014328	A	20080212	MX 2007-14328	20071115
	US 20080287437	A1	20081120	US 2007-914492	20071115
	KR 2008015409	A	20080219	KR 2007-726987	20071120
	CN 101238116	A	20080806	CN 2006-80025767	20080114
PRAI	US 2005-681515P	P	20050516		
	US 2005-722282P	P	20050930		
	WO 2006-GB1760	W	20060512		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 146:7977; MARPAT 146:7977

AB This invention relates to compds. having the formula I and to their pharmaceutical compns. and to their methods of use. These compds. provide a treatment for cancer. Compds. of formula I wherein R1 is H, OH, amino, mercapto, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, etc.; R2 and R3 are independently H, halo, NO2, CN, OH, amino, carboxy, carbamoyl, mercapto, sulfamoyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, etc.; R4 is CN, carboxy, carbamoyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkanoyl, etc.; each R5 is independently halo, NO2, CN, OH, amino, carboxyl, carbamoyl, mercapto, sulfamoyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, etc.; n is 1, 2 and 3; and their pharmaceutically acceptable

salts are claimed. Example compound II was prepared by nucleophilic aromatic substitution of 5-bromo-2-chloro-4-(5-cyclopropyl-1H-pyrazol-3-ylamino)pyrimidine with (S)-1-(5-fluoropyridin-2-yl)ethanamine. All the invention compds. were evaluated for their Trk inhibitory activity. From the assay, it was determined that compound II exhibited an IC<sub>50</sub> value fo 0.005  $\mu$ M.


IT 915720-41-1P 915720-42-2P 915720-43-3P  
915720-44-4P 915720-45-5P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate and intermediate; preparation of pyrazolylaminopyrimidines  
Trk A kinase inhibitors and their use in the treatment and prophylaxis  
of cancer)

RN 915720-41-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-6-[(cis-2-phenyl-1,3-dioxan-5-yl)oxy]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 915720-42-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-6-[(cis-2-phenyl-1,3-dioxan-5-yl)oxy]-  
(CA INDEX NAME)


Absolute stereochemistry.



RN 915720-43-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-6-[[ (4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-44-4 CAPLUS


CN 2,4-Pyrimidinediamine, 6-chloro-5-fluoro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 915720-45-5 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5,6-dichloro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 915720-20-6P  
 RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)  
 (drug candidate; preparation of pyrazolylaminopyrimidines Trk A kinase inhibitors and their use in the treatment and prophylaxis of cancer)  
 RN 915720-20-6 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[1-(5-fluoro-6-methyl-2-pyridinyl)ethyl]- (CA INDEX NAME)



IT 915720-46-6P 915720-47-7P  
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (drug candidate; preparation of pyrazolylaminopyrimidines Trk A kinase inhibitors and their use in the treatment and prophylaxis of cancer)  
 RN 915720-46-6 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(5-fluoro-6-methyl-2-pyridinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 915720-47-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1R)-1-(5-fluoro-6-methyl-2-pyridinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT	915720-16-0P	915720-17-1P	915720-18-2P
	915720-19-3P	915720-21-7P	915720-22-8P
	915720-23-9P	915720-24-0P	915720-25-1P
	915720-26-2P	915720-27-3P	915720-28-4P
	915720-29-5P	915720-30-8P	915720-31-9P
	915720-32-0P	915720-33-1P	915720-34-2P
	915720-35-3P	915720-36-4P	915720-37-5P
	915720-38-6P	915720-39-7P	915720-40-0P
	915720-49-9P	915720-50-2P	915720-51-3P
	915720-53-5P	1107653-72-4P	


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of pyrazolylaminopyrimidines Trk A kinase inhibitors and their use in the treatment and prophylaxis of cancer)

RN 915720-16-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-17-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-18-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-5-fluoro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-19-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[1-


(5-fluoro-2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 915720-21-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-22-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-fluoro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-23-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-24-0 CAPLUS

CN 1,3-Propanediol, 2-[[5-chloro-2-[[[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]amino]-6-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-25-1 CAPLUS

CN 1,2-Propanediol, 3-[[5-chloro-2-[[[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]amino]-6-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-4-pyrimidinyl]amino]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-26-2 CAPLUS

CN 1,2-Propanediol, 3-[[5-fluoro-2-[[[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]amino]-6-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-4-pyrimidinyl]oxy]-, (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 915720-27-3 CAPLUS

CN 1,3-Propanediol, 2-[[5-fluoro-2-[[[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]amino]-6-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-4-pyrimidinyl]oxy]- (CA INDEX NAME)

Absolute stereochemistry.


10/595,807



RN 915720-28-4 CAPLUS

CN 1,3-Propanediol, 2-[[5-chloro-2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]amino]-6-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-4-pyrimidinyl]oxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-29-5 CAPLUS

CN 1,3-Propanediol, 2-[[2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]amino]-6-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-4-pyrimidinyl]oxy]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-30-8 CAPLUS

CN 1,2-Propanediol, 3-[[5-chloro-2-[[[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]amino]-6-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-4-pyrimidinyl]oxy]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-31-9 CAPLUS

CN 2,4,6-Pyrimidinetriamine, 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-32-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(3,5-difluoro-2-pyridinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-33-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(3,5-difluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 915720-34-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(1S)-1-(3,5-difluoro-2-pyridinyl)ethyl]-



N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-35-3 CAPLUS


CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(3,5-difluoro-2-pyridinyl)ethyl]-5-fluoro-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 915720-36-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[1-(3,5-difluoro-2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 915720-37-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-bromo-2-pyridinyl)ethyl]-5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-38-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-bromo-2-pyridinyl)ethyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-5-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-39-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(5-bromo-2-pyridinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-40-0 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[[ (4R)-2,2-dimethyl-1,3-dioxolan-4-yl]methoxy]-5-fluoro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 915720-49-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-(5-methoxy-1H-pyrazol-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 915720-50-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.


10/595,807



RN 915720-51-3 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 915720-53-5 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 915720-21-7

CMF C17 H19 Cl F N7 O

Absolute stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



RN 1107653-72-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 1149339-93-4


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrazolylaminopyrimidines Trk A kinase inhibitors and their use in the treatment and prophylaxis of cancer)

RN 1149339-93-4 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(5-fluoro-2-pyridinyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-6-[(cis-2-phenyl-1,3-dioxan-5-yl)oxy]- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G	7	THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
RE.CNT	6	THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2006:1155496 CAPLUS  
 DN 145:465701  
 TI Use of pyrazolyl-pyrimidine derivatives in the treatment of pain  
 IN Claesson, Alf  
 PA Astrazeneca AB, Swed.  
 SO PCT Int. Appl., 99pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006115452	A1	20061102	WO 2006-SE476	20060425
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	EP 1877057	A1	20080116	EP 2006-733332	20060425
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	JP 2008540335	T	20081120	JP 2008-508792	20060425
	US 20090005396	A1	20090101	US 2007-912268	20071022
	CN 101208093	A	20080625	CN 2006-80023038	20071226
PRAI	SE 2005-959	A	20050427		
	WO 2006-SE476	W	20060425		

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 145:465701

AB This invention relates to the use of a pyrazolyl-pyrimidine of the formula I, n = 0,1,2 or 3 in the manufacture of a medicament for use in the treatment or prophylaxis of pain. and to their pharmaceutical formulations and to their methods of use. Oral administration of (2R)-2-{[5-Chloro-4-(1H-pyrazol-5-ylamino)pyrimidin-2-yl]amino}-2-(4-fluorophenyl)ethanol at a dose of 80 µmol/kg significantly reduced the pain score induced by carrageenan monoarthritis within 5 h after administration. The animals did not show signs of side-effects.

IT 852441-69-1 852441-86-2 852441-88-4  
 852442-60-5 852442-62-7 852442-79-6  
 852442-83-2 852443-19-7 852443-24-4  
 852443-27-7 852443-47-1


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(use of pyrazolyl-pyrimidine derivs. in treatment of pain)

RN 852441-69-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852441-86-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852441-88-4 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 852442-60-5 CAPLUS

CN Benzenepropanol,  $\gamma$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-



yl)amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\gamma$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-62-7 CAPLUS

CN Benzeneethanol,  $\beta$ -[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-fluoro-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-79-6 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-83-2 CAPLUS

CN Benzenepropanamide,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro-N-methyl-, ( $\beta$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-19-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-24-4 CAPLUS

CN 1,3-Propanediol, 2-[[5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-27-7 CAPLUS

CN 1,3-Propanediol, 2-[[5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-47-1 CAPLUS

CN 1,3-Propanediol, 2-[[5-chloro-2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino]-6-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)  
 RE.CNT 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 15 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2006:841618 CAPLUS  
 DN 145:271544  
 TI Preparation of purine derivatives and analogs as antitumor agents  
 IN Lamb, Michelle; Mohr, Peter; Wang, Bin; Wang, Tao; Yu, Dingwei  
 PA AstraZeneca AB, Swed.; AstraZeneca UK Limited  
 SO PCT Int. Appl., 95pp.  
 CODEN: PIXXD2

DT Patent  
 LA English

common inventors

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006087530	A1	20060824	WO 2006-GB513	20060215
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2006215386	A1	20060824	AU 2006-215386	20060215
	AU 2006215386	B2	20090611		
	CA 2597813	A1	20060824	CA 2006-2597813	20060215
	EP 1853588	A1	20071114	EP 2006-709750	20060215
	EP 1853588	B1	20080618		
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
	AT 398613	T	20080715	AT 2006-709750	20060215
	JP 2008530190	T	20080807	JP 2007-555688	20060215
	ES 2308731	T3	20081201	ES 2006-709750	20060215
	NO 2007003788	A	20070903	NO 2007-3788	20070720
	ZA 2007006493	A	20080827	ZA 2007-6493	20070803
	MX 2007009843	A	20070823	MX 2007-9843	20070814
	CN 101119988	A	20080206	CN 2006-80005004	20070815
	IN 2007DN06857	A	20070921	IN 2007-DN6857	20070905
	KR 2007103773	A	20071024	KR 2007-720887	20070912
	US 20080176872	A1	20080724	US 2008-816374	20080110
	HK 1114375	A1	20090522	HK 2008-102715	20080307
PRAI	US 2005-653575P	P	20050216		
	US 2005-742138P	P	20051201		
	WO 2006-GB513	W	20060215		
	WO 2006-US513	W	20060215		

OS MARPAT 145:271544

AB Title compds. I [X, Y and Z independently = N or CR8; R1 and R2 independently = H, halo, NO<sub>2</sub>, CN, OH, etc.; R3 and R8 independently = H, halo, NH<sub>2</sub>, alkyl, etc.; R4 = H or (un)substituted alkyl; R5 and R6 = H, halo, NO<sub>2</sub>, CF<sub>3</sub>, etc.; R7 = substituted carbocycle or N-heterocycle; A = direct bond or (un)substituted alkylene]; and their pharmaceutically acceptable salts, are prepared and disclosed as antitumor agents. Thus, e.g., II was prepared via a multistep sequence employing a cyclization step with formamidine acetate to form purine ring. I act as antitumor agents

via inhibition of tyrosine kinases, particularly Trks. In Trk inhibition assays, selected example compds. possessed IC<sub>50</sub> values of 0.02, 0.022 and 0.015  $\mu$ M.

IT	852442-65-0P	852442-66-1P	852442-94-5P
	852442-95-6P	907203-55-8P	907203-56-9P
	907203-57-0P	907203-58-1P	907203-59-2P
	907203-60-5P	907203-71-8P	907203-72-9P
	907203-73-0P	907203-74-1P	907203-75-2P
	907203-76-3P		


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of purine derivs. and analogs as antitumor agents)

RN 852442-65-0 CAPLUS

CN Benzeneethanol,  $\beta$ -[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-nitro-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-66-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]-5-nitro- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-94-5 CAPLUS

CN 2,4,5-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-95-6 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-amino-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 907203-55-8 CAPLUS


CN Benzeneethanol,  $\beta$ -[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-methyl-5-nitro-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 907203-56-9 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(4-fluorophenyl)methyl]-5-nitro- (CA INDEX NAME)



RN 907203-57-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1R)-1-(4-fluorophenyl)ethyl]-5-nitro- (CA INDEX NAME)


Absolute stereochemistry.



RN 907203-58-1 CAPLUS

CN Benzeneethanol, 4-fluoro-β-[[4-[(5-methyl-1H-pyrazol-3-yl)amino]-5-nitro-2-pyrimidinyl]amino]-, (βR)- (CA INDEX NAME)


Absolute stereochemistry.






RN 907203-59-2 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[(1S)-1-(4-fluorophenyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]-5-nitro- (CA INDEX NAME)

Absolute stereochemistry.




RN 907203-60-5 CAPLUS  
 CN 4-Pyrimidinecarboxylic acid, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino]-5-nitro-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 907203-71-8 CAPLUS  
 CN Benzeneethanol,  $\beta$ -[[[5-amino-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-methyl-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 907203-72-9 CAPLUS


CN 2,4,5-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(4-fluorophenyl)methyl]- (CA INDEX NAME)



RN 907203-73-0 CAPLUS

CN 2,4,5-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1R)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 907203-74-1 CAPLUS

CN Benzeneethanol,  $\beta$ -[[[5-amino-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.


10/595,807



RN 907203-75-2 CAPLUS

CN 2,4,5-Pyrimidinetriamine, N2-[(1S)-1-(4-fluorophenyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 907203-76-3 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 5-amino-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

10/595,807

RE.CNT 3      THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 16 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2006:681435 CAPLUS  
 DN 145:137879  
 TI Pyrimidine derivative kinase modulators and therapeutic use  
 IN Chen, Jeff; Dalrymple, Lisa Esther; Epshteyn, Sergey; Forsyth, Timothy  
 Patrick; Huynh, Tai Phat; Ibrahim, Mohamed Abdulkader; Leahy, James W.;  
 Lewis, Gary Lee; Mann, Grace; Mann, Lary W.; Noguchi, Robin Tammie;  
 Ridgway, Brian Hugh; Sangalang, Joan Cruz; Schnepf, Kevin Luke; Shi, Xian;  
 Takeuchi, Craig Stacy; Williams, Matthew Alan; Nuss, John; Cheung, Atwood  
 K.  
 PA Exelixis, Inc., USA  
 SO PCT Int. Appl., 194 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006074057	A2	20060713	WO 2005-US47402	20051228
WO 2006074057	A3	20061026		
W:	AE, AG, AL, AM, AN, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
AU 2005322855	A1	20060713	AU 2005-322855	20051228
CA 2590110	A1	20060713	CA 2005-2590110	20051228
EP 1841760	A2	20071010	EP 2005-855893	20051228
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
JP 2008526759	T	20080724	JP 2007-549634	20051228
US 20080249079	A1	20081009	US 2008-722719	20080321
PRAI US 2004-640439P	P	20041230		
US 2005-704863P	P	20050801		
WO 2005-US47402	W	20051228		

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 145:137879; MARPAT 145:137879

AB The invention provides pyrimidine derivs. and methods for inhibition of kinases, more specifically IGF1R kinases. The invention also provides compds. and methods for inhibition of wildtype Abl. The invention provides compds. for modulating protein kinase enzymic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compds. of the invention inhibit, regulate and/or modulate kinase receptor signal transduction pathways related to the changes in cellular activities as mentioned above, and the invention includes compns. which contain these compds., and methods of using them to treat kinase-dependent diseases and conditions. Preparation of pyrimidine derivs. is included.

IT 543711-08-6 543711-24-6 543712-32-9


852441-70-4	852441-77-1	852441-78-2
898276-24-9	898276-26-1	898276-28-3
898276-29-4	898276-30-7	898276-32-9
898276-34-1	898276-37-4	898276-38-5
898276-39-6	898276-41-0	898276-43-2
898276-45-4	898276-61-4	898276-71-6
898276-72-7	898276-73-8	898276-78-3
898276-82-9	898276-83-0	898276-93-2
898277-00-4	898277-06-0	898277-12-8
898277-37-7	898277-56-0	898277-62-8
898277-64-0	898277-65-1	898277-68-4
898277-74-2	898277-76-4	898277-78-6
898277-92-4	898277-93-5	898278-04-1
898278-05-2	898278-06-3	898278-10-9
898278-12-1	898278-13-2	898278-14-3
898278-15-4	898278-16-5	898278-20-1
898278-24-5	898278-25-6	898278-27-8
898278-29-0	898278-31-4	898278-32-5
898278-33-6	898278-43-8	898278-50-7
898278-54-1	898278-59-6	898278-63-2
898278-66-5	898278-68-7	898278-69-8
898278-71-2	898278-74-5	898278-75-6
898278-76-7	898278-81-4	898278-86-9
898278-87-0	898278-89-2	898278-90-5
898278-95-0	898278-96-1	898278-99-4
898279-01-1	898279-12-4	898279-13-5
898279-14-6	898279-30-6	898279-39-5
898279-42-0	898279-46-4	898279-47-5
898279-52-2	898279-53-3	898279-58-8
898279-80-6	898279-81-7	898279-82-8
898279-83-9	898279-84-0	898279-86-2
898279-87-3	898279-88-4	898279-89-5
898279-90-8	898279-91-9	898279-92-0
898279-93-1	898279-95-3	898279-96-4
898279-97-5	898279-98-6	898279-99-7
898280-00-7	898280-03-0	898280-04-1
898280-05-2	898280-06-3	898280-07-4
898280-08-5	898280-09-6	898280-10-9
898280-11-0	898280-13-2	898280-14-3
898280-15-4	898280-16-5	898280-17-6
898280-18-7	898280-19-8	898280-20-1
898280-22-3	898280-23-4	898280-25-6
898280-26-7	898280-29-0	898280-31-4
898280-42-7	898280-44-9	898280-45-0
898280-46-1	898280-47-2	898280-48-3
898280-49-4	898280-50-7	898280-55-2
898280-56-3	898280-57-4	898280-58-5
898280-59-6	898280-60-9	898280-61-0
898280-62-1	898280-63-2	898280-64-3
898280-65-4	898280-66-5	898280-67-6
898280-68-7	898280-69-8	898280-70-1
898280-71-2	898280-72-3	898280-73-4
898280-75-6	898280-76-7	898280-77-8
898280-78-9	898280-79-0	898280-80-3
898280-81-4	898280-82-5	898280-83-6
898280-84-7	898280-85-8	898280-86-9
898280-87-0	898280-88-1	898280-89-2

898280-90-5	898280-91-6	898280-92-7
898280-93-8	898280-94-9	898280-95-0
898280-96-1	898280-97-2	898280-98-3
898280-99-4	898281-00-0	898281-01-1
898281-02-2	898281-03-3	898281-04-4
898281-05-5	898281-06-6	898281-07-7
898281-08-8	898281-09-9	898281-10-2
898281-11-3	898281-12-4	898281-13-5
898281-14-6	898281-15-7	898281-16-8
898281-17-9	898281-18-0	898281-19-1
898281-20-4	898281-21-5	898281-22-6
898281-23-7	898281-24-8	898281-25-9
898281-26-0	898281-27-1	898281-28-2
898281-29-3	898281-30-6	898281-31-7
898281-32-8	898281-33-9	898281-34-0
898281-35-1	898281-36-2	898281-37-3
898281-38-4	898281-39-5	898281-40-8
898281-41-9	898281-42-0	898281-43-1
898281-44-2	898281-47-5	898281-48-6
898281-50-0		

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(pyrimidine derivative kinase modulators and therapeutic use)


RN 543711-08-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 543711-24-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 543712-32-9 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 852441-70-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852441-77-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(1-phenylethyl)- (CA INDEX NAME)




RN 852441-78-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.






RN 898276-24-9 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-methyl-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-26-1 CAPLUS

CN 2,4-Pyrimidinediamine, 6-methyl-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898276-28-3 CAPLUS


CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898276-29-4 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methoxy-N2-[(3-

phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-30-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-32-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-5-methyl-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-34-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-phenyl-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-37-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-38-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]-6-propoxy- (CA INDEX NAME)




RN 898276-39-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]-6-(1-pyrrolidinyl)- (CA INDEX NAME)




RN 898276-41-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-43-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-45-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopentyl-1H-pyrazol-3-yl)-6-methyl-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898276-61-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopentyl-1H-pyrazol-3-yl)-N2-[(2-methoxyphenyl)methyl]- (CA INDEX NAME)



RN 898276-71-6 CAPLUS


CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[3-(diethylamino)propyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)

10/595,807




RN 898276-72-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-73-8 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[2-(diethylamino)ethyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-78-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898276-82-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(dimethylamino)ethoxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898276-83-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[3-(3-phenyl-5-isoxazolyl)methyl]amino]-, methyl ester (CA INDEX NAME)




RN 898276-93-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898277-00-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(3-bromo-5-isoxazolyl)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898277-06-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898277-12-8 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-cyclohexyl-5-isoxazolyl)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl- (CA INDEX NAME)




RN 898277-37-7 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N6-(5-cyclopropyl-1H-pyrazol-3-yl)-N4,N4-dimethyl-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898277-56-0 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-cyclohexyl-5-isoxazolyl)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898277-62-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(2-methyl-5-thiazolyl)methyl]- (CA INDEX NAME)




RN 898277-64-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopentyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898277-65-1 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-furanylmethyl)- (CA INDEX NAME)



RN 898277-68-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(5-methyl-2-furanyl)methyl]- (CA INDEX NAME)






RN 898277-74-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 898277-76-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-phenylethyl)- (CA INDEX NAME)




RN 898277-78-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(4-chlorophenyl)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898277-92-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[2-(2-thienyl)ethyl]- (CA INDEX NAME)




RN 898277-93-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclohexyl-1H-pyrazol-3-yl)-6-methyl-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898278-04-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)




RN 898278-05-2 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl- (CA INDEX NAME)




RN 898278-06-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-thiazolylmethyl)- (CA INDEX NAME)




RN 898278-10-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[4-(dimethylamino)phenyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898278-12-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(2-chlorophenyl)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898278-13-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[4-(4-methyl-1-piperazinyl)phenyl]methyl]- (CA INDEX NAME)




RN 898278-14-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3,5-dimethoxyphenyl)methyl]- (CA INDEX NAME)




RN 898278-15-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(phenylmethyl)- (CA INDEX NAME)




RN 898278-16-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-phenylpropyl)- (CA INDEX NAME)




RN 898278-20-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(3-cyclohexyl-5-isoxazolyl)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 898278-24-5 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(4-piperidinylmethyl)- (CA INDEX NAME)



RN 898278-25-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 898278-27-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)




RN 898278-29-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(2-chlorophenyl)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-methyl- (CA INDEX NAME)




RN 898278-31-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(2,5-dimethoxyphenyl)methyl]- (CA INDEX NAME)




RN 898278-32-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(2-methoxyphenyl)methyl]-6-methyl- (CA INDEX NAME)




RN 898278-33-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 898278-43-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[2-(2-thienyl)-4-thiazolyl]methyl]- (CA INDEX NAME)




RN 898278-50-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[2-(3-chlorophenyl)ethyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 898278-54-1 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-[2-(4-chlorophenyl)ethyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 898278-59-6 CAPLUS




CN 2,4-Pyrimidinediamine, N2-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898278-63-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[2-(2,4-dichlorophenyl)ethyl]- (CA INDEX NAME)




RN 898278-66-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(4-methoxyphenyl)-5-isoxazolyl]methyl]-6-methyl- (CA INDEX NAME)




RN 898278-68-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[2-(3,4-dimethoxyphenyl)ethyl]- (CA INDEX NAME)




RN 898278-69-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]-6-(phenylmethoxy)- (CA INDEX NAME)




RN 898278-71-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(2-furanyl)-1H-pyrazol-3-yl]-6-methyl-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898278-74-5 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(2-furanyl)-1H-pyrazol-3-yl]-N2-(4-pyridinylmethyl)- (CA INDEX NAME)



RN 898278-75-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(2-furanyl)-1H-pyrazol-3-yl]-N2-[(1R)-1-phenylpropyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 898278-76-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[(3-phenyl-5-isothiazolyl)methyl]- (CA INDEX NAME)




RN 898278-81-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[2-(4-methoxyphenyl)ethyl]- (CA INDEX NAME)




RN 898278-86-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclohexyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898278-87-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)




RN 898278-89-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(4-methoxyphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898278-90-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(2-phenyl-2H-1,2,3-triazol-4-yl)methyl]- (CA INDEX NAME)




RN 898278-95-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(4-phenyl-2-thienyl)methyl]- (CA INDEX NAME)




RN 898278-96-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[2-(2-chlorophenyl)ethyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898278-99-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898279-01-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(4-methoxyphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898279-12-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-[4-(trifluoromethyl)phenyl]-5-isothiazolyl]methyl]- (CA INDEX NAME)




RN 898279-13-5 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[3-(4-chlorophenyl)-5-isothiazolyl]methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898279-14-6 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[3-(3-chlorophenyl)-5-isothiazolyl]methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 898279-30-6 CAPLUS  
 CN 1H-Pyrazole-4-carbonitrile, 3-[[6-methyl-2-[[3-(phenyl-5-isoxazolyl)methyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)




RN 898279-39-5 CAPLUS  
 CN 1-Piperidinecarboxylic acid, 4-[[[5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]methyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 898279-42-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(diphenylmethyl)- (CA INDEX NAME)




RN 898279-46-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(3-phenyl-5-isoxazolyl)methyl]-N4-(5-phenyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898279-47-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[5-(4-chlorophenyl)-2-thienyl]methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)- (CA INDEX NAME)







RN 898279-52-2 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3,3-diphenylpropyl)- (CA INDEX NAME)




RN 898279-53-3 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2,2-diphenylethyl)- (CA INDEX NAME)



RN 898279-58-8 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(1,2-diphenylethyl)- (CA INDEX NAME)




RN 898279-80-6 CAPLUS  
 CN 2,4,6-Pyrimidinetriamine, N4-[3-(diethylamino)propyl]-N6-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898279-81-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-morpholinyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898279-82-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-methyl-1-piperazinyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898279-83-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 898279-84-0 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(3-phenyl-5-isoxazolyl)methyl]-6-(1-piperazinyl)- (CA INDEX NAME)




RN 898279-86-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(4-fluorophenyl)-5-isoxazolyl]methyl]-6-methyl- (CA INDEX NAME)

10/595,807




RN 898279-87-3 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(4-morpholinyl)ethoxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898279-88-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[[ (2S)-1-methyl-2-pyrrolidinyl]methoxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 898279-89-5 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(3S)-3-methyl-1-piperazinyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 898279-90-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(1-methyl-4-piperidinyl)oxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898279-91-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-morpholinyl)- (CA INDEX NAME)




RN 898279-92-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]-6-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)




RN 898279-93-1 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898279-95-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]-6-[4-(1-piperazinyl)phenyl]- (CA INDEX NAME)



RN 898279-96-4 CAPLUS


CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[2-(4-methyl-1-piperazinyl)ethyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898279-97-5 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]-N6-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)






RN 898279-98-6 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(3R)-3-methyl-1-piperazinyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 898279-99-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-00-7 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[2-(4-morpholinyl)ethyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-03-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(1-methyl-3-pyrrolidinyl)oxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-04-1 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]-N6-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 898280-05-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[(1-methyl-3-piperidinyl)oxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-06-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[2-(dimethylamino)ethoxy]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-07-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl)methyl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898280-08-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-(4-morpholinyl)- (CA INDEX NAME)




RN 898280-09-6 CAPLUS

CN 4-Pyrimidinecarboxamide, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[3-(3-phenyl-5-isoxazolyl)methyl]amino]-N-[2-(1-pyrrolidinyl)ethyl]- (CA INDEX NAME)




RN 898280-10-9 CAPLUS

CN Methanone, [6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[(3-phenyl-5-isoxazolyl)methyl]amino]-4-pyrimidinyl]](1-methyl-4-piperidiny]- (CA INDEX NAME)




RN 898280-11-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[(5-phenyl-3-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-13-2 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(2-bromophenyl)methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl- (CA INDEX NAME)




RN 898280-14-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-methyl-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 898280-15-4 CAPLUS


CN 4-Pyrimidinecarboxamide, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-N-[2-(4-methyl-1-piperazinyl)ethyl]-2-[[3-(phenyl-5-isoxazolyl)methyl]amino]- (CA INDEX NAME)



RN 898280-16-5 CAPLUS


CN 4-Pyrimidinecarboxamide, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-N-[3-

(diethylamino)propyl]-2-[[ (3-phenyl-5-isoxazolyl)methyl]amino]- (CA INDEX NAME)




RN 898280-17-6 CAPLUS

CN 4-Pyrimidinecarboxamide, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-N-[2-(diethylamino)ethyl]-2-[[ (3-phenyl-5-isoxazolyl)methyl]amino]- (CA INDEX NAME)



RN 898280-18-7 CAPLUS

CN 4-Pyrimidinecarboxamide, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[ (3-phenyl-5-isoxazolyl)methyl]amino]-N-[2-(1-piperidinyl)ethyl]- (CA INDEX NAME)




RN 898280-19-8 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[ (3-phenyl-5-isoxazolyl)methyl]amino]-, phenylmethyl ester (CA INDEX NAME)




NAME)




RN 898280-20-1 CAPLUS

CN 4-Pyrimidinecarboxamide, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-N-[2-(4-morpholinyl)ethyl]-2-[[3-(3-phenyl-5-isoxazolyl)methyl]amino]- (CA INDEX NAME)




RN 898280-22-3 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(3-chlorophenyl)-5-isoxazolyl]methyl]-6-methyl-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 898280-23-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-(1H-pyrazol-3-ylmethyl)- (CA INDEX NAME)




RN 898280-25-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(3-chlorophenyl)-5-isoxazolyl]methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl- (CA INDEX NAME)




RN 898280-26-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(1H-imidazol-2-ylmethyl)-6-methyl- (CA INDEX NAME)




RN 898280-29-0 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(3-bromophenyl)-5-isoxazolyl]methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl- (CA INDEX NAME)




RN 898280-31-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 898280-42-7 CAPLUS


CN Methanone, [5-[[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-methyl-2-pyrimidinyl]amino]methyl]-3-isoxazolyl](4-methyl-1-piperazinyl)- (CA INDEX NAME)



RN 898280-44-9 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-[(3R)-3-methyl-1-piperazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 898280-45-0 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N6-[2-(4-methyl-1-piperazinyl)ethyl]- (CA INDEX NAME)




RN 898280-46-1 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N6-[2-(4-methyl-1-piperazinyl)ethyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-47-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinylmethyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-48-3 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[4-(4-chlorophenyl)-2-thienyl]methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl- (CA INDEX NAME)




RN 898280-49-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-furanylmethyl)-6-methyl- (CA INDEX NAME)




RN 898280-50-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[(5-methyl-3-phenyl-4-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-55-2 CAPLUS

CN 4-Thiazolecarboxamide, N-[2-(3-chlorophenyl)ethyl]-2-[[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-methyl-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 898280-56-3 CAPLUS

CN 4-Thiazolecarboxamide, 2-[[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-methyl-2-pyrimidinyl]amino]methyl]-N-[2-(2-fluorophenyl)ethyl]- (CA INDEX NAME)




RN 898280-57-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[phenyl(4-phenyl-2-oxazolyl)methyl]- (CA INDEX NAME)




RN 898280-58-5 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[3-(diethylamino)propyl]-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 898280-59-6 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[2-(diethylamino)ethyl]-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898280-60-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(3S)-3-methyl-1-piperazinyl]- (CA INDEX NAME)


Absolute stereochemistry.






RN 898280-61-0 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[2-(dimethylamino)ethyl]-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898280-62-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methyl-3-pyrrolidinyl)oxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-63-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-[(1-methyl-3-pyrrolidinyl)oxy]- (CA INDEX NAME)




RN 898280-64-3 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methyl-3-pyrrolidinyl)oxy]- (CA INDEX NAME)




RN 898280-65-4 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-[2-(diethylamino)ethyl]-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N6-[5-(1-methylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 898280-66-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 898280-67-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methyl-3-piperidinyl)oxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-68-7 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methyl-3-piperidinyl)oxy]- (CA INDEX NAME)




RN 898280-69-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-70-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[(5-phenyl-1H-imidazol-2-yl)methyl]- (CA INDEX NAME)




RN 898280-71-2 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[2-(dimethylamino)ethoxy]-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 898280-72-3 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 898280-73-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[2-(4-morpholinyl)ethoxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-75-6 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-[3-(diethylamino)propyl]-N2-[3-(1-methylethyl)-5-isoxazolyl]methyl-N6-[5-(1-methylethyl)-1H-pyrazol-3-yl]-(CA INDEX NAME)




RN 898280-76-7 CAPLUS


2,4-Pyrimidinediamine, N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methyl-4-piperidinyloxy)-N2-[(3-phenyl-5-isoxazolyl)methyl]]- (CA INDEX NAME)



RN 898280-77-8 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 898280-78-9 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)



RN 898280-79-0 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[3-(diethylamino)propyl]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898280-80-3 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl)methyl]-6-[2-(1-piperidinyl)ethoxy]- (CA INDEX NAME)






RN 898280-81-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-[(1-methyl-3-piperidinyl)oxy]- (CA INDEX NAME)




RN 898280-82-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[(1-methyl-4-piperidinyl)oxy]- (CA INDEX NAME)




RN 898280-83-6 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]-6-(4-morpholinyl)- (CA INDEX NAME)




RN 898280-84-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898280-85-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-[(1-methyl-4-piperidinyl)oxy]- (CA INDEX NAME)




RN 898280-86-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(4-fluorophenyl)-5-isoxazolyl]methyl]-6-(4-morpholinyl)- (CA INDEX NAME)



RN 898280-87-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(4-fluorophenyl)-5-isoxazolyl]methyl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898280-88-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(4-


10/595,807

fluorophenyl)-5-isoxazolyl]methyl]-6-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 898280-89-2 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(4-fluorophenyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-morpholinyl)- (CA INDEX NAME)




RN 898280-90-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(4-fluorophenyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898280-91-6 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(4-fluorophenyl)-5-isoxazolyl]methyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-6-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 898280-92-7 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 898280-93-8 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898280-94-9 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-(1-piperazinyl)- (CA INDEX NAME)



RN 898280-95-0 CAPLUS


CN Ethanone, 1-[4-[6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[3-(1-methylethyl)-5-isoxazolyl]methyl]amino]-4-pyrimidinyl]-1-piperazinyl]-  
(CA INDEX NAME)



RN 898280-96-1 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-[4-(methanesulfonyl)-1-piperazinyl]-  
(CA INDEX NAME)






RN 898280-97-2 CAPLUS

CN 1-Piperazinecarboxaldehyde, 4-[6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[3-(1-methylethyl)-5-isoxazolyl]methyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 898280-98-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898280-99-4 CAPLUS

CN 2,4-Pyrimidinediamine, 6-(4-methyl-1-piperazinyl)-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-00-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-6-[2-(4-morpholinyl)ethoxy]-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-01-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[[3-(4-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-02-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(3,4-difluorophenyl)-5-isoxazolyl]methyl]-6-methyl- (CA INDEX NAME)




RN 898281-03-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(2,4-difluorophenyl)-5-isoxazolyl]methyl]-6-methyl- (CA INDEX NAME)




RN 898281-04-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[[3-(2-pyrazinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-05-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-06-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-07-7 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-6-(4-methyl-1-piperazinyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898281-08-8 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)- (CA INDEX NAME)




RN 898281-09-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-N2-[[3-(4-pyrimidinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-10-2 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(3-furanyl)-5-isoxazolyl]methyl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898281-11-3 CAPLUS  
 CN 2,4,6-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N6-[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 898281-12-4 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898281-13-5 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)






RN 898281-14-6 CAPLUS

CN 2,4,6-Pyrimidinetriamine, N4-bicyclo[2.2.1]hept-2-yl-N6-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 898281-15-7 CAPLUS


CN 2,4,6-Pyrimidinetriamine, N4-bicyclo[2.2.1]hept-2-yl-N6-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898281-16-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]-6-[(1R,4R)-5-(phenylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 898281-17-9 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl)methyl]-6-[(1R,4R)-5-(phenylmethyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 898281-18-0 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-N2-[[3-(4-pyrimidinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 898281-19-1 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(dimethylamino)ethoxy]-N2-[[3-(4-pyrimidinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)

10/595,807




RN 898281-20-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(5-fluoro-2-pyridinyl)-5-isoxazolyl]methyl]-6-methyl- (CA INDEX NAME)



RN 898281-21-5 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-N2-[[3-(2-thienyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 898281-22-6 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-

(dimethylamino)ethoxy]-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-23-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-N2-[[3-(5-pyrimidinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-24-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-morpholinyl)-N2-[[3-(5-pyrimidinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-25-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(diethylamino)ethoxy]-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-26-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]-6-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 898281-27-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(diethylamino)ethoxy]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-28-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]-6-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 898281-29-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)-N2-[[3-(2-thiazolyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 898281-30-6 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(dimethylamino)ethoxy]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)






RN 898281-31-7 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[2-(dimethylamino)ethoxy]-N2-[(3-methyl-5-isoxazolyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898281-32-8 CAPLUS

CN 2,4-Pyrimidinediamine, 6-[2-(diethylamino)ethoxy]-N2-[(3-methyl-5-isoxazolyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 898281-33-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[(3-methyl-5-isoxazolyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)-6-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 898281-34-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[2-(3-phenyl-5-isoxazolyl)ethyl]- (CA INDEX NAME)




RN 898281-35-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[1-(3-phenyl-5-isoxazolyl)ethyl]- (CA INDEX NAME)




RN 898281-36-2 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[1-(3-ethyl-5-isoxazolyl)methyl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898281-37-3 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[1-(3-ethyl-5-isoxazolyl)methyl]-6-(4-morpholinyl)- (CA INDEX NAME)




RN 898281-38-4 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(dimethylamino)ethoxy]-N2-[(3-ethyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-39-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-[2-(diethylamino)ethoxy]-N2-[(3-ethyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-40-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-ethyl-5-isoxazolyl)methyl]-6-[2-(1-pyrrolidinyl)ethoxy]- (CA INDEX NAME)




RN 898281-41-9 CAPLUS

CN 2,4-Pyrimidinediamine, N2-[[3-(2-amino-4-pyrimidinyl)-5-isoxazolyl]methyl]-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)




RN 898281-42-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-ethyl-1-piperazinyl)-N2-[[3-(1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 898281-43-1 CAPLUS

CN 4-Piperidineethanol, 1-[6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[3-(1-methylethyl)-5-isoxazolyl]methyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 898281-44-2 CAPLUS

CN 1-Piperazineethanol, 4-[6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[3-(1-methylethyl)-5-isoxazolyl]methyl]amino]-4-pyrimidinyl]- (CA INDEX NAME)




RN 898281-47-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[4-(dimethylamino)phenyl]methyl]- (CA INDEX NAME)




RN 898281-48-6 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 898281-50-0 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-methyl-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



IT 898281-46-4P 898281-49-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (pyrimidine derivative kinase modulators and therapeutic use)  
 RN 898281-46-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-chloro-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-  
 [(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)



RN 898281-49-7 CAPLUS  
 CN 2,4-Pyrimidinediamine, 6-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[[3-  
 (1-methylethyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)

L7 ANSWER 17 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2005:1042231 CAPLUS  
 DN 143:347180  
 TI Preparation of heterocyclic compounds as G protein-coupled receptor kinase (GRK) inhibitors  
 IN Kawamoto, Tetsuji; Okawa, Tomohiro; Aramaki, Yoshio; Fukumoto, Shoji; Toyoda, Yukio; Ikeda, Shota  
 PA Takeda Pharmaceutical Company Limited, Japan  
 SO PCT Int. Appl., 460 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA Japanese  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005090328	A1	20050929	WO 2005-JP5995	20050323
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

	JP 2007223901	A	20070906	JP 2004-86115	20040324
PRAI	JP 2004-86115	A	20040324		

OS MARPAT 143:347180

AB G protein-coupled receptor kinase (GRK) inhibitors containing heterocyclic compds. represented by the formula (I) [wherein ring A represents an optionally substituted aromatic ring; ring B represents an optionally substituted, 5-membered nitrogenous aromatic heterocycle; ring C represents an optionally substituted nitrogenous aromatic heterocycle; X1 represents optionally substituted C1-4 alkylene; and Y1 represents optionally substituted imino, -O-, or -S(O)n- (wherein n is 0, 1, or 2)] or salts thereof, or prodrugs of either are disclosed. These compds. are useful for the prevention or treatment of heart failure, etc. Thus, 175 mg 3-[[[4-methyl-5-(4-pyridyl)-4H-1,2,4-triazol-3-yl]methyl]amino]benzoic acid, 175 mg 2-(trifluoromethyl)benzylamine, 144 mg 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride, and 7.7 mg 1-hydroxy-1H-benzotriazole monohydrate were mixed in 2.0 mL DMF and stirred at room temperature for 18 h to give, after workup and silica gel chromatog., 96% 3-[[[4-Methyl-5-(4-pyridyl)-4H-1,2,4-triazol-3-yl]methyl]amino]-N-[2-(trifluoromethyl)benzyl]benzamide (II). II and N-(2,6-Difluorobenzyl)-3-[[[4-propyl-3-(4-pyrimidyl)-4H-1,2,4-triazol-5-yl]methyl]amino]benzamide showed IC50 of 35 and 13 nM, resp., for inhibiting the GRK2-dependent bovine tubulin oxidation. Pharmaceutical formulations, e.g. tablet containing II, were also prepared

IT	543710-77-6P	543710-79-8P	543711-86-0P
	543712-01-2P	543712-03-4P	543712-05-6P
	543712-07-8P	543712-09-0P	543712-11-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of heterocyclic compds. as G protein-coupled receptor kinase



(GRK) inhibitors)


RN 543710-77-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 543710-79-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 543711-86-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[3-(2-methoxy-3-pyridinyl)-5-isoxazolyl]methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543712-01-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[[3-(3-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 543712-03-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 543712-05-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-propyl-1H-pyrazol-3-yl)-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 543712-07-8 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)

10/595,807




RN 543712-09-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-ethyl-1H-pyrazol-3-yl)-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



RN 543712-11-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)



OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)  
RE.CNT 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 18 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2005:471958 CAPLUS  
 DN 143:7708  
 TI Preparation of pyrazole derivatives as inhibitors of receptor tyrosine kinases  
 IN Block, Michael Howard; Han, Yongxin; Josey, John Anthony; Lee, John W.; Scott, David; Wang, Bin; Wang, Haixia; Wang, Tao; Yu, Dingwei  
 PA Astrazeneca AB, Swed.; Astrazeneca UK Limited  
 SO PCT Int. Appl., 145 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

Applicant's

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049033	A1	20050602	WO 2004-GB4784	20041115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004290948	A1	20050602	AU 2004-290948	20041115
AU 2004290948	B2	20090409		
CA 2545527	A1	20050602	CA 2004-2545527	20041115
EP 1686999	A1	20060809	EP 2004-798505	20041115
EP 1686999	B1	20090701		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS				
BR 2004016605	A	20070130	BR 2004-16605	20041115
CN 1905884	A	20070131	CN 2004-80040487	20041115
JP 2007511589	T	20070510	JP 2006-540576	20041115
AT 435017	T	20090715	AT 2004-798505	20041115
US 20070142413	A1	20070621	US 2006-595807	20060512
NO 2006002188	A	20060727	NO 2006-2188	20060515
ZA 2006003938	A	20071128	ZA 2006-3938	20060516
MX 2006005597	A	20060804	MX 2006-5597	20060517
IN 2006DN02870	A	20070810	IN 2006-DN2870	20060519
KR 2006126660	A	20061208	KR 2006-711985	20060616
PRAI US 2003-520581P	P	20031117		
US 2004-556213P	P	20040325		
WO 2004-GB4784	W	20041115		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS CASREACT 143:7708; MARPAT 143:7708

AB Title compds. I [A = direct bond, (un)substituted-alkylene; B = carbo- or heterocycle; R1 and R4 independently = H, halo, CN, etc.; R2 = NO2, OH, NH2, etc.; R3 = trifluoromethoxy, carboxy, carbamoyl, etc.; R5 = H, (un)substituted-alkyl; R6 and R7 independently = mercapto, sulphamoyl, alkyl, etc. or R6 and R7 together with the pyrimidine bond to which they are attached = (un)substituted 5- or 6-membered carbocycle or (un)substituted 5- or 6-membered heterocycle; n = 0-3] and their

pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of tyrosine kinases. Thus, e.g., II was prepared by coupling of 1-phenylethylamine with 2,5-dichloro-4-(5-cyclopropyl-1H-pyrazole-3-ylamino)pyrimidine (preparation given). The activity of I was evaluated in TrkB kinase inhibition assays and it revealed that selected compds. of the invention possessed IC<sub>50</sub> values in the range of 0.059 up to 0.087  $\mu$ M. I as inhibitors of receptor tyrosine kinases should prove useful in the treatment of certain cancers. Pharmaceutical compns. comprising I are disclosed.


IT 852443-54-0P

RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)

(preparation of pyrazole derivs. as inhibitors of receptor tyrosine kinases)

RN 852443-54-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)



IT 852442-97-8P 852442-98-9P


RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazole derivs. as inhibitors of receptor tyrosine kinases)

RN 852442-97-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1R)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 852442-98-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-

[(1S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 852441-69-1P 852441-92-0P 852442-02-5P  
 852442-03-6P 852442-49-0P 852442-65-0P  
 852442-66-1P 852443-57-3P 852443-58-4P  
 852443-59-5P 852443-60-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of pyrazole derivs. as inhibitors of receptor tyrosine kinases)

RN 852441-69-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 852441-92-0 CAPLUS

CN 4-Pyrimidinecarboxylic acid, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.






RN 852442-02-5 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-  
[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-03-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5,6-dichloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-  
[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 852442-49-0 CAPLUS

CN Benzeneethanol,  $\beta$ -[[4,5-dichloro-6-[(5-cyclopropyl-1H-pyrazol-3-

yl)amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-65-0 CAPLUS

CN Benzeneethanol,  $\beta$ -[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-nitro-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-66-1 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]-5-nitro- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-57-3 CAPLUS

CN 2,4-Pyrimidinediamine, 6-chloro-N2-[(1S)-1-(4-fluorophenyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-58-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5,6-dichloro-N4-(5-ethoxy-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-59-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5,6-dichloro-N2-[(1S)-1-(4-fluorophenyl)ethyl]-N4-[5-(1-methylethoxy)-1H-pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-60-8 CAPLUS

CN Benzeneethanol,  $\beta$ -[[4,5-dichloro-6-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.



IT	852441-65-7P	852441-66-8P	852441-67-9P
	852441-68-0P	852441-70-4P	852441-71-5P
	852441-72-6P	852441-73-7P	852441-74-8P
	852441-75-9P	852441-76-0P	852441-77-1P
	852441-78-2P	852441-79-3P	852441-80-6P
	852441-81-7P	852441-82-8P	852441-83-9P
	852441-84-0P	852441-85-1P	852441-86-2P
	852441-87-3P	852441-88-4P	852441-89-5P
	852441-90-8P	852441-91-9P	852441-93-1P
	852441-94-2P	852441-95-3P	852441-96-4P
	852441-97-5P	852441-98-6P	852441-99-7P
	852442-00-3P	852442-01-4P	852442-04-7P
	852442-05-8P	852442-06-9P	852442-07-0P
	852442-08-1P	852442-09-2P	852442-10-5P
	852442-11-6P	852442-12-7P	852442-13-8P
	852442-47-8P	852442-48-9P	852442-50-3P
	852442-51-4P	852442-52-5P	852442-53-6P
	852442-54-7P	852442-55-8P	852442-56-9P
	852442-57-0P	852442-58-1P	852442-59-2P


852442-60-5P	852442-61-6P	852442-62-7P
852442-64-9P	852442-67-2P	852442-68-3P
852442-69-4P	852442-70-7P	852442-71-8P
852442-72-9P	852442-73-0P	852442-74-1P
852442-75-2P	852442-76-3P	852442-77-4P
852442-78-5P	852442-79-6P	852442-80-9P
852442-81-0P	852442-82-1P	852442-83-2P
852442-84-3P	852442-85-4P	852442-86-5P
852442-87-6P	852442-88-7P	852442-89-8P
852442-90-1P	852442-91-2P	852442-92-3P
852442-93-4P	852442-94-5P	852442-95-6P
852442-96-7P	852443-08-4P	852443-09-5P
852443-10-8P	852443-11-9P	852443-12-0P
852443-13-1P	852443-14-2P	852443-15-3P
852443-16-4P	852443-17-5P	852443-18-6P
852443-19-7P	852443-20-0P	852443-21-1P
852443-22-2P	852443-23-3P	852443-24-4P
852443-25-5P	852443-26-6P	852443-27-7P
852443-28-8P	852443-29-9P	852443-30-2P
852443-31-3P	852443-32-4P	852443-33-5P
852443-34-6P	852443-36-8P	852443-38-0P
852443-39-1P	852443-40-4P	852443-41-5P
852443-42-6P	852443-43-7P	852443-44-8P
852443-45-9P	852443-46-0P	852443-47-1P
852443-48-2P		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazole derivs. as inhibitors of receptor tyrosine kinases)


RN 852441-65-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(1-phenylethyl)- (CA INDEX NAME)




RN 852441-66-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-ethyl-1H-pyrazol-3-yl)-N2-(1-phenylethyl)- (CA INDEX NAME)




RN 852441-67-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(1-phenylethyl)- (CA INDEX NAME)



RN 852441-68-0 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(1-phenylethyl)-5-(trifluoromethyl)- (CA INDEX NAME)



RN 852441-70-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-phenylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852441-71-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-nitrophenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852441-72-6 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852441-73-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(1-

phenylethyl)- (CA INDEX NAME)



RN 852441-74-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(1-phenylethyl)- (CA INDEX NAME)




RN 852441-75-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 852441-76-0 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852441-77-1 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(1-phenylpropyl)- (CA INDEX NAME)



RN 852441-78-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852441-79-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852441-80-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852441-81-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]-6-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 852441-82-8 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-methyl-2-pyrimidinyl]amino]-, ( $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 852441-83-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(1-


10/595,807

phenylethyl)- (CA INDEX NAME)



RN 852441-84-0 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-5-methyl-N2-(1-phenylethyl)- (CA INDEX NAME)



RN 852441-85-1 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-, ( $\beta$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852441-86-2 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852441-87-3 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[1-(4-fluorophenyl)-2-hydroxyethyl]amino]-, butyl ester (CA INDEX NAME)



RN 852441-88-4 CAPLUS

CN Benzeneethanol, β-[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro-, (βR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852441-89-5 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852441-90-8 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852441-91-9 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852441-93-1 CAPLUS

CN 4-Pyrimidinecarboxamide, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-N-[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]-2-[[ (1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852441-94-2 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-bromo-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852441-95-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(4-fluorophenyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)

Absolute stereochemistry.






RN 852441-96-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(1S)-1-(4-fluorophenyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852441-97-5 CAPLUS

CN Benzeneethanol,  $\beta$ -[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-fluoro-2-pyrimidinyl]amino]-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852441-98-6 CAPLUS


CN 4-Pyrimidinecarboxylic acid, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino]-, ethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 852441-99-7 CAPLUS


CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro- (CA INDEX NAME)



RN 852442-00-3 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]-6-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 852442-01-4 CAPLUS


CN Benzeneethanol,  $\beta$ -[[5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro- (CA INDEX NAME)



RN 852442-04-7 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-05-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-5-fluoro-N2-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-06-9 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-07-0 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-, ( $\beta$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-08-1 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-09-2 CAPLUS


CN Benzenepropanoic acid,  $\beta$ -[[5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro- (CA INDEX NAME)

10/595,807



RN 852442-10-5 CAPLUS


CN Ethanol, 2-[[5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]](1-phenylethyl)amino]- (CA INDEX NAME)



RN 852442-11-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1R)-1-(4-fluorophenyl)-2-methoxyethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 852442-12-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[1-(4-fluorophenyl)-2-(4-morpholinyl)ethyl]- (CA INDEX NAME)



RN 852442-13-8 CAPLUS


CN 2-Thiopheneethanol,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 852442-47-8 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-bromo-4-[(5-methoxy-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-48-9 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[[5-(methylthio)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-50-3 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[(1H-pyrazol-3-ylamino)-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.




RN 852442-51-4 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[[5-(dimethylamino)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-52-5 CAPLUS

CN Benzenepropanoic acid,  $\beta$ -[[5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]- $\alpha$ -methyl- (CA INDEX NAME)

RN 852442-53-6 CAPLUS


CN Benzenepropanol,  $\gamma$ -[[5-bromo-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]- $\beta$ -methyl- (CA INDEX NAME)

RN 852442-54-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)-3-(4-morpholinyl)propyl]- (CA INDEX NAME)

Absolute stereochemistry.






RN 852442-55-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)-3-(1-pyrrolidinyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-56-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-3-(diethylamino)-1-(4-fluorophenyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-57-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-  
[(1S)-1-(4-fluorophenyl)-3-(4-methyl-1-piperazinyl)propyl]- (CA INDEX  
NAME)

Absolute stereochemistry.




RN 852442-58-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-  
[(1S)-1-(4-fluorophenyl)-3-[(2-methoxyethyl)methylamino]propyl]- (CA  
INDEX NAME)

Absolute stereochemistry.


10/595,807



RN 852442-59-2 CAPLUS

CN Ethanol, 2-[[[(3S)-3-[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-3-(4-fluorophenyl)propyl]methylamino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-60-5 CAPLUS

CN Benzenepropanol,  $\gamma$ -[[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\gamma$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-61-6 CAPLUS

CN Benzeneethanol,  $\beta$ -[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-methyl-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-62-7 CAPLUS

CN Benzeneethanol,  $\beta$ -[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-fluoro-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-64-9 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(2-methoxyphenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 852442-67-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-methyl-N2-[1-(2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 852442-68-3 CAPLUS


CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]- $\alpha$ -methyl- (CA INDEX NAME)



RN 852442-69-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(4-fluorophenyl)ethyl]-N4-[5-(trifluoromethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852442-70-7 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[1-(2-pyridinyl)ethyl]- (CA INDEX NAME)



RN 852442-71-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(4-fluorophenyl)ethyl]-N4-[5-(phenylmethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-72-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(1S)-1-(4-fluorophenyl)ethyl]-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-73-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(cyclopropylmethyl)-1H-pyrazol-3-yl]-N2-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-74-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(cyclopropylmethoxy)-1H-pyrazol-3-yl]-N2-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 852442-75-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-


1-[4-(trifluoromethyl)-2-thiazolyl]ethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852442-76-3 CAPLUS


CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[1-(2-thiazolyl)ethyl)- (CA INDEX NAME)



RN 852442-77-4 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[[5-(1-methylpropoxy)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 852442-78-5 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[[5-(1-methylpropoxy)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)




Absolute stereochemistry.



RN 852442-79-6 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-80-9 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[(5-ethoxy-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-81-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-  
[(1S)-3-(dimethylamino)-1-(4-fluorophenyl)propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-82-1 CAPLUS

CN Benzenepropanamide,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro-N,N-dimethyl-, ( $\beta$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-83-2 CAPLUS


CN Benzenepropanamide,  $\beta$ -[[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro-N-methyl-, ( $\beta$ S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 852442-84-3 CAPLUS

CN Benzenepropanol,  $\gamma$ -[[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-2-fluoro- (CA INDEX NAME)




RN 852442-85-4 CAPLUS  
 CN Benzenepropanamide,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro-N-(2-hydroxyethyl)-, ( $\beta$ S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-86-5 CAPLUS  
 CN Benzenepropanol,  $\gamma$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-2-methoxy- (CA INDEX NAME)




RN 852442-87-6 CAPLUS  
 CN 2-Thiophenepropanol,  $\gamma$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]- (CA INDEX NAME)



RN 852442-88-7 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1R)-1-(4-fluorophenyl)-2-(4-morpholinyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-89-8 CAPLUS

CN Benzeneethanol, 4-fluoro- $\beta$ -[[5-fluoro-4-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-90-1 CAPLUS

CN Acetamide, N-[(2R)-2-[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-2-(4-fluorophenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-91-2 CAPLUS

CN Benzeneethanol,  $\beta$ -[[4-[(5-ethoxy-1H-pyrazol-3-yl)amino]-5-fluoro-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-92-3 CAPLUS


CN Benzenepropanol,  $\gamma$ -[[4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-5-fluoro-2-pyrimidinyl]amino]-4-fluoro-, ( $\gamma$ S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852442-93-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, N2-[(1R)-2-amino-1-(4-fluorophenyl)ethyl]-5-chloro-  
 N4-(5-cyclopropyl-1H-pyrazol-3-yl)-, hydrochloride (1:?) (CA INDEX NAME)


Absolute stereochemistry.



●x HCl


RN 852442-94-5 CAPLUS  
 CN 2,4,5-Pyrimidinetriamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852442-95-6 CAPLUS  
 CN Benzeneethanol,  $\beta$ -[[5-amino-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852442-96-7 CAPLUS

CN 5-Pyrimidinecarbonitrile, 4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 852443-08-4 CAPLUS

CN Benzeneethanol,  $\beta$ -[[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-[[2-(4-morpholinyl)ethyl]amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.






RN 852443-09-5 CAPLUS

CN 1,2-Propanediol, 3-[[[5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-10-8 CAPLUS

CN Benzeneethanol,  $\beta$ -[[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-[(3-hydroxypropyl)amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-11-9 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-[[3-(4-methyl-1-piperazinyl)propyl]amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-12-0 CAPLUS


CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-[[2-(1-pyrrolidinyl)ethyl]amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 852443-13-1 CAPLUS  
 CN 4-Pyrimidinecarboxamide, 6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[ (1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino]-N-[2-(4-morpholinyl)ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852443-14-2 CAPLUS  
 CN 1,2-Propanediol, 3-[[6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[ (1S)-1-(4-fluorophenyl)ethyl]amino]-4-pyrimidinyl]amino]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-15-3 CAPLUS

CN 1,2-Propanediol, 3-[[2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-4-pyrimidinyl]amino]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-16-4 CAPLUS

CN Ethanol, 2-[[6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-17-5 CAPLUS

CN Ethanol, 2-[[2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino]-6-[(5-methyl-1H-pyrazol-3-yl)amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-18-6 CAPLUS

CN 2,4,6-Pyrimidinetriamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-19-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]-6-(4-methyl-1-piperazinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-20-0 CAPLUS

CN 2-Propanol, 1-amino-3-[[5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-21-1 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-[[2-(dimethylamino)ethyl]amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-22-2 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-[[3-(1-pyrrolidinyl)propyl]amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-23-3 CAPLUS


CN Ethanol, 2-[[5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[1-(4-fluorophenyl)ethyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 852443-24-4 CAPLUS  
 CN 1,3-Propanediol, 2-[[5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852443-25-5 CAPLUS  
 CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(dimethylamino)-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-26-6 CAPLUS  
 CN Benzeneethanol,  $\beta$ -[[4-[(3-amino-2-hydroxypropyl)amino]-5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.






RN 852443-27-7 CAPLUS

CN 1,3-Propanediol, 2-[[5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-28-8 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-[[2-(2-hydroxyethoxy)ethyl]amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-29-9 CAPLUS

CN 1,2-Propanediol, 3-[[[5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino]-4-pyrimidinyl]amino]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-30-2 CAPLUS


CN Benzeneethanol,  $\beta$ -[[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(ethylamino)-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 852443-31-3 CAPLUS  
 CN 1,2-Propanediol, 3-[[5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-  
 [[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino]-4-pyrimidinyl]amino]-,  
 (2S)- (CA INDEX NAME)

Absolute stereochemistry.




RN 852443-32-4 CAPLUS  
 CN 1,2-Propanediol, 3-[[5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-  
 [[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino]-4-pyrimidinyl]amino]-,  
 (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 852443-33-5 CAPLUS  
 CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-  
 6-[(2-hydroxyethyl)amino]-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 852443-34-6 CAPLUS

CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-6-(methylamino)-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-36-8 CAPLUS

CN 1,2-Propanediol, 3-[[5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[ (1S)-1-(4-fluorophenyl)ethyl]amino]-4-pyrimidinyl]amino]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-38-0 CAPLUS

CN 2-Propanol, 3-[[5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[ (1S)-1-(4-fluorophenyl)ethyl]amino]-4-pyrimidinyl]amino]-1,1,1-trifluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-39-1 CAPLUS


CN 1,2-Propanediol, 3-[[[5-chloro-6-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-2-[[ (1S)-1-(4-fluorophenyl)ethyl]amino]-4-pyrimidinyl]methylamino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 852443-40-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-  
 [(1S)-1-(4-fluorophenyl)ethyl]-6-(4-morpholinyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 852443-41-5 CAPLUS  
 CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-  
 6-(4-morpholinyl)-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA INDEX  
 NAME)

Absolute stereochemistry.



RN 852443-42-6 CAPLUS  
 CN Benzeneethanol,  $\beta$ -[[5-chloro-4-[(5-cyclopropyl-1H-pyrazol-3-yl)amino]-  
 6-(4-methyl-1-piperazinyl)-2-pyrimidinyl]amino]-4-fluoro-, ( $\beta$ R)- (CA  
 INDEX NAME)


Absolute stereochemistry.



RN 852443-43-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(1S)-1-(4-fluorophenyl)ethyl]-6-(1-pyrrolidinyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-44-8 CAPLUS

CN 1,2-Propanediol, 3-[[5-chloro-6-[(5-ethoxy-1H-pyrazol-3-yl)amino]-2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino]-4-pyrimidinyl]amino]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-45-9 CAPLUS

CN 1,2-Propanediol, 3-[[5-chloro-2-[[[(1S)-1-(4-fluorophenyl)ethyl]amino]-6-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-4-pyrimidinyl]amino]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 852443-46-0 CAPLUS

CN 1,2-Propanediol, 3-[[5-chloro-2-[[[(1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino]-6-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-4-pyrimidinyl]amino]-, (2R)- (CA INDEX NAME)


Absolute stereochemistry.






RN 852443-47-1 CAPLUS  
 CN 1,3-Propanediol, 2-[[5-chloro-2-[[ (1S)-1-(4-fluorophenyl)ethyl]amino]-6-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 852443-48-2 CAPLUS  
 CN 1,3-Propanediol, 2-[[5-chloro-2-[[ (1R)-1-(4-fluorophenyl)-2-hydroxyethyl]amino]-6-[[5-(1-methylethoxy)-1H-pyrazol-3-yl]amino]-4-pyrimidinyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



OSC.G 17 THERE ARE 17 CAPLUS RECORDS THAT CITE THIS RECORD (19 CITINGS)  
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

10/595,807

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 19 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2005:140796 CAPLUS  
 DN 142:240444  
 TI Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase  
 inhibitors, especially of Aurora-2 and GSK-3  
 IN Bebbington, David; Charrier, Jean-damien; Golec, Julian; Miller, Andrew;  
 Knegt, Ronald  
 PA UK  
 SO U.S. Pat. Appl. Publ., 164 pp.  
 CODEN: USXXCO  
 DT Patent same as #26  
 LA English  
 FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050038023	A1	20050217	US 2003-632428	20030801
	US 7531536	B2	20090512		
	EP 1698627	A1	20060906	EP 2006-10798	20010914
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	CA 2432303	A1	20020829	CA 2001-2432303	20011219
	AU 2002255452	A1	20020904	AU 2002-255452	20011219
	AU 2002255452	B2	20060608		
	CA 2432223	A1	20020906	CA 2001-2432223	20011219
	CA 2432223	C	20080520		
	AU 2001297619	A1	20020912	AU 2001-297619	20011219
	AU 2001297619	B2	20060608		
	US 20030036543	A1	20030220	US 2001-25164	20011219
	US 6664247	B2	20031216		
	EP 1345922	A1	20030924	EP 2001-271061	20011219
	EP 1345922	B1	20060531		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EP 1355905	A1	20031029	EP 2001-273861	20011219
	EP 1355905	B1	20070221		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	NZ 526472	A	20040430	NZ 2001-526472	20011219
	JP 2004518743	T	20040624	JP 2002-565976	20011219
	JP 2004519479	T	20040702	JP 2002-567928	20011219
	JP 4234435	B2	20090304		
	HU 2004000842	A2	20040728	HU 2004-842	20011219
	NZ 526473	A	20050624	NZ 2001-526473	20011219
	EP 1702920	A1	20060920	EP 2006-11799	20011219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	ZA 2003004468	A	20040624	ZA 2003-4468	20030609
	ZA 2003004469	A	20040624	ZA 2003-4469	20030609
	ZA 2003004470	A	20040624	ZA 2003-4470	20030609
	ZA 2003004471	A	20040624	ZA 2003-4471	20030609
	ZA 2003004473	A	20040624	ZA 2003-4473	20030609
	ZA 2003004475	A	20040624	ZA 2003-4475	20030609
	ZA 2003004472	A	20040625	ZA 2003-4472	20030609
	ZA 2003004474	A	20040625	ZA 2003-4474	20030609
	NO 2003002704	A	20030821	NO 2003-2704	20030613
	MX 2003005609	A	20031006	MX 2003-5609	20030620
	MX 2003005610	A	20031006	MX 2003-5610	20030620

US	20040224944	A1	20041111	US	2003-624800	20030722
US	7008948	B2	20060307			
US	20040116454	A1	20040617	US	2003-692355	20031023
US	7390815	B2	20080624			
US	20040157893	A1	20040812	US	2003-722374	20031125
US	20040132781	A1	20040708	US	2003-736426	20031215
US	7087603	B2	20060808			
US	20040167141	A1	20040826	US	2004-775699	20040210
US	7427681	B2	20080923			
HK	1060347	A1	20061201	HK	2004-101883	20040315
JP	2005097322	A	20050414	JP	2004-366925	20041217
US	20070270444	A1	20071122	US	2006-369220	20060306
AU	2006201228	A1	20060413	AU	2006-201228	20060321
AU	2006201229	A1	20060413	AU	2006-201229	20060321
AU	2006201229	B2	20081120			
AU	2006201230	A1	20060413	AU	2006-201230	20060321
AU	2006201230	B2	20080911			
AU	2006201262	A1	20060427	AU	2006-201262	20060321
AU	2006201262	B2	20080904			
AU	2006201263	A1	20060427	AU	2006-201263	20060321
AU	2006201263	B2	20081030			
AU	2006201264	A1	20060427	AU	2006-201264	20060321
AU	2006201265	A1	20060427	AU	2006-201265	20060321
AU	2006201265	B2	20080904			
US	20060258658	A1	20061116	US	2006-492450	20060725
IN	2007KN02703	A	20080801	IN	2007-KN2703	20070723
JP	2008115195	A	20080522	JP	2008-15681	20080125
JP	2008189682	A	20080821	JP	2008-95581	20080401
JP	2008260767	A	20081030	JP	2008-95584	20080401
JP	2008222719	A	20080925	JP	2008-97620	20080403
JP	2008189687	A	20080821	JP	2008-98506	20080404
US	20080287444	A1	20081120	US	2008-109598	20080425
JP	2008201808	A	20080904	JP	2008-121723	20080507
JP	2008247920	A	20081016	JP	2008-121724	20080507
JP	2008247921	A	20081016	JP	2008-121727	20080507
AU	2008252044	A1	20090122	AU	2008-252044	20081203
JP	2009155352	A	20090716	JP	2009-101481	20090417
PRAI	US 2000-257887P	P	20001221			
	US 2001-286949P	P	20010427			
	US 2001-25164	A1	20011219			
	US 2000-232795P	P	20000915			
	AU 2001-296871	A3	20010914			
	AU 2001-296875	A3	20010914			
	AU 2001-90914	A	20010914			
	AU 2001-90944	A3	20010914			
	AU 2001-91013	A3	20010914			
	AU 2001-94558	A3	20010914			
	AU 2001-96871	T0	20010914			
	AU 2001-96875	T0	20010914			
	EP 2001-971082	A3	20010914			
	JP 2002-526860	A3	20010914			
	US 2001-952671	A3	20010914			
	US 2001-953471	A3	20010914			
	US 2001-955601	A3	20010914			
	AU 2002-234047	A3	20011219			
	AU 2002-34047	T0	20011219			
	EP 2001-273861	A	20011219			


EP 2001-994323 A3 20011219  
 JP 2002-551561 A3 20011219  
 JP 2002-557938 A3 20011219  
 JP 2002-559413 A3 20011219  
 JP 2002-563142 A3 20011219  
 JP 2002-565976 A3 20011219  
 JP 2002-567928 A3 20011219  
 US 2001-26966 A1 20011219  
 WO 2001-US49139 W 20011219  
 WO 2001-US50312 W 20011219  
 JP 2002-551562 A3 20011220  
 JP 2002-559414 A3 20011220  
 US 2001-34019 A3 20011220  
 US 2001-34683 A1 20011220  
 IN 2003-KN795 A3 20030619  
 US 2003-624800 A3 20030722  
 US 2004-775699 A1 20040210  
 JP 2004-366925 A3 20041217  
 AU 2006-201396 A3 20060404

OS CASREACT 142:240444; MARPAT 142:240444

AB The title compds. I [Z1 = N, CR8; Z2 = N, CH; and at least one of Z1 and Z2 = N; Rb, Rc = TR3, LZR3; C2RbRc = (un)substituted fused (hetero)cycle; Q = NR4, O, S, etc.; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, carbocyclyl; T = a bond, alkylidene (un)interrupted by O, S, NR4, CO, etc.; Z = alkylidene; L = O, S, SO, SO2, etc.; R2, R2a = R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, etc.; R = H, (un)substituted aliphatic, (hetero)aryl, heterocyclyl; R4 = R7, COR7, SO2R7, etc.; W = CO, CO2, CONR6, etc.; R6, R7 = H, alkyl; or N(R6)2 or N(R7)2 = heterocyclyl, heteroaryl] were prepared For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in tert-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20  $\mu$ M: GSK-3 $\beta$ , AURORA-2, CDK-2, ERK2, AKT, and human Src kinase. I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).

IT 438205-78-8P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 438205-78-8 CAPLUS  
 CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-phenyl-N2-(3-pyridinylmethyl)- (CA INDEX NAME)



The claims contain a R2 sub on this carbon which is not H

10/595,807

OSC.G 10 THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (42 CITINGS)

L7 ANSWER 20 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2003:757700 CAPLUS  
 DN 139:276913  
 TI Preparation of thiazolylaminopyrimidines and related compounds as  
 inhibitors of protein kinases  
 IN Bebbington, David  
 PA Vertex Pharmaceuticals, Inc., USA; Binch, Hayley; Charrier, Jean-Damien;  
 Everitt, Simon; Golec, Julian M. C.; Kay, David; Knegetel, Ronald; Miller,  
 Andrew; Pierard, Francoise; et al.  
 SO PCT Int. Appl., 68 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003078423	A1	20030925	WO 2003-US7958	20030314
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003220300	A1	20030929	AU 2003-220300	20030314
	US 20030225073	A1	20031204	US 2003-389707	20030314
	US 6846928	B2	20050125		
	EP 1485376	A1	20041215	EP 2003-716598	20030314
	EP 1485376	B1	20070627		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	AT 365733	T	20070715	AT 2003-716598	20030314
	ES 2289279	T3	20080201	ES 2003-716598	20030314
PRAI	US 2002-364842P	P	20020315		
	WO 2003-US7958	W	20030314		

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 139:276913


AB Title compds. I [X = O, S, (un)substituted NH; Y = N, (un)substituted CH; one of Z1 and Z2 = (un)substituted CH, the other is N; Q = (un)substituted NH, CH2, S, O, bond; D = aryl, heteroaryl] were prepared for use as inhibitors of GSK-3, Aurora-2, or Src protein kinases (no data). Thus, the quinazoline II was obtained by chlorinating 4-quinazolinone and reaction with 2-aminothiazole.

IT 606092-46-0P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of thiazolylaminopyrimidines and related compds. as inhibitors of protein kinases)

RN 606092-46-0 CAPLUS

CN 2,4-Pyrimidinediamine, N2-ethyl-N2-[(3-fluorophenyl)methyl]-5,6-dimethyl-N4-[5-(1-methylethyl)-1H-imidazol-2-yl]- (CA INDEX NAME)



OSC.G	6	THERE ARE 6 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
RE.CNT	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
		ALL CITATIONS AVAILABLE IN THE RE FORMAT



L7 ANSWER 21 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2003:757527 CAPLUS  
 DN 139:255405  
 TI Azinylaminoazoles as inhibitors of protein kinases, and their therapeutic use  
 IN Bebbington, David; Binch, Hayley; Charrier, Jean-Damien; Everitt, Simon; Golec, Julian M. C.; Kay, David; Knegt, Ronald; Miller, Andrew; Pierard, Francoise  
 PA Vertex Pharmaceuticals, Inc., USA  
 SO PCT Int. Appl., 68 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003077921	A1	20030925	WO 2003-US7957	20030314
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2003220299	A1	20030929	AU 2003-220299	20030314
	US 20040009974	A1	20040115	US 2003-389296	20030314
	US 7091343	B2	20060815		
	EP 1485100	A1	20041215	EP 2003-716597	20030314
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	US 20070179133	A1	20070802	US 2006-504528	20060815
PRAI	US 2002-365003P	P	20020315		
	US 2003-389296	A3	20030314		
	WO 2003-US7957	W	20030314		

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


OS MARPAT 139:255405

AB The invention provides azinylaminoazole compds. useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compns. comprising the compds. and methods of using the compns. in the treatment of various diseases, conditions, or disorders.

IT 603932-69-0  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (azinylaminoazoles as inhibitors of protein kinases, therapeutic use, and use with other agents)

RN 603932-69-0 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(4-cyclopropyl-1H-pyrazol-1-yl)-N2-ethyl-N2-[(3-fluorophenyl)methyl]-5,6-dimethyl- (CA INDEX NAME)



OSC.G 8 THERE ARE 8 CAPLUS RECORDS THAT CITE THIS RECORD (9 CITINGS)  
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 22 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2003:454299 CAPLUS  
 DN 139:36535  
 TI Preparation of pyrimidine derivatives as modulators of insulin-like growth factor-1 receptor (IGF-1)  
 IN Barlaam, Bernard; Pape, Andrew; Thomas, Andrew  
 PA Astrazeneca AB, Swed.  
 SO PCT Int. Appl., 78 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003048133	A1	20030612	WO 2002-SE2221	20021203
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2467838	A1	20030612	CA 2002-2467838	20021203
	AU 2002365864	A1	20030617	AU 2002-365864	20021203
	AU 2002365864	B2	20070830		
	BR 2002014605	A	20040914	BR 2002-14605	20021203
	EP 1456182	A1	20040915	EP 2002-791165	20021203
	EP 1456182	B1	20090311		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	HU 2004001855	A2	20041228	HU 2004-1855	20021203
	HU 2004001855	A3	20080630		
	CN 1617858	A	20050518	CN 2002-827802	20021203
	CN 1289486	C	20061213		
	JP 2005515998	T	20050602	JP 2003-549325	20021203
	NZ 533130	A	20061130	NZ 2002-533130	20021203
	RU 2317291	C2	20080220	RU 2004-121029	20021203
	AT 425150	T	20090315	AT 2002-791165	20021203
	ES 2323125	T3	20090707	ES 2002-791165	20021203
	IN 2004DN01377	A	20050401	IN 2004-DN1377	20040521
	ZA 2004004223	A	20050829	ZA 2004-4223	20040528
	MX 2004005347	A	20040927	MX 2004-5347	20040603
	NO 2004002872	A	20040706	NO 2004-2872	20040706
	US 20050054638	A1	20050310	US 2004-497744	20041108
	US 7521453	B2	20090421		
	US 20090131463	A1	20090521	US 2009-359541	20090126
PRAI	SE 2001-4140	A	20011207		
	WO 2002-SE2221	W	20021203		
	US 2004-497744	A1	20041108		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 139:36535

AB Pyrimidinediamines I [ R1, R4 = (un)substituted heteroarom.; R2 = alkyl, haloalkyl, hydroxyalkyl, alkoxy (sic); R3 = H, halogen, CF3] were prepared for use as modulators of IGF-1 in the treatment of cancer with IC50 in the


IGF-1R kinase assay of  $\leq 100 \mu\text{M}$  and in the IGF-stimulated cell proliferation test of  $\leq 50 \mu\text{M}$ . Thus, 5-bromo-2,4-dichloropyrimidine was treated with 3-amino-5-methyl-1H-pyrazole, followed by 5-aminomethyl-3-methylisoxazole hydrochloride to give the diamine II.

IT 543712-73-8P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of pyrimidine derivs. as modulators of insulin-like growth factor-1 receptor (IGF-1))

RN 543712-73-8 CAPLUS

CN 3-Isloxazolecarboxylic acid, 5-[[[5-bromo-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]methyl]-, methyl ester (CA INDEX NAME)



IT	543710-62-9P	543710-64-1P	543710-66-3P
	543710-68-5P	543710-71-0P	543710-73-2P
	543710-75-4P	543710-77-6P	543710-79-8P
	543710-81-2P	543710-83-4P	543710-85-6P
	543710-87-8P	543710-89-0P	543710-91-4P
	543710-93-6P	543710-95-8P	543710-97-0P
	543710-99-2P	543711-01-9P	543711-04-2P
	543711-06-4P	543711-08-6P	543711-11-1P
	543711-13-3P	543711-15-5P	543711-17-7P
	543711-19-9P	543711-21-3P	543711-24-6P
	543711-27-9P	543711-29-1P	543711-31-5P
	543711-33-7P	543711-35-9P	543711-38-2P
	543711-40-6P	543711-42-8P	543711-44-0P
	543711-46-2P	543711-48-4P	543711-50-8P
	543711-52-0P	543711-57-5P	543711-59-7P
	543711-60-0P	543711-62-2P	543711-63-3P
	543711-68-8P	543711-70-2P	543711-72-4P
	543711-74-6P	543711-76-8P	543711-78-0P
	543711-80-4P	543711-82-6P	543711-84-8P
	543711-86-0P	543711-88-2P	543711-90-6P
	543711-92-8P	543711-94-0P	543711-95-1P
	543711-97-3P	543711-99-5P	543712-01-2P
	543712-03-4P	543712-05-6P	543712-07-8P
	543712-09-0P	543712-11-4P	543712-13-6P
	543712-15-8P	543712-17-0P	543712-18-1P
	543712-20-5P	543712-22-7P	543712-24-9P
	543712-26-1P	543712-28-3P	543712-30-7P
	543712-32-9P	543712-34-1P	543712-36-3P
	543712-38-5P	543712-40-9P	543712-42-1P
	543712-44-3P	543712-46-5P	543712-48-7P
	543712-50-1P	543712-52-3P	543712-54-5P
	543712-56-7P	543712-58-9P	543712-61-4P


543712-63-6P      543712-65-8P      543712-67-0P  
 543712-69-2P      543712-71-6P      543712-75-0P  
 543712-77-2P      543712-79-4P      543713-64-0P  
 543713-65-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrimidine derivs. as modulators of insulin-like growth factor-1 receptor (IGF-1))


RN 543710-62-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(3-methyl-5-isoxazolyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543710-64-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[(3-methyl-5-isoxazolyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543710-66-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 543710-68-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[[3-(1-methylethyl)-5-isoxazolyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543710-71-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 543710-73-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[3-(2-methoxyphenyl)-5-isoxazolyl]methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543710-75-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[[3-(2-methoxyphenyl)-5-isoxazolyl]methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543710-77-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 543710-79-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 543710-81-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 543710-83-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 543710-85-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-ethyl-1H-pyrazol-3-yl)-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)







RN 543710-87-8 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-bromo-N2-[2-(2-furanyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 543710-89-0 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 543710-91-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 543710-93-6 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(2-pyridinylmethyl)- (CA INDEX NAME)

10/595,807




RN 543710-95-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 543710-97-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[2-(1H-imidazol-5-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543710-99-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 543711-01-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[2-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 543711-04-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[2-(3-pyridinyl)ethyl]- (CA INDEX NAME)



RN 543711-06-4 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(5-methyl-2-pyrazinyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 543711-08-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (CA INDEX NAME)

10/595,807




RN 543711-11-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[3-(2-chlorophenyl)-5-isoxazolyl]methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543711-13-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[3-(2-chlorophenyl)-5-isoxazolyl]methyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 543711-15-5 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-methyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 543711-17-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[2-(3-methyl-5-isoxazolyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543711-19-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[[3-(2-chlorophenyl)-5-isoxazolyl]methyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)




RN 543711-21-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-propyl-1H-pyrazol-3-yl)-N2-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 543711-24-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 543711-27-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-ethyl-1H-pyrazol-3-yl)-N2-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 543711-29-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-ethyl-1H-pyrazol-3-yl)-N2-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 543711-31-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-propyl-1H-pyrazol-3-yl)-N2-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 543711-33-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[[3-(2-fluorophenyl)-5-isoxazolyl]methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543711-35-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-(2-pyridinylmethyl)- (CA INDEX NAME)



RN 543711-38-2 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-[2-(trifluoromethoxy)phenyl]-5-isoxazolyl]methyl)- (CA INDEX NAME)






RN 543711-40-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-cyclopropyl-1H-pyrazol-3-yl)-N2-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 543711-42-8 CAPLUS

CN Benzonitrile, 2-[5-[[[5-chloro-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]methyl]-3-isoxazolyl]- (CA INDEX NAME)




RN 543711-44-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[3-(2-fluorophenyl)-5-isoxazolyl]methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543711-46-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[[3-(2-fluorophenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 543711-48-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 543711-50-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[[3-(2-fluorophenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 543711-52-0 CAPLUS

CN Benzonitrile, 2-[5-[[[5-bromo-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]methyl]-3-isoxazolyl]- (CA INDEX NAME)




RN 543711-57-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-(3-methyl-5-isoxazolyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543711-59-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-ethyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 543711-60-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(3-methyl-5-isoxazolyl)methyl]-N4-(5-propyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543711-62-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 543711-63-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[[3-(2-ethoxyphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 543711-68-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[[3-[2-(trifluoromethyl)phenyl]-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 543711-70-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[[3-(2-methylphenyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 543711-72-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[2-(3-pyridazinyl)ethyl]- (CA INDEX NAME)




RN 543711-74-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[3-(2-bromophenyl)-5-isoxazolyl]methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543711-76-8 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[2-(4-pyrimidinyl)ethyl]- (CA INDEX NAME)




RN 543711-78-0 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(2-pyrazinylmethyl)- (CA INDEX NAME)



RN 543711-80-4 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[(5-methyl-3-isoxazolyl)methyl]- (CA INDEX NAME)




RN 543711-82-6 CAPLUS  
 CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-propyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 543711-84-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-(3-pyridinylmethyl)- (CA INDEX NAME)



RN 543711-86-0 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-[[3-(2-methoxy-3-pyridinyl)-5-isoxazolyl]methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)



RN 543711-88-2 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[3-(3-methyl-1H-pyrazol-4-yl)propyl]- (CA INDEX NAME)






RN 543711-90-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[3-(3-methyl-1H-pyrazol-4-yl)propyl]- (CA INDEX NAME)




RN 543711-92-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 543711-94-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 543711-95-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-(4-pyridinylmethyl)- (CA INDEX NAME)




RN 543711-97-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[2-(1H-imidazol-5-yl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543711-99-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N2-[[3-(3-methoxyphenyl)-5-isoxazolyl]methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543712-01-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[[3-(3-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 543712-03-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 543712-05-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-propyl-1H-pyrazol-3-yl)-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 543712-07-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 543712-09-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-ethyl-1H-pyrazol-3-yl)-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 543712-11-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[[3-(2-pyridinyl)-5-isoxazolyl]methyl]- (CA INDEX NAME)




RN 543712-13-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[(5-methyl-2-furanyl)methyl]- (CA INDEX NAME)




RN 543712-15-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-(3-furanylmethyl)-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543712-17-0 CAPLUS

CN 2-Pyridinecarbonitrile, 5-[[[5-bromo-4-[[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN 543712-18-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(2-pyridinylmethyl)- (CA INDEX NAME)




RN 543712-20-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(3-furanylmethyl)- (CA INDEX NAME)




RN 543712-22-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[(6-methoxy-3-pyridinyl)methyl]- (CA INDEX NAME)



RN 543712-24-9 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(5-bromo-3-pyridinyl)methyl]-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 543712-26-1 CAPLUS


CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-(2-furanylmethyl)- (CA INDEX NAME)






RN 543712-28-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[2-(3-thienyl)ethyl]- (CA INDEX NAME)




RN 543712-30-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]- (CA INDEX NAME)




RN 543712-32-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[(3-phenyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 543712-34-1 CAPLUS

CN 2,4-Pyrimidinediamine, N2-([2,4'-bipyridin]-2'-ylmethyl)-5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543712-36-3 CAPLUS

CN 2,4-Pyrimidinediamine, N2-([2,3'-bipyridin]-5'-ylmethyl)-5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543712-38-5 CAPLUS

CN 2,4-Pyrimidinediamine, N2-([2,3'-bipyridin]-5'-ylmethyl)-5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543712-40-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(6-chloro-2-pyridinyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543712-42-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[(3-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 543712-44-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[(6-methyl-2-pyridinyl)methyl]- (CA INDEX NAME)




RN 543712-46-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(5,6-dimethyl-2-pyridinyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543712-48-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-[(3-methyl-5-isoxazolyl)methyl]- (CA INDEX NAME)




RN 543712-50-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[1-(2-pyridinyl)ethyl]- (CA INDEX NAME)




RN 543712-52-3 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[1-(3-pyridinyl)ethyl]- (CA INDEX NAME)




RN 543712-54-5 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[1-(3-pyridinyl)ethyl]- (CA INDEX NAME)




RN 543712-56-7 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[1-(3-pyridinyl)propyl]- (CA INDEX NAME)




RN 543712-58-9 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[1-(2-pyridinyl)propyl]- (CA INDEX NAME)




RN 543712-61-4 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[1-(3-pyridinyl)propyl]- (CA INDEX NAME)




RN 543712-63-6 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N2-[(5-bromo-3-pyridinyl)methyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)




RN 543712-65-8 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]- (CA INDEX NAME)




RN 543712-67-0 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-[5-(1,1-dimethylethyl)-1H-pyrazol-3-yl]-N2-[2-(5-pyrimidinyl)ethyl]- (CA INDEX NAME)




RN 543712-69-2 CAPLUS

CN 2,4-Pyrimidinediamine, 5-chloro-N4-(5-propyl-1H-pyrazol-3-yl)-N2-(3-pyridinylmethyl)- (CA INDEX NAME)




RN 543712-71-6 CAPLUS


CN 2,4-Pyrimidinediamine, 5-chloro-N4-[5-(1-methylethyl)-1H-pyrazol-3-yl]-N2-(3-pyridinylmethyl)- (CA INDEX NAME)




RN	543712-75-0	CAPLUS
CN	Methanone, [5-[[[5-bromo-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]methyl]-3-isoxazolyl]-1-pyrrolidinyl- (CA INDEX NAME)	



RN 543712-77-2 CAPLUS  
CN 3-Isoxazolemethanol, 5-[[[5-bromo-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)




RN	543712-79-4	CAPLUS
CN	3-Isoxazolecarboxamide, 5-[[[5-bromo-4-[(5-methyl-1H-pyrazol-3-yl)amino]-2-pyrimidinyl]amino]methyl]- (CA INDEX NAME)	




RN	543713-64-0	CAPLUS
CN	2,4-Pyrimidinediamine, 5-bromo-N2-[1-(3-methyl-5-isoxazolyl)ethyl]-N4-(5-methyl-1H-pyrazol-3-yl)- (CA INDEX NAME)	





RN 543713-65-1 CAPLUS

CN 2,4-Pyrimidinediamine, 5-bromo-N4-(5-methyl-1H-pyrazol-3-yl)-N2-[1-(2-pyridinyl)propyl]- (CA INDEX NAME)



OSC.G 13 THERE ARE 13 CAPLUS RECORDS THAT CITE THIS RECORD (13 CITINGS)  
 RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 23 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2002:615605 CAPLUS  
 DN 137:169539  
 TI Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3, for treatment of cancer, diabetes, and Alzheimer's disease  
 IN Bebbington, David; Charrier, Jean-Damien; Golec, Julian M. C.; Miller, Andrew; Knegetel, Ronald  
 PA Vertex Pharmaceuticals Incorporated, USA  
 SO PCT Int. Appl., 335 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002062789	A1	20020815	WO 2001-US51031	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP	1698627	A1	20060906	EP 2006-10798	20010914
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA	2432222	A1	20020815	CA 2001-2432222	20011219
CA	2432222	C	20080729		
AU	2002246899	A1	20020819	AU 2002-246899	20011219
CA	2432303	A1	20020829	CA 2001-2432303	20011219
WO	2002066461	A1	20020829	WO 2001-US49139	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU	2002255452	A1	20020904	AU 2002-255452	20011219
AU	2002255452	B2	20060608		
CA	2432223	A1	20020906	CA 2001-2432223	20011219
CA	2432223	C	20080520		
WO	2002068415	A1	20020906	WO 2001-US50312	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

AU 2001297619	A1	20020912	AU 2001-297619	20011219
AU 2001297619	B2	20060608		
US 20030004161	A1	20030102	US 2001-26975	20011219
US 6653300	B2	20031125		
US 20030055068	A1	20030320	US 2001-26967	20011219
US 6989385	B2	20060124		
US 20030078275	A1	20030424	US 2001-27001	20011219
US 6653301	B2	20031125		
US 20030105090	A1	20030605	US 2001-26966	20011219
EP 1345922	A1	20030924	EP 2001-271061	20011219
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1345927	A1	20030924	EP 2001-994510	20011219
EP 1345927	B1	20060517		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1355905	A1	20031029	EP 2001-273861	20011219
EP 1355905	B1	20070221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004518703	T	20040624	JP 2002-563142	20011219
JP 4160395	B2	20081001		
JP 2004518743	T	20040624	JP 2002-565976	20011219
HU 2004000638	A2	20040628	HU 2004-638	20011219
JP 2004519479	T	20040702	JP 2002-567928	20011219
JP 4234435	B2	20090304		
HU 2004000842	A2	20040728	HU 2004-842	20011219
US 20040214814	A1	20041028	US 2001-26992	20011219
CN 1549812	A	20041124	CN 2001-822105	20011219
NZ 526473	A	20050624	NZ 2001-526473	20011219
NZ 526471	A	20050826	NZ 2001-526471	20011219
AT 327989	T	20060615	AT 2001-271061	20011219
AT 326460	T	20060615	AT 2001-985059	20011219
AT 326461	T	20060615	AT 2001-993360	20011219
AT 326462	T	20060615	AT 2001-994510	20011219
EP 1702920	A1	20060920	EP 2006-11799	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 340172	T	20061015	AT 2001-994323	20011219
ES 2265446	T3	20070216	ES 2001-985059	20011219
ES 2265450	T3	20070216	ES 2001-993360	20011219
ES 2265452	T3	20070216	ES 2001-994510	20011219
ES 2266095	T3	20070301	ES 2001-271061	20011219
AT 354573	T	20070315	AT 2001-273861	20011219
ES 2272567	T3	20070501	ES 2001-994323	20011219
ES 2280313	T3	20070916	ES 2001-273861	20011219
CN 100340555	C	20071003	CN 2001-822136	20011219
CN 100408573	C	20080806	CN 2001-822135	20011219
CN 100436452	C	20081126	CN 2001-822102	20011219
KR 909665	B1	20090729	KR 2003-708409	20011219
US 20030004164	A1	20030102	US 2001-34683	20011220
US 6656939	B2	20031202		
US 20030022885	A1	20030130	US 2001-34019	20011220
US 6727251	B2	20040427		
AT 326463	T	20060615	AT 2001-994347	20011220

AT 353890	T	20070315	AT 2001-991439	20011220
TW 290551	B	20071201	TW 2001-90131846	20011225
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002704	A	20030821	NO 2003-2704	20030613
NO 2003002736	A	20030818	NO 2003-2736	20030616
IN 2003KN00795	A	20050204	IN 2003-KN795	20030619
MX 2003005608	A	20031006	MX 2003-5608	20030620
MX 2003005609	A	20031006	MX 2003-5609	20030620
MX 2003005610	A	20031006	MX 2003-5610	20030620
IN 2003KN00869	A	20050708	IN 2003-KN869	20030703
US 20040224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 20040116454	A1	20040617	US 2003-692355	20031023
US 7390815	B2	20080624		
US 20040157893	A1	20040812	US 2003-722374	20031125
US 20040132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 20040167141	A1	20040826	US 2004-775699	20040210
US 7427681	B2	20080923		
HK 1060347	A1	20061201	HK 2004-101883	20040315
HK 1061389	A1	20061201	HK 2004-102099	20040322
JP 2005097322	A	20050414	JP 2004-366925	20041217
US 20070270444	A1	20071122	US 2006-369220	20060306
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321
AU 2006201229	B2	20081120		
AU 2006201230	A1	20060413	AU 2006-201230	20060321
AU 2006201230	B2	20080911		
AU 2006201262	A1	20060427	AU 2006-201262	20060321
AU 2006201262	B2	20080904		
AU 2006201263	A1	20060427	AU 2006-201263	20060321
AU 2006201263	B2	20081030		
AU 2006201264	A1	20060427	AU 2006-201264	20060321
AU 2006201265	A1	20060427	AU 2006-201265	20060321
AU 2006201265	B2	20080904		
US 20060258658	A1	20061116	US 2006-492450	20060725
IN 2007KN02703	A	20080801	IN 2007-KN2703	20070723
JP 2008115195	A	20080522	JP 2008-15681	20080125
JP 2008189682	A	20080821	JP 2008-95581	20080401
JP 2008260767	A	20081030	JP 2008-95584	20080401
JP 2008222719	A	20080925	JP 2008-97620	20080403
JP 2008189687	A	20080821	JP 2008-98506	20080404
US 20080287444	A1	20081120	US 2008-109598	20080425
JP 2008201808	A	20080904	JP 2008-121723	20080507
JP 2008247920	A	20081016	JP 2008-121724	20080507
JP 2008247921	A	20081016	JP 2008-121727	20080507
AU 2008252044	A1	20090122	AU 2008-252044	20081203
JP 2009155352	A	20090716	JP 2009-101481	20090417
PRAI US 2000-257887P	P	20001221		
US 2001-286949P	P	20010427		

US 2000-232795P	P	20000915
AU 2001-296871	A3	20010914
AU 2001-296875	A3	20010914
AU 2001-90914	A	20010914
AU 2001-90944	A3	20010914
AU 2001-91013	A3	20010914
AU 2001-94558	A3	20010914
AU 2001-96871	T0	20010914
AU 2001-96875	T0	20010914
EP 2001-971082	A3	20010914
JP 2002-526860	A3	20010914
US 2001-952671	A3	20010914
US 2001-953471	A3	20010914
US 2001-955601	A3	20010914
AU 2002-234047	A3	20011219
AU 2002-34047	T0	20011219
EP 2001-273861	A	20011219
EP 2001-994323	A3	20011219
JP 2002-551561	A3	20011219
JP 2002-557938	A3	20011219
JP 2002-559413	A3	20011219
JP 2002-563142	A3	20011219
JP 2002-565976	A3	20011219
JP 2002-567928	A3	20011219
US 2001-26966	A1	20011219
WO 2001-US49139	W	20011219
WO 2001-US50312	W	20011219
WO 2001-US51031	W	20011219
JP 2002-551562	A3	20011220
JP 2002-559414	A3	20011220
US 2001-34019	A3	20011220
US 2001-34683	A1	20011220
IN 2003-KN795	A3	20030619
US 2003-624800	A3	20030722
US 2004-775699	A1	20040210
JP 2004-366925	A3	20041217
AU 2006-201396	A3	20060404

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 137:169539

AB 285 Title compds. I [wherein Z1 = N or CR8; Z2 = N or CH; and at least 1 of Z1 and Z2 = N; Rx and Ry = independently TR3 or LZR3; or C2RxRy = (un)substituted fused (hetero)cycle; Q = NR4, O, S, C(R6')2, 1,2-cyclo(prop/but)anediyl, or 1,3-cyclobutanediyl; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, or carbocyclyl; T = a bond or alkylidene chain (un)interrupted by O, S, NR4, CO, CONH, NHCO, SO2, SO2NH, NHSO2, CO2, OCO, OCONH, or NHCO2, with provisos; Z = alkylidene chain; L = O, S, SO, SO2, NR6SO2, SO2NR6, NR6, NR6CO, NR6CO2, NR6CONR6, NR6SO2NR6, NR6NR6, OCONR6, or W; R2 and R2a = independently R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, COR, CO2R, CO(CH2)0-1COR, NO2, CN, SO0-2R, N(R4)2, carbamoyl, sulfamoyl, OCOR, acylamino, hydrazino, ureido, etc.; R = independently H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl; R4 = independently R7, COR7, carboxy, CON(R7)2, or SO2R7; W = CO, CO2, CONR6, C(R6)2O, C(R6)2SO0-2, C(R6)2SO2NR6, C(R6)2NR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, or C(R6)2NR6CONR6; R6, R6', R7 = independently H or aliphatic; or N(R6)2 or N(R7)2 = independently heterocyclyl or heteroaryl; or C(R6')2 =

carbocycle; R8 = R, halo, OR, COR, CO2R, COCOR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2] were prepared

However, the claims pertain only to

3-(2-amino-4-pyrimidinylamino)-1H-pyrazoles, i.e. Z1 = Z2 = N, and Q = NH.

I are protein kinase inhibitors, especially of Aurora-2 and GSK-3. For

example,

the (pyrazolylamino)quinazoline II was refluxed with thiophenol in t-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20  $\mu$ M: GSK-3 $\beta$  (232 compds.), AURORA-2 (227 compds.), CDK-2 (13 compds.), ERK2 (8 compds.), AKT (10 compds.), and Human Src kinase (183 compds.). I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).


IT 438205-78-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 438205-78-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-phenyl-N2-(3-pyridinylmethyl)- (CA INDEX NAME)



OSC.G 11 THERE ARE 11 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)  
 RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 24 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2002:575069 CAPLUS  
 DN 137:109292  
 TI Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3, for treatment of cancer, diabetes, and Alzheimer's disease  
 IN Bebbington, David; Charrier, Jean-Damien; Davies, Robert; Golec, Julian; Kay, David; Knegetel, Ronald; Patel, Sanjay  
 PA Vertex Pharmaceuticals Incorporated, USA  
 SO PCT Int. Appl., 337 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002059111	A2	20020801	WO 2001-US51120	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP	1698627	A1	20060906	EP 2006-10798	20010914
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
CA	2432131	A1	20020801	CA 2001-2432131	20011219
CA	2432131	C	20080708		
AU	2002245198	A1	20020806	AU 2002-245198	20011219
CA	2432303	A1	20020829	CA 2001-2432303	20011219
WO	2002066461	A1	20020829	WO 2001-US49139	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU	2002255452	A1	20020904	AU 2002-255452	20011219
AU	2002255452	B2	20060608		
CA	2432223	A1	20020906	CA 2001-2432223	20011219
CA	2432223	C	20080520		
WO	2002068415	A1	20020906	WO 2001-US50312	20011219
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

AU 2001297619	A1	20020912	AU 2001-297619	20011219
AU 2001297619	B2	20060608		
US 20030004161	A1	20030102	US 2001-26975	20011219
US 6653300	B2	20031125		
US 20030055068	A1	20030320	US 2001-26967	20011219
US 6989385	B2	20060124		
US 20030078275	A1	20030424	US 2001-27001	20011219
US 6653301	B2	20031125		
US 20030105090	A1	20030605	US 2001-26966	20011219
EP 1345922	A1	20030924	EP 2001-271061	20011219
EP 1345922	B1	20060531		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
EP 1345926	A2	20030924	EP 2001-993360	20011219
EP 1345926	B1	20060517		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001016493	A	20030930	BR 2001-16493	20011219
EP 1355905	A1	20031029	EP 2001-273861	20011219
EP 1355905	B1	20070221		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
NZ 526468	A	20040326	NZ 2001-526468	20011219
NZ 526472	A	20040430	NZ 2001-526472	20011219
JP 2004517926	T	20040617	JP 2002-559413	20011219
JP 4160392	B2	20081001		
JP 2004518743	T	20040624	JP 2002-565976	20011219
JP 2004519479	T	20040702	JP 2002-567928	20011219
JP 4234435	B2	20090304		
HU 2004000842	A2	20040728	HU 2004-842	20011219
HU 2004000908	A2	20040728	HU 2004-908	20011219
US 20040214814	A1	20041028	US 2001-26992	20011219
CN 1549812	A	20041124	CN 2001-822105	20011219
NZ 526473	A	20050624	NZ 2001-526473	20011219
AT 327989	T	20060615	AT 2001-271061	20011219
AT 326460	T	20060615	AT 2001-985059	20011219
AT 326461	T	20060615	AT 2001-993360	20011219
AT 326462	T	20060615	AT 2001-994510	20011219
EP 1702920	A1	20060920	EP 2006-11799	20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
AT 340172	T	20061015	AT 2001-994323	20011219
ES 2265446	T3	20070216	ES 2001-985059	20011219
ES 2265450	T3	20070216	ES 2001-993360	20011219
ES 2265452	T3	20070216	ES 2001-994510	20011219
ES 2266095	T3	20070301	ES 2001-271061	20011219
AT 354573	T	20070315	AT 2001-273861	20011219
ES 2272567	T3	20070501	ES 2001-994323	20011219
ES 2280313	T3	20070916	ES 2001-273861	20011219
CN 100340555	C	20071003	CN 2001-822136	20011219
CN 100408573	C	20080806	CN 2001-822135	20011219
RU 2332415	C2	20080827	RU 2003-122210	20011219
CN 100436452	C	20081126	CN 2001-822102	20011219
US 20030004164	A1	20030102	US 2001-34683	20011220
US 6656939	B2	20031202		
US 20030022885	A1	20030130	US 2001-34019	20011220
US 6727251	B2	20040427		



AT 326463	T	20060615	AT 2001-994347	20011220
AT 353890	T	20070315	AT 2001-991439	20011220
TW 290551	B	20071201	TW 2001-90131846	20011225
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002670	A	20030815	NO 2003-2670	20030612
NO 2003002704	A	20030821	NO 2003-2704	20030613
IN 2003KN00795	A	20050204	IN 2003-KN795	20030619
IN 2003KN00796	A	20070105	IN 2003-KN796	20030619
MX 2003005605	A	20031006	MX 2003-5605	20030620
MX 2003005609	A	20031006	MX 2003-5609	20030620
MX 2003005610	A	20031006	MX 2003-5610	20030620
KR 889246	B1	20090319	KR 2003-708385	20030620
US 20040224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 20040116454	A1	20040617	US 2003-692355	20031023
US 7390815	B2	20080624		
US 20040157893	A1	20040812	US 2003-722374	20031125
US 20040132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 20040167141	A1	20040826	US 2004-775699	20040210
US 7427681	B2	20080923		
HK 1059776	A1	20061201	HK 2004-100960	20040212
HK 1060347	A1	20061201	HK 2004-101883	20040315
JP 2005097322	A	20050414	JP 2004-366925	20041217
US 20070270444	A1	20071122	US 2006-369220	20060306
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321
AU 2006201229	B2	20081120		
AU 2006201230	A1	20060413	AU 2006-201230	20060321
AU 2006201230	B2	20080911		
AU 2006201262	A1	20060427	AU 2006-201262	20060321
AU 2006201262	B2	20080904		
AU 2006201263	A1	20060427	AU 2006-201263	20060321
AU 2006201263	B2	20081030		
AU 2006201264	A1	20060427	AU 2006-201264	20060321
AU 2006201265	A1	20060427	AU 2006-201265	20060321
AU 2006201265	B2	20080904		
US 20060258658	A1	20061116	US 2006-492450	20060725
IN 2007KN02703	A	20080801	IN 2007-KN2703	20070723
JP 2008115195	A	20080522	JP 2008-15681	20080125
JP 2008189682	A	20080821	JP 2008-95581	20080401
JP 2008260767	A	20081030	JP 2008-95584	20080401
JP 2008222719	A	20080925	JP 2008-97620	20080403
JP 2008189687	A	20080821	JP 2008-98506	20080404
US 20080287444	A1	20081120	US 2008-109598	20080425
JP 2008201808	A	20080904	JP 2008-121723	20080507
JP 2008247920	A	20081016	JP 2008-121724	20080507
JP 2008247921	A	20081016	JP 2008-121727	20080507
AU 2008252044	A1	20090122	AU 2008-252044	20081203
JP 2009155352	A	20090716	JP 2009-101481	20090417

PRAI	US	2000-257887P	P	20001221
	US	2001-286949P	P	20010427
	US	2000-232795P	P	20000915
	AU	2001-296871	A3	20010914
	AU	2001-296875	A3	20010914
	AU	2001-90914	A	20010914
	AU	2001-90944	A3	20010914
	AU	2001-91013	A3	20010914
	AU	2001-94558	A3	20010914
	AU	2001-96871	T0	20010914
	AU	2001-96875	T0	20010914
	EP	2001-971082	A3	20010914
	JP	2002-526860	A3	20010914
	US	2001-952671	A3	20010914
	US	2001-953471	A3	20010914
	US	2001-955601	A3	20010914
	AU	2002-234047	A3	20011219
	AU	2002-34047	T0	20011219
	EP	2001-273861	A	20011219
	EP	2001-994323	A3	20011219
	JP	2002-551561	A3	20011219
	JP	2002-557938	A3	20011219
	JP	2002-559413	A3	20011219
	JP	2002-563142	A3	20011219
	JP	2002-565976	A3	20011219
	JP	2002-567928	A3	20011219
	US	2001-26966	A1	20011219
	WO	2001-US49139	W	20011219
	WO	2001-US50312	W	20011219
	WO	2001-US51120	W	20011219
	JP	2002-551562	A3	20011220
	JP	2002-559414	A3	20011220
	US	2001-34019	A3	20011220
	US	2001-34683	A1	20011220
	IN	2003-KN795	A3	20030619
	US	2003-624800	A3	20030722
	US	2004-775699	A1	20040210
	JP	2004-366925	A3	20041217
	AU	2006-201396	A3	20060404

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 137:109292

AB Title compds. I [wherein Z1 = N or CR8; Z2 = N or CH; and at least 1 of Z1 and Z2 = N; Rx and Ry = independently TR3 or LZR3; or C2RxRy = (un)substituted fused (hetero)cycle; Q = NR4, O, S, C(6a)2, 1,2-cyclo(prop/but)anediyl, or 1,3-cyclobutanediyl; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, or carbocyclyl; T = a bond or alkylidene chain (un)interrupted by O, S, NR4, CO, CONH, NHCO, SO2, SO2NH, NHSO2, CO2, OCO, OCONH, or NHC02, with provisos; Z = alkylidene chain; L = O, S, SO, SO2, NR6SO2, SO2NR6, NR6, NR6CO, NR6CO2, NR6CONR6, NR6SO2NR6, NR6NR6, OCONR6, or W; R2 and R2a = independently R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, COR, CO2R, CO(CH2)0-1COR, NO2, CN, SO0-2R, N(R4)2, carbamoyl, sulfamoyl, OCOR, acylamino, hydrazino, ureido, etc.; R = independently H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl; R4 = independently R7, COR7, carboxy, CON(R7)2, or SO2R7; W = CO, CO2, CONR6, C(R6)2O, C(R6)2SO0-2, C(R6)2SO2NR6, C(R6)2NR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, or

C(R6)2NR6CONR6; R6, R6a, R7 = independently H or aliphatic; or N(R6)2 or N(R7)2 = independently heterocyclcyl or heteroaryl; or C(R6a)2 = carbocycle; R8 = R, halo, OR, COR, CO2R, COCOR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2] were prepared I are protein kinase inhibitors, especially of Aurora-2 and GSK-3. For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in t-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20  $\mu$ M: GSK-3 $\beta$  (232 compds.), AURORA-2 (227 compds.), CDK-2 (13 compds.), ERK2 (8 compds.), AKT (10 compds.), and Human Src kinase (183 compds.). I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).


IT 438205-78-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 438205-78-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-phenyl-N2-(3-pyridinylmethyl)- (CA INDEX NAME)



OSC.G 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)  
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 25 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2002:555487 CAPLUS  
 DN 137:125169  
 TI Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3  
 IN Bebbington, David; Charrier, Jean-Damien; Golec, Julian; Miller, Andrew; Knegtel, Ronald  
 PA Vertex Pharmaceuticals Incorporated, USA  
 SO PCT Int. Appl., 333 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002057259	A2	20020725	WO 2001-US49401	20011219
	WO 2002057259	A3	20030424		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP	1698627	A1	20060906	EP 2006-10798	20010914
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
CA	2432129	A1	20020725	CA 2001-2432129	20011219
CA	2432129	C	20080826		
AU	2002246731	A1	20020730	AU 2002-246731	20011219
CA	2432303	A1	20020829	CA 2001-2432303	20011219
WO	2002066461	A1	20020829	WO 2001-US49139	20011219
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU	2002255452	A1	20020904	AU 2002-255452	20011219
AU	2002255452	B2	20060608		
CA	2432223	A1	20020906	CA 2001-2432223	20011219
CA	2432223	C	20080520		
WO	2002068415	A1	20020906	WO 2001-US50312	20011219
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,			

	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
AU 2001297619	A1	20020912	AU 2001-297619 20011219
AU 2001297619	B2	20060608	
US 20030004161	A1	20030102	US 2001-26975 20011219
US 6653300	B2	20031125	
US 20030055068	A1	20030320	US 2001-26967 20011219
US 6989385	B2	20060124	
US 20030078275	A1	20030424	US 2001-27001 20011219
US 6653301	B2	20031125	
US 20030105090	A1	20030605	US 2001-26966 20011219
EP 1345922	A1	20030924	EP 2001-271061 20011219
EP 1345922	B1	20060531	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
EP 1353916	A2	20031022	EP 2001-994323 20011219
EP 1353916	B1	20060920	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
EP 1355905	A1	20031029	EP 2001-273861 20011219
EP 1355905	B1	20070221	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
BR 2001016411	A	20031111	BR 2001-16411 20011219
NZ 526472	A	20040430	NZ 2001-526472 20011219
JP 2004517894	T	20040617	JP 2002-557938 20011219
JP 4210520	B2	20090121	
JP 2004518743	T	20040624	JP 2002-565976 20011219
HU 2004000641	A2	20040628	HU 2004-641 20011219
JP 2004519479	T	20040702	JP 2002-567928 20011219
JP 4234435	B2	20090304	
HU 2004000842	A2	20040728	HU 2004-842 20011219
US 20040214814	A1	20041028	US 2001-26992 20011219
CN 1549812	A	20041124	CN 2001-822105 20011219
NZ 526473	A	20050624	NZ 2001-526473 20011219
NZ 526470	A	20060331	NZ 2001-526470 20011219
AP 1588	A	20060430	AP 2003-2816 20011219
AT 327989	T	20060615	AT 2001-271061 20011219
AT 326460	T	20060615	AT 2001-985059 20011219
AT 326461	T	20060615	AT 2001-993360 20011219
AT 326462	T	20060615	AT 2001-994510 20011219
EP 1702920	A1	20060920	EP 2006-11799 20011219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
AT 340172	T	20061015	AT 2001-994323 20011219
ES 2265446	T3	20070216	ES 2001-985059 20011219
ES 2265450	T3	20070216	ES 2001-993360 20011219
ES 2265452	T3	20070216	ES 2001-994510 20011219
ES 2266095	T3	20070301	ES 2001-271061 20011219
AT 354573	T	20070315	AT 2001-273861 20011219
ES 2272567	T3	20070501	ES 2001-994323 20011219
ES 2280313	T3	20070916	ES 2001-273861 20011219
CN 100340555	C	20071003	CN 2001-822136 20011219
CN 100408573	C	20080806	CN 2001-822135 20011219
CN 100436452	C	20081126	CN 2001-822102 20011219
RU 2355688	C2	20090520	RU 2003-122209 20011219
US 20030004164	A1	20030102	US 2001-34683 20011220
US 6656939	B2	20031202	

US 20030022885	A1	20030130	US 2001-34019	20011220
US 6727251	B2	20040427		
AT 326463	T	20060615	AT 2001-994347	20011220
AT 353890	T	20070315	AT 2001-991439	20011220
TW 290551	B	20071201	TW 2001-90131846	20011225
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002703	A	20030819	NO 2003-2703	20030613
NO 2003002704	A	20030821	NO 2003-2704	20030613
IN 2003KN00795	A	20050204	IN 2003-KN795	20030619
IN 2003KN00797	A	20060217	IN 2003-KN797	20030619
MX 2003005607	A	20031006	MX 2003-5607	20030620
MX 2003005609	A	20031006	MX 2003-5609	20030620
MX 2003005610	A	20031006	MX 2003-5610	20030620
KR 843114	B1	20080702	KR 2003-708387	20030620
US 20040224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 20040116454	A1	20040617	US 2003-692355	20031023
US 7390815	B2	20080624		
US 20040157893	A1	20040812	US 2003-722374	20031125
US 20040132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 20040167141	A1	20040826	US 2004-775699	20040210
US 7427681	B2	20080923		
HK 1060347	A1	20061201	HK 2004-101883	20040315
HK 1060349	A1	20070323	HK 2004-101996	20040317
JP 2005097322	A	20050414	JP 2004-366925	20041217
US 20070270444	A1	20071122	US 2006-369220	20060306
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321
AU 2006201229	B2	20081120		
AU 2006201230	A1	20060413	AU 2006-201230	20060321
AU 2006201230	B2	20080911		
AU 2006201262	A1	20060427	AU 2006-201262	20060321
AU 2006201262	B2	20080904		
AU 2006201263	A1	20060427	AU 2006-201263	20060321
AU 2006201263	B2	20081030		
AU 2006201264	A1	20060427	AU 2006-201264	20060321
AU 2006201265	A1	20060427	AU 2006-201265	20060321
AU 2006201265	B2	20080904		
US 20060258658	A1	20061116	US 2006-492450	20060725
IN 2007KN01971	A	20090403	IN 2007-KN1971	20070531
IN 2007KN02703	A	20080801	IN 2007-KN2703	20070723
JP 2008115195	A	20080522	JP 2008-15681	20080125
JP 2008189682	A	20080821	JP 2008-95581	20080401
JP 2008260767	A	20081030	JP 2008-95584	20080401
JP 2008222719	A	20080925	JP 2008-97620	20080403
JP 2008189687	A	20080821	JP 2008-98506	20080404
US 20080287444	A1	20081120	US 2008-109598	20080425
JP 2008201808	A	20080904	JP 2008-121723	20080507
JP 2008247920	A	20081016	JP 2008-121724	20080507

	JP 2008247921	A	20081016	JP 2008-121727	20080507
	AU 2008252044	A1	20090122	AU 2008-252044	20081203
	JP 2009155352	A	20090716	JP 2009-101481	20090417
PRAI	US 2000-257887P	P	20001221		
	US 2001-286949P	P	20010427		
	US 2000-232795P	P	20000915		
	AU 2001-296871	A3	20010914		
	AU 2001-296875	A3	20010914		
	AU 2001-90914	A	20010914		
	AU 2001-90944	A3	20010914		
	AU 2001-91013	A3	20010914		
	AU 2001-94558	A3	20010914		
	AU 2001-96871	T0	20010914		
	AU 2001-96875	T0	20010914		
	EP 2001-971082	A3	20010914		
	JP 2002-526860	A3	20010914		
	US 2001-952671	A3	20010914		
	US 2001-953471	A3	20010914		
	US 2001-955601	A3	20010914		
	AU 2002-234047	A3	20011219		
	AU 2002-34047	T0	20011219		
	EP 2001-273861	A	20011219		
	EP 2001-994323	A3	20011219		
	JP 2002-551561	A3	20011219		
	JP 2002-557938	A3	20011219		
	JP 2002-559413	A3	20011219		
	JP 2002-563142	A3	20011219		
	JP 2002-565976	A3	20011219		
	JP 2002-567928	A3	20011219		
	US 2001-26966	A1	20011219		
	WO 2001-US49139	W	20011219		
	WO 2001-US49401	W	20011219		
	WO 2001-US50312	W	20011219		
	JP 2002-551562	A3	20011220		
	JP 2002-559414	A3	20011220		
	US 2001-34019	A3	20011220		
	US 2001-34683	A1	20011220		
	IN 2003-KN795	A3	20030619		
	IN 2003-KN797	A3	20030619		
	US 2003-624800	A3	20030722		
	US 2004-775699	A1	20040210		
	JP 2004-366925	A3	20041217		
	AU 2006-201396	A3	20060404		

# ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 137:125169

AB The title compds. I [Z1 = N, CR8; Z2 = N. CH; and at least one of Z1 and Z2 = N; Rb, Rc = TR3, LZR3; C2RbRc = (un)substituted fused (hetero)cycle; Q = NR4, O, S, etc.; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, carbocyclyl; T = a bond, alkylidene (un)interrupted by O, S, NR4, CO, etc.; Z = alkylidene; L = O, S, SO, SO2, etc.; R2, R2a = R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, etc.; R = H, (un)substituted aliphatic, (hetero)aryl, heterocyclyl; R4 = R7, COR7, SO2R7, etc.; W = CO, CO2, CONR6, etc.; R6, R7 = H, alkyl; or N(R6)2 or N(R7)2 = heterocyclyl, heteroaryl] were prepared For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in tert-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20  $\mu$ M: GSK-3 $\beta$  (232

comps.), AURORA-2 (227 comps.), CDK-2 (13 comps.), ERK2 (8 comps.), AKT (10 comps.), and Human Src kinase (183 comps.). I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).


IT 438205-78-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 438205-78-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-phenyl-N2-(3-pyridinylmethyl)- (CA INDEX NAME)



OSC.G 12 THERE ARE 12 CAPLUS RECORDS THAT CITE THIS RECORD (18 CITINGS)  
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT



L7 ANSWER 26 OF 26 CAPLUS COPYRIGHT 2009 ACS on STN  
 AN 2002:487556 CAPLUS  
 DN 137:47221  
 TI Preparation of 3-(4-pyrimidinylamino)-1H-pyrazoles as protein kinase inhibitors, especially of Aurora-2 and GSK-3, for treatment of cancer, diabetes, and Alzheimer's disease  
 IN Bebbington, David; Charrier, Jean-Damien; Davies, Robert; Everitt, Simon; Kay, David; Knegetel, Ronald; Patel, Sanjay  
 PA Vertex Pharmaceuticals Incorporated, USA  
 SO PCT Int. Appl., 342 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 FAN.CNT 15

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002050065	A2	20020627	WO 2001-US49140	20011219
	WO 2002050065	A3	20021024		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP	1698627	A1	20060906	EP 2006-10798	20010914
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
CA	2432799	A1	20020627	CA 2001-2432799	20011219
CA	2432799	C	20080819		
AU	2002034047	A	20020701	AU 2002-34047	20011219
CA	2432303	A1	20020829	CA 2001-2432303	20011219
WO	2002066461	A1	20020829	WO 2001-US49139	20011219
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU	2002255452	A1	20020904	AU 2002-255452	20011219
AU	2002255452	B2	20060608		
CA	2432223	A1	20020906	CA 2001-2432223	20011219
CA	2432223	C	20080520		
WO	2002068415	A1	20020906	WO 2001-US50312	20011219
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,			

	BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
AU 2001297619	A1	20020912	AU 2001-297619 20011219
AU 2001297619	B2	20060608	
US 20030004161	A1	20030102	US 2001-26975 20011219
US 6653300	B2	20031125	
US 20030055068	A1	20030320	US 2001-26967 20011219
US 6989385	B2	20060124	
US 20030078275	A1	20030424	US 2001-27001 20011219
US 6653301	B2	20031125	
US 20030105090	A1	20030605	US 2001-26966 20011219
EP 1345922	A1	20030924	EP 2001-271061 20011219
EP 1345922	B1	20060531	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
EP 1345925	A2	20030924	EP 2001-985059 20011219
EP 1345925	B1	20060517	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
EP 1355905	A1	20031029	EP 2001-273861 20011219
EP 1355905	B1	20070221	
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
NZ 526472	A	20040430	NZ 2001-526472 20011219
JP 2004516291	T	20040603	JP 2002-551561 20011219
JP 4160389	B2	20081001	
JP 2004518743	T	20040624	JP 2002-565976 20011219
HU 2004000639	A2	20040628	HU 2004-639 20011219
JP 2004519479	T	20040702	JP 2002-567928 20011219
JP 4234435	B2	20090304	
HU 2004000842	A2	20040728	HU 2004-842 20011219
US 20040214814	A1	20041028	US 2001-26992 20011219
CN 1549812	A	20041124	CN 2001-822105 20011219
NZ 526473	A	20050624	NZ 2001-526473 20011219
NZ 526469	A	20051028	NZ 2001-526469 20011219
AT 327989	T	20060615	AT 2001-271061 20011219
AT 326460	T	20060615	AT 2001-985059 20011219
AT 326461	T	20060615	AT 2001-993360 20011219
AT 326462	T	20060615	AT 2001-994510 20011219
EP 1702920	A1	20060920	EP 2006-11799 20011219
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR		
AT 340172	T	20061015	AT 2001-994323 20011219
ES 2265446	T3	20070216	ES 2001-985059 20011219
ES 2265450	T3	20070216	ES 2001-993360 20011219
ES 2265452	T3	20070216	ES 2001-994510 20011219
ES 2266095	T3	20070301	ES 2001-271061 20011219
AT 354573	T	20070315	AT 2001-273861 20011219
ES 2272567	T3	20070501	ES 2001-994323 20011219
ES 2280313	T3	20070916	ES 2001-273861 20011219
CN 100340555	C	20071003	CN 2001-822136 20011219
CN 100408573	C	20080806	CN 2001-822135 20011219
CN 100436452	C	20081126	CN 2001-822102 20011219
US 20030004164	A1	20030102	US 2001-34683 20011220
US 6656939	B2	20031202	
US 20030022885	A1	20030130	US 2001-34019 20011220
US 6727251	B2	20040427	
AT 326463	T	20060615	AT 2001-994347 20011220

AT 353890	T	20070315	AT 2001-991439	20011220
TW 290551	B	20071201	TW 2001-90131846	20011225
ZA 2003004468	A	20040624	ZA 2003-4468	20030609
ZA 2003004469	A	20040624	ZA 2003-4469	20030609
ZA 2003004470	A	20040624	ZA 2003-4470	20030609
ZA 2003004471	A	20040624	ZA 2003-4471	20030609
ZA 2003004473	A	20040624	ZA 2003-4473	20030609
ZA 2003004475	A	20040624	ZA 2003-4475	20030609
ZA 2003004472	A	20040625	ZA 2003-4472	20030609
ZA 2003004474	A	20040625	ZA 2003-4474	20030609
NO 2003002671	A	20030818	NO 2003-2671	20030612
NO 2003002704	A	20030821	NO 2003-2704	20030613
IN 2003KN00795	A	20050204	IN 2003-KN795	20030619
IN 2003KN00794	A	20061027	IN 2003-KN794	20030619
MX 2003005606	A	20031006	MX 2003-5606	20030620
MX 2003005609	A	20031006	MX 2003-5609	20030620
MX 2003005610	A	20031006	MX 2003-5610	20030620
KR 875091	B1	20081222	KR 2003-708427	20030620
US 20040224944	A1	20041111	US 2003-624800	20030722
US 7008948	B2	20060307		
US 20040116454	A1	20040617	US 2003-692355	20031023
US 7390815	B2	20080624		
US 20040157893	A1	20040812	US 2003-722374	20031125
US 20040132781	A1	20040708	US 2003-736426	20031215
US 7087603	B2	20060808		
US 20040167141	A1	20040826	US 2004-775699	20040210
US 7427681	B2	20080923		
HK 1060346	A1	20061201	HK 2004-101882	20040315
HK 1060347	A1	20061201	HK 2004-101883	20040315
JP 2005097322	A	20050414	JP 2004-366925	20041217
US 20070270444	A1	20071122	US 2006-369220	20060306
AU 2006201228	A1	20060413	AU 2006-201228	20060321
AU 2006201229	A1	20060413	AU 2006-201229	20060321
AU 2006201229	B2	20081120		
AU 2006201230	A1	20060413	AU 2006-201230	20060321
AU 2006201230	B2	20080911		
AU 2006201262	A1	20060427	AU 2006-201262	20060321
AU 2006201262	B2	20080904		
AU 2006201263	A1	20060427	AU 2006-201263	20060321
AU 2006201263	B2	20081030		
AU 2006201264	A1	20060427	AU 2006-201264	20060321
AU 2006201265	A1	20060427	AU 2006-201265	20060321
AU 2006201265	B2	20080904		
US 20060258658	A1	20061116	US 2006-492450	20060725
IN 2007KN02703	A	20080801	IN 2007-KN2703	20070723
JP 2008115195	A	20080522	JP 2008-15681	20080125
JP 2008189682	A	20080821	JP 2008-95581	20080401
JP 2008260767	A	20081030	JP 2008-95584	20080401
JP 2008222719	A	20080925	JP 2008-97620	20080403
JP 2008189687	A	20080821	JP 2008-98506	20080404
US 20080287444	A1	20081120	US 2008-109598	20080425
JP 2008201808	A	20080904	JP 2008-121723	20080507
JP 2008247920	A	20081016	JP 2008-121724	20080507
JP 2008247921	A	20081016	JP 2008-121727	20080507
AU 2008252044	A1	20090122	AU 2008-252044	20081203
JP 2009155352	A	20090716	JP 2009-101481	20090417
PRAI US 2000-257887P	P	20001221		

US 2001-286949P	P	20010427
US 2000-232795P	P	20000915
AU 2001-296871	A3	20010914
AU 2001-296875	A3	20010914
AU 2001-90914	A	20010914
AU 2001-90944	A3	20010914
AU 2001-91013	A3	20010914
AU 2001-94558	A3	20010914
AU 2001-96871	T0	20010914
AU 2001-96875	T0	20010914
EP 2001-971082	A3	20010914
JP 2002-526860	A3	20010914
US 2001-952671	A3	20010914
US 2001-953471	A3	20010914
US 2001-955601	A3	20010914
AU 2002-234047	A3	20011219
AU 2002-34047	T0	20011219
EP 2001-273861	A	20011219
EP 2001-994323	A3	20011219
JP 2002-551561	A3	20011219
JP 2002-557938	A3	20011219
JP 2002-559413	A3	20011219
JP 2002-563142	A3	20011219
JP 2002-565976	A3	20011219
JP 2002-567928	A3	20011219
US 2001-26966	A1	20011219
WO 2001-US49139	W	20011219
WO 2001-US49140	W	20011219
WO 2001-US50312	W	20011219
JP 2002-551562	A3	20011220
JP 2002-559414	A3	20011220
US 2001-34019	A3	20011220
US 2001-34683	A1	20011220
IN 2003-KN795	A3	20030619
US 2003-624800	A3	20030722
US 2004-775699	A1	20040210
JP 2004-366925	A3	20041217
AU 2006-201396	A3	20060404

## ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OS MARPAT 137:47221

AB Title compds. I [wherein Z1 = N or CR8; Z2 = N or CH; and at least 1 of Z1 and Z2 = N; Rx and Ry = independently TR3 or LZR3; or C2RxRy = (un)substituted fused (hetero)cycle; Q = NR4, O, S, C(6a)2, 1,2-cyclo(prop/but)anediyl, or 1,3-cyclobutanediyl; R1 = TD; D = (un)substituted mono- or bicyclic (hetero)aryl, heterocyclyl, or carbocyclyl; T = a bond or alkylidene chain (un)interrupted by O, S, NR4, CO, CONH, NHCO, SO2, SO2NH, NHSO2, CO2, OCO, OCONH, or NHCO2, with provisos; Z = alkylidene chain; L = O, S, SO, SO2, NR6SO2, SO2NR6, NR6, NR6CO, NR6CO2, NR6CONR6, NR6SO2NR6, NR6NR6, OCONR6, or W; R2 and R2a = independently R, TWR6, or C2R2R2a = (un)substituted fused (hetero)cycle; R3 = R, halo, OR, COR, CO2R, CO(CH2)0-1COR, NO2, CN, SO0-2R, N(R4)2, carbamoyl, sulfamoyl, OCOR, acylamino, hydrazino, ureido, etc.; R = independently H or (un)substituted aliphatic, (hetero)aryl, or heterocyclyl; R4 = independently R7, COR7, carboxy, CON(R7)2, or SO2R7; W = CO, CO2, CONR6, C(R6)2O, C(R6)2SO0-2, C(R6)2SO2NR6, C(R6)2NR6, C(R6)2NR6CO, C(R6)2NR6CO2, CR6:NNR6, CR6:NO, C(R6)2NR6NR6, C(R6)2NR6SO2NR6, or C(R6)2NR6CONR6; R6, R6a, R7 = independently H or aliphatic; or N(R6)2 or

N(R7)2 = independently heterocyclyl or heteroaryl; or C(R6a)2 = carbocycle; R8 = R, halo, OR, COR, CO2R, COCOR, NO2, CN, SO0-2R, N(R4)2, CON(R4)2, SO2(R4)2, OCOR, NR4COR, NR4CO2(aliphatic), NR4N(R4)2, C:NN(R4)2, C:NOR, NR4CO(R4)2, NR4SO2N(R4)2, NR4SO2R, or OCON(R4)2] were prepared I are protein kinase inhibitors, especially of Aurora-2 and GSK-3. For example, the (pyrazolylamino)quinazoline II was refluxed with thiophenol in t-BuOH to give III. In bioassays, I inhibited the following kinases with Ki values reported < 20  $\mu$ M: GSK-3 $\beta$  (232 compds.), AURORA-2 (227 compds.), CDK-2 (13 compds.), ERK2 (8 compds.), AKT (10 compds.), and Human Src kinase (183 compds.). I are useful for the treatment of diseases associated with protein kinases, such as diabetes, cancer, and Alzheimer's disease (no data).


IT 438205-78-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(protein kinase inhibitor; preparation of (pyrimidinylamino)pyrazoles as protein kinase inhibitors for treatment of cancer, diabetes, and Alzheimer's disease)

RN 438205-78-8 CAPLUS

CN 2,4-Pyrimidinediamine, N4-(5-cyclopropyl-1H-pyrazol-3-yl)-6-phenyl-N2-(3-pyridinylmethyl)- (CA INDEX NAME)



OSC.G 46 THERE ARE 46 CAPLUS RECORDS THAT CITE THIS RECORD (70 CITINGS)  
 RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/595,807

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

149.14

336.20

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-21.32

-21.32

STN INTERNATIONAL LOGOFF AT 16:42:32 ON 23 AUG 2009